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Abstract  
In the latter half of the 20th Century increases in the availability of inexpensive, 
energy-dense foods combined with an estimated 60-70% reduction in daily energy 
expenditure, created an “obesogenic” environment. The epidemic of obesity that has 
emerged has been associated with the Metabolic Syndrome (MetS) which is a cluster of 
risk factors that are precursors to chronic diseases including cardiovascular disease 
(CVD), type II diabetes (T2D), stroke, and dementia. These chronic diseases are having a 
significant social and economic impact worldwide with their related morbidity and 
mortality. 
Epidemiological and interventional studies have shown that lifestyle 
interventions based on a low-fat, plant-based diet are effective for the management of 
MetS and associated chronic diseases. To date, the research has focused on lifestyle 
interventions delivered by professional facilitators, mostly in clinical settings. The 
primary aim of this dissertation was to examine the effectiveness of a lifestyle 
intervention known as the Coronary Health Improvement Program (CHIP), when 
delivered by volunteer facilitators to free-living participants in their community. The 
secondary aim of the dissertation was to examine the impact of selected participant 
factors including age, gender, religious affiliation, marital status, previous history, family 
history and body mass index on the participants’ responsiveness to the CHIP 
intervention. 
This study adopted a pre-test post-test design involving, a large cohort of 5070 
individuals who participated in one of 178 community-based CHIP interventions 
delivered by volunteers between 2006 to 2009 in the United States and Canada. 
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In 30 days, significant reductions (p < 0.001) were recorded in body mass index 
(3.2%), total cholesterol (11.0%), low-density lipoprotein cholesterol (13.0%), 
triglycerides (7.7%), fasting plasma glucose (6.1%) and systolic and diastolic blood 
pressure (4.9% and 5.3%, respectively). Stratification of the data revealed larger 
reductions in those participants who presented to the program with the greatest risk 
factor levels.  
Regardless of age, gender, marital status, religious affiliation, previous history, 
family history and body weight, participants in the CHIP intervention achieved 
significant improvements in the risk factors associated with MetS however these factors 
influenced the responsiveness of the participants to the program. In general, male 
participants achieved better results than the females, and males tended to achieve their 
best outcomes at a younger age than the female participants. Married participants 
achieved better outcomes than single, divorced or widowed participants. Seventh-day 
Adventist (SDA) participants had better risk profiles at baseline, however, the non-SDA 
participants achieved better outcomes during the intervention. Participants who had the 
highest body mass index (BMI) at baseline achieved the greatest changes in BMI, fasting 
plasma glucose and blood pressure, however, those participants with a BMI greater than 
35 kg/m2 showed significantly less improvement in their lipid profile than those 
participants with a BMI between 25 and 35 kg/m2. 
It was concluded that significant reductions in the risk factors associated with 
MetS can be achieved in 30 days using the CHIP lifestyle intervention when delivered by 
volunteers to free-living participants in their local community. Significant reductions in 
risk factors associated with MetS can be achieved regardless of age, gender, marital 
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status, religious affiliation or baseline biometrics. Utilising volunteers may therefore 
provide an effective and cost-efficient mode of delivering lifestyle interventions 
targeting MetS.  
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Chapter 1. Introduction  
 
1.1. Research rationale 
Environmental and sociological changes arising in the latter half of the 20th 
century have created an “obesogenic” environment (Egger & Swinburn, 1997) . 
Increases in the availability of inexpensive, energy-dense foods, combined with an 
estimated 60-70% reduction in daily energy expenditure (Vogels, Egger, Plasqui, & 
Westerterp, 2004) has resulted in an epidemic of obesity (Agatston, 2012). The rise of 
obesity has been paralleled by a rise in a cluster of abnormalities that has been label 
the Metabolic Syndrome (MetS). MetS is defined as having three of the following five 
risk factors: increased body mass index (BMI), high triglyceride (TG) levels, low high 
density lipoprotein cholesterol (HDL) levels, hypertension, and raised fasting plasma 
glucose (FPG) levels (Alberti et al., 2009). The sequelae to MetS, including 
cardiovascular disease (CVD), type II diabetes (T2D), stroke, and dementia, with their 
related morbidity and mortality, have had a significant social and economic impact 
worldwide.  
It has been suggested that the prevalence of MetS in the US adult population 
over the age of 20 is 42% in males and 38% in females (Alberti et al., 2009), and that 
health care costs increase by approximately 24% for each additional MetS component 
identified in an individual (Boudreau et al., 2009; Roger et al., 2012).  
The medical establishment has a largely adopted a pharmaceutical and/or 
surgical approach for the management of MetS and its related symptoms. While 
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pharmaceutical and surgical interventions have benefits, the cost of these treatments 
has risen dramatically. In the United States it is estimated that in 2008 the direct 
medical cost of overweight and obesity alone was $113.9 billion which represents 
upwards of 10% of the total US health care spending (Tsai, Williamson, & Glick, 2011). 
The estimated fiscal burden of heart disease in the US was in excess of $500 billion in 
2010 as a result of direct health care costs and lost productivity (Allen, 2009; Esselstyn, 
2010). In 2010 the global health expenditure on diabetes was estimated to have been 
$USD 376 billion, representing 12% of the global health expenditure and this figure is 
forecast to rise to $490 billion annually by 2030 (Zhang et al., 2010). 
As well as being costly, the pharmaceutical and/or surgical approach for the 
management of MetS does not treat the underlying cause of the syndrome. In fact, as 
they only target the symptoms of the condition, they have been referred to as 
“palliative care” (Esselstyn, 1999; Ornish, 2002). Indeed medication cannot 
compensate for, or neutralise, unhealthy lifestyle choices. Ferenczi, Asaria, Hughes, 
Chaturvedi, and Francis (2010) accurately assert that offering a free sashay of statins at 
fast food outlets to accompany the unhealthy meal will not remedy the growing 
burden of chronic disease. 
Lifestyle intervention has been shown to be viable for the management of 
MetS and even superior to the prevailing medical treatment paradigm (Alberti, 
Zimmet, & Shaw, 2006). In a landmark study that compared the efficacy of lifestyle 
intervention to pharmaceuticals (Metformin ) for preventing at-risk individuals 
progressing to develop T2D, the Diabetes Prevention Program (DPP) showed lifestyle 
intervention to be more than twice as effective (Herman et al., 2005). Similarly, 
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Orchard et al. (2005) found lifestyle intervention to reduce the incidence of MetS by 
41% compared to a placebo while Metformin only reduced the incidence by 17%. 
Lifestyle intervention has been shown to be more cost effective than pharmaceutical 
intervention (Herman et al., 2005) as well as delivering  significantly better outcomes 
overall and cardiovascular-event-free survival after first myocardial infarction than 
usual care (Tuttle et al., 2008).   
In recent times, there has been an increasing interest in the lifestyle-centred 
approach for the management of chronic disease, and several lifestyle interventions 
have been developed. These interventions have been shown to be effective for the 
treatment of MetS when delivered by professional facilitators in residential settings 
(Barnard & Wen, 1994; Ornish et al., 1983), clinical settings and healthcare sites 
(Esselstyn, 1999; Silberman et al., 2010), workplace environments (Aldana, Greenlaw, 
Diehl, Englert, & Jackson, 2002), and in community settings (Diehl, 1998; Merrill & 
Aldana, 2008).  
One such lifestyle intervention is the Coronary Health Improvement Program 
(CHIP). The CHIP lifestyle intervention was designed by Dr Hans Diehl 27 years ago 
(Diehl, 1998; Gidley, 2008). CHIP builds off a number of behaviour change strategies 
(Aldana, Greenlaw, et al., 2006) but leans heavily on the Theory of Planned Behaviour 
(TPB) (Ajzen, 1985) as described in more detail in Chapter 4. CHIP has been shown to 
be effective when delivered using paid health professionals as facilitators in workplace 
and hospital settings (Aldana et al., 2002; Englert, Diehl, Greenlaw, Willich, & Aldana, 
2007; Merrill & Aldana, 2009).  
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The primary aim of this study was to examine the effectiveness of CHIP 
interventions facilitated by volunteers, in a community setting. The study analysed a 
large cohort of 5046 individuals who participated in one of 178 CHIP programs 
delivered throughout North America between 2006 and 2009. The programs were 
community-based meaning that they were offered to free-living individuals in their 
own environment, as opposed to participants in residential lifestyle centres. The 
programs were volunteer-delivered in that the facilitators donated their time. If 
effective the use of volunteer facilitators means that lifestyle intervention can be 
delivered at a significantly reduced cost when compared with professionally facilitated 
programs. 
To date, not a lot is known about the responsiveness of different individuals to 
lifestyle interventions. The secondary aim of the present study was therefore to 
identify the impact of selected participant factors, such as age, gender, marital status, 
religious affiliation, previous history, family history and weight at program entry on the 
outcome of the CHIP intervention. 
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1.1 Research questions 
The aim of this research project was to examine the effectiveness of the 
Coronary Health Improvement Program (CHIP) lifestyle modification program, 
delivered by volunteers to free-living participants in their community, targeting the 
cluster of risk factors associated with the Metabolic Syndrome (MetS).  
In particular this research was guided by the following specific questions: 
1. How effective is the Coronary Health Improvement Program (CHIP) 
lifestyle intervention for reducing the selected risk factors of 
chronic disease that constitute the Metabolic Syndrome, when 
delivered by volunteers to free-living participants in their 
community? 
2. What is the impact of selected participant factors, including age, 
gender, marital status, religious affiliation, previous history, family 
history and body weight on the outcomes achieved by participants 
in the CHIP intervention? 
This dissertation is presented in six chapters. Chapter 1 provides an 
introduction to the topic and an overview of the research questions. Chapter 2 
provides a review of the relevant literature. The methodology undertaken in the study 
are presented in Chapter 3. Chapter 4 presents the results relating to the first research 
question by examining the effectiveness of the CHIP intervention, as delivered by 
volunteers. Chapter 5 presents the results relating to the second research question 
exploring the impact of selected participant factors on the outcomes achieved by 
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participants in the CHIP intervention. Finally, conclusions, limitations and 
recommendations for further study are presented in Chapter 6. 
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Chapter 2 Review of related literature 
2.1 Introduction 
This dissertation examines the effectiveness of volunteer-delivered, 
community-based Coronary Health Improvement Program (CHIP) interventions. This 
review of the related literature is organised into six major sections. The first section 
examines the changing dietary and activity patterns in the Western world over the last 
several generations which have led to an epidemic of obesity and the rise of chronic 
diseases. The second section introduces the Metabolic Syndrome (MetS) which is a 
cluster of abnormalities seen as a precursor to a number of chronic diseases. The 
relevance, aetiology and treatment of MetS are presented. The third section examines 
the literature relating to the development of the emerging field of Lifestyle Medicine 
which underpins the CHIP intervention, focusing on epidemiological studies and the 
work of significant pioneers in this area who influenced development of CHIP. 
Limitations of Lifestyle Medicine are also presented. In section four an overview of the 
CHIP intervention is presented with a review of publications arising from the CHIP 
intervention to date. The fifth section examines the literature relating to the use of 
volunteers in health education settings. The final section presents a summary of this 
chapter. 
2.2  The rise of chronic disease 
Since the Industrial Revolution there has been a dramatic change in the primary 
causes of mortality and morbidity in the Western World (Caballero, 2007; Caldwell, 
2001). Changes in public health and hygiene around the time of the Industrial 
Revolution to the late 19th century, combined with the development of medical 
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"miracles" such as vaccinations and antibiotics in the early 20th century, resulted in a 
dramatic reduction in morbidity and mortality caused by communicable diseases. By 
the 1960s, described as “the age of optimism”, it appeared that the battle against 
disease had been all but won (Le Fanu, 2000, p. 213). However, for the first time in 
human history, machines were beginning to carry out work previously done by 
humans. The mechanisation of food production and associated changes in farming 
practice combined with state subsidisation of the agricultural sector enabled a 
dramatic increase in the production of food, making what had been formally a 
relatively scarce resource now a common commodity (Pollan, 2007). The technological 
revolution of the late 20th century increased the processing potential for food. This 
enabling food manufacturers to artificially increase the caloric content, and thus the 
energy density, of the food but not the nutrient density (Egger, Binns, & Rossner, 2011, 
p. 12). This increase of cheap, readily available, energy-dense food, combined with an 
estimated 60-70% reduction in daily energy expenditure since the 1950s (Vogels et al., 
2004), has resulted in a substantial portion of the population of the Western world 
now consuming more calories in their diet than they burn in their daily activity 
(Agatston, 2012). In the year 2000, for the first time in human history, more people 
were overweight than underweight (Caballero, 2007; Gardner, Halweil, & Peterson, 
2000). 
Obesity and inactivity are not new phenomena, Lucretius is reputed to have 
stated in 50 BC, "In primitive times, lack of food gave languishing bodies to death; now, 
on the other hand, it is abundance that buries them" (Potter, 2005). Some 3000 years 
ago Solomon admonished the slothful "Go to the ant, thou sluggard; consider her 
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ways, and be wise:" (Proverbs 6:6). However it is only very recently that the conditions 
in Western society have become “obesogenic”, leading to an epidemic in obesity (Hill 
& Peters, 1998). It appears that epidemic increased dramatically in the 1980s in the 
United States (Friedewald et al., 2007; Sturm, 2002; Taubes, 1998). While this study 
focuses on the United States a similar rise in obesity in the eighties has been observed 
in Australia, (Kent & Worsley, 2009) and is continuing to have a significant impact 
worldwide (Yanovski & Yanovski, 2011). This change in obesity levels is illustrated in 
Figure 1 which shows the dramatic rise in the percentage of the population classified 
as obese by state, in the United States since 1990. It has been estimated that during 
the 80s and 90s the average Australian adult was adding 1g in body weight per day 
(Egger & Swinburn, 1997). Further, the obesity epidemic is now impacting children and 
teens (Ogden, Carroll, Kit, & Flegal, 2012).  
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Figure 1 US obesity trends by state 1990 - 2009. (Agatston, 2012) 
 
In recent decades the global epidemic of obesity has driven a dramatic increase 
in chronic diseases (Ford, Giles, & Mokdad, 2004). Using Quality Adjusted Life Years 
(QALY) to assess the overall burden of disease caused by smoking and obesity, from 
1993 to 2008, Jia and Lubetkin (2010) showed that while the proportion of smokers in 
the US adult population declined by 18.5% over this period, the proportion of obese 
adults increased by 85%. The QALYs lost from smoking has remained relatively stable 
at 0.0438 QALYs lost per population, however, there has been a dramatic increase in 
the QALYs lost attributed to obesity from 0.0204 lost per population, in 1993, to 
0.0464 in 2008. This represents a 127% increase over a 15 year period. It has been 
suggested that obesity is now a greater health risk than both smoking and the 
unhealthy consumption of alcohol (Sturm, 2002).  
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Lifestyle factors including smoking, an unhealthy diet, obesity and reduced 
physical activity have been linked to a number of chronic diseases including type II 
diabetes (T2D) (Freemantle, Holmes, Hockey, & Kumar, 2008), diseases of the 
circulatory system including cardiovascular disease (CVD), myocardial infarction (Yusuf 
et al., 2004) and stroke (Mokdad, Marks, Stroup, & Gerberding, 2004), depression 
(Pischke, Frenda, Ornish, & Weidner, 2010) (An Pan et al., 2012), the Metabolic 
Syndrome (MetS) (Eckel, Grundy, & Zimmet, 2005), some cancers (McNaughton, 
Marks, & Green, 2005) (Pan, Sun, & Bernstein, 2012) (Larsson & Wolk, 2012), kidney 
disease (Tang, Yan, & Zhuaig, 2012) and dementias and Alzheimer's disease (de la 
Monte & Wands, 2008).  
This “toxic environment” (Yanovski & Yanovski, 2011) has created a situation 
where the incidence of T2D has risen to epidemic proportions (Wild, Roglic, Green, 
Sicree, & King, 2004) and cardiovascular disease (CVD) is the leading cause of 
premature death globally, accounting for almost one third of worldwide mortality 
(Ascunce, Berger, Weintraub, & Schwartzbard, 2012). Increasingly this burden of 
disease is being borne by developing countries (Alwan, 2011; Salehi, Hanifi, 
Khaleghparast, Ghadrdoost, & Zamari Nobari Shabnam, 2011) where it is estimated 
that 80% of all CVD mortality occurs (Perk et al., 2012).  
For the first time we have a situation where more people are dying from causes 
related to how they live, that is their lifestyle, than from infectious disease or injury. In 
1971, Omran applied the term "epidemiological transition" to describe this change. He 
proposed that there were three ages in relation to the primary causes of mortality: the 
Age of Pestilence and Famine followed by the Age of Receding Pandemics and then 
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finally the Age of Degenerative and Man-Made Disease. Modifications to Omran’s 
theory have been suggested (Olshansky & Ault, 1986), however, it is well established 
that a clear transition has occurred over the past few decades from the primary cause 
of death being contagious diseases and injury to the current situation in the Western 
World where the primary cause of death is chronic diseases such as CVD, cancer and 
diabetes (Lopez & Mathers, 2006; Mackenbach, 1994; Magee, Henry, & Narayan, 
2011).  
The burgeoning rise in chronic disease has also become a major financial 
problem worldwide. In the United States it is estimated that the direct medical cost of 
overweight and obesity was $113.9 billion, in 2008 which representing upwards of 10% 
of the US health care spending (Tsai et al., 2011). The estimated cost of heart disease 
in the United States was in excess of $500 billion in 2010 as a result of health care 
costs and lost productivity (Allen, 2009; Esselstyn, 2010).The estimated healthcare 
related cost of CVD in the UK in 2004 was £17.4 billion representing 18% of the overall 
health expenditure in the UK for that year (Luengo-Fernández, Leal, Gray, Petersen, & 
Rayner, 2006). The global health expenditure on diabetes is estimated to have been 
$USD 376 billion in 2010 representing 12% of worldwide health expenditure (Zhang et 
al., 2010). This figure is projected to rise to $490 billion by 2030 (Zhang et al., 2010). 
While the rise in the incidence of chronic diseases such as CVD and T2D has had 
a major impact on individuals and populations, there are a number of risk factors that 
are seen as precursors to these chronic diseases. A cluster of these abnormalities 
including obesity, dyslipidaemia, hypertension and hypoglycaemia has been labelled 
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the Metabolic Syndrome (MetS). The next section will review the development of 
MetS, followed by a discussion of the relevance, aetiology and treatment of Mets. 
2.3 The Metabolic Syndrome 
The Metabolic Syndrome (MetS) is the contemporary name given to a cluster of 
abnormalities that have increased substantially in modern times: obesity, 
hyperlipidaemia, hypertension and raised blood sugar (Eckel, Alberti, Grundy, & 
Zimmet, 2010). MetS is seen as a precursor to T2D and is associated with increased risk 
of CVD and stroke (Daskalopoulou, Athyros, Kolovou, Anagnostopoulou, & Mikhailidis, 
2006). 
There has been an evolution in both the naming of MetS and its defining 
characteristics. Historically, the condition has been labelled Syndrome X (Reaven, 
1988), Reaven's Syndrome, Insulin Resistance Syndrome, Deadly Quartet, Dismetabolic 
Syndrome (Eckel et al., 2005) and the acronym CHAOS—Coronary artery disease, 
Hypertension, Atherosclerosis, Obesity, and Stroke (Gale, 1998).  While the term 
‘Insulin Resistance Syndrome’ is still used occasionally, 'Metabolic Syndrome' remains 
the most widely accepted label (K. G. Alberti et al., 2006) after being introduced to the 
Medical Subject Headings (MeSH) database in 2002.  
MetS is an important concept in the present dissertation as it is used as the 
framework for evaluating the effectiveness of the lifestyle intervention studied. 
Accordingly, the evolution of the definition of MetS is presented in detail below.  
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2.4 Definitions of the Metabolic Syndrome 
The Swedish physician Kylin first noted an association between hypertension, 
hyperglycaemia and gout in the 1920s (Levesque & Lamarche, 2008).  In 1947, Vague 
noted that upper body adiposity was commonly associated with metabolic 
abnormalities found in T2D and CVD (Daskalopoulou et al., 2006). However, it was not 
until 1988 that Reaven published his Banting Medal Award Lecture where he described 
a condition that he referred to as ‘Syndrome X’ (Reaven, 1988). Reaven defined 
Syndrome X as a constellation of insulin resistance, hyperglycaemia, hypertension, low 
high-density lipoprotein cholesterol (HDL-C), increased very low density lipoprotein 
(VLDL) and raised triglyceride (TG) levels. Surprisingly, Reaven did not link obesity with 
Syndrome X (Alberti, Zimmet, & Shaw, 2005). 
Since Reaven (1988), various groups and agencies have attempted to define 
and categorise MetS resulting in considerable discussion as to what should and should 
not be included in its definition. Clearly, the deliberations have been influenced by the 
different backgrounds of the groups involved in the discussion; groups with a primary 
focus on T2D have applied different emphases to groups with a primary interest on 
CVD. 
The first official definition of MetS was published by the World Health 
Organisation (WHO) in 1998, as part of the document entitled "Definition Diagnosis 
and Classification of Diabetes Mellitus and Its Complications" (World Health 
Organisation, 1999). The report introduced MetS as a major classification and 
diagnostic tool to meet the therapeutic challenge of the person with hypertension, 
central (upper body) obesity, and dyslipidaemia, with or without hyperglycaemia. 
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While the WHO considered several other components of the MetS that had been 
proposed such as hyperuricaemia, coagulation disorders, and raised plasminogen 
activator inhibitor-1, they concluded that these were not necessary for the diagnosis of 
the condition. The WHO proposed definition of MetS is shown in Table 2-1. This 
definition required that insulin resistance be present for a diagnosis of MetS, plus any 
two of the other criteria. 
The major limitation of the WHO definition was that it required measuring 
insulin resistance using the euglycaemic clamp method or oral glucose tolerance test 
(OGTT), as well as measurement of microalbuminuria, making it difficult to apply in 
clinical practice and epidemiological studies (Grundy, Brewer, Cleeman, Smith, & 
Lenfant, 2004). Another criticism of the WHO report was that it limited the ability to 
use the diagnosis for "pre-diabetic" or non-diabetic subjects (Daskalopoulou et al., 
2006).  
In the WHO definition of MetS normal levels for fasting plasma glucose (FPG) 
were defined as being less than 6.1 mmol/L which was a reduction from the formerly 
recommended level of 6.7mmol/L. 
The WHO report, while having a major focus on diabetes and insulin 
abnormalities, noted the relationship between MetS and CVD (Beck-Nielsen, 1999). 
The WHO report suggested that insulin resistance was the underpinning aetiological 
factor for the individual components of MetS. 
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Table 2-1 Definitions of the Metabolic Syndrome 
 
 
World Health 
Organization(1999) 
(WHO)  
European Group for 
the Study of Insulin 
Resistance (1999) 
(EGIR) 
National Cholesterol 
Education Program 
Adult Treatment Panel 
III (2001)  
(ATPIII) 
American College of 
Endocrinology / 
American Ass of Clinical 
Endocrinologists (2003) 
(ACE/AACE) 
International Diabetes 
Federation 
(2006)  
(IDF) 
Harmonized Definition 
(2009) 
Criteria for Diagnosis Insulin resistance (plus 
two other factors) 
Insulin resistance or 
fasting 
hyperinsulinaemia  
(in non-diabetic 
people) 
Three or more of the 
following five risk 
factors 
No specific definition 
but relies on clinical 
judgement 
Central obesity plus 
any two of the other 
factors or specific 
treatment for these 
factors 
Three or more of the 
following five risk 
factors or specific 
treatment for these 
factors 
Insulin Resistance Glucose intolerance, 
IGT or diabetes and/or 
insulin resistance 
Insulin resistance is 
defined as the top 25% 
of fasting insulin in the 
non-diabetic 
population 
    
Central Obesity Waist-hip ratio  
Male >0.9 
Female >0.85 
and/or BMI >30kg/m2 
Waist circumference 
Male ≥0.94m 
Female ≥0.80m 
Waist circumference 
Male ≥1.02m 
Female ≥0.88m 
 Waist circumference 
Ethnic Specific or a BMI 
of greater than 30 
kg/m2 
Waist circumference 
Ethnic Specific 
HDL*  Male ≤0.9 mmol/L 
Female ≤1 mmol/L 
≤1 mmol/L Male <1.0mmol/L 
Female<1.3mmol/L 
Male <1.0mmol/L 
Female<1.3mmol/L 
Male <1.0mmol/L 
Female<1.3mmol/L 
Male <1.0mmol/L 
Female<1.3mmol/L 
TG * ≥1.7 mmol/L ≥2.0 mmol/L >1.7 mmol/L  >1.7 mmol/L >1.7 mmol/L  >1.7 mmol/L 
FPG    6.1mmol/L ≥6.1  6.1-6.9mmol/L  >5.6mmol/L  >5.6mmol/L 
BP  Systolic>140mmHg 
Diastolic>90mmHg 
Systolic>140mmHg 
Diastolic>90mmHg 
Systolic>130mmHg 
Diastolic>85mmHg 
Systolic>130mmHg 
Diastolic >85mmHg 
Systolic>130mmHg 
Diastolic>85 mmHg 
Systolic>130mmHg 
Diastolic>85 mmHg 
Microalbuminuria Urinary albumin 
excretion rate ≥ 20 
µg/min or album in: 
creatinine ratio≥ 30 
mg/g 
     
Reference (World Health 
Organisation, 1999) 
(Balkau & Charles, 
1999) 
(National Cholesterol 
Education Program, 
2002) 
(Grundy et al., 2004) (K. G. Alberti et al., 
2006) 
(Alberti et al., 2009) 
*Abnormal HDL and triglycerides were combined as one criteria, dyslipidaemia, in the WHO and EGIR definitions 
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The European Group for the Study of Insulin Resistance (EGIR) modified the WHO 
criteria in 1999. This report expanded the definition of MetS to include people who did 
not have diabetes but required hyperinsulinaemia to be present along with any two of 
the following: central obesity, dyslipidaemia, hypertension and/or raised fasting plasma 
glucose (FPG).  
For the EGIR report waist circumference was used as a measure of central obesity 
as opposed to hip-waist ratio or body mass index (BMI). The cut-off level for triglycerides 
(TG) was raised to greater than 2.0 mmol/L and a fasting plasma glucose (FPG) greater 
than or equal to 6.1 mmol/L was included as an independent criteria (Balkau & Charles, 
1999). Consistent with the WHO report, dyslipidaemia was defined by either low HDL or 
raised triglycerides and these two factors were not itemised as separate criteria, unlike 
later definitions of MetS (Table 2-1). As with the WHO report, the EGIR definition of MetS 
primarily focused on diabetes and its associated conditions. 
In their third report the National Cholesterol Education Program Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III) (ATP III), primarily focused on lowering blood cholesterol and thus 
their definition of MetS focused on CVD rather than diabetes (National Cholesterol 
Education Program, 2002). Further, while the WHO and EGIR definitions focused on 
international and European populations, the ATP III report justified each defining criteria 
by its prevalence in the American population (Daskalopoulou et al., 2006). The ATP III 
defined MetS as having at any three of abdominal obesity, atherogenic dyslipidaemia 
(elevated triglyceride (TG), small (low density lipoprotein (LDL) particles, low HDL 
cholesterol), raised blood pressure, insulin resistance (with or without glucose 
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intolerance) or prothrombotic and proinflammatory states (Table 2-1). Abdominal obesity 
was defined by waist circumference but more generous limits were applied than the EGIR 
criteria probably as a concession to the American norms, which caused some criticism. 
The Adult Treatment Panel Third Report was welcomed for its use of Fasting 
Plasma Glucose (FPG) as a measure of the insulin resistant characteristic, as it provided a 
measurement that was relatively easy-to-use in a clinical setting. However, the inclusion 
of FPG in the definition of MetS received criticism due to a perception that there is a lack 
of clinical and experimental evidence supporting its inclusion (Kahn, Buse, Ferrannini, & 
Stern, 2005). The ATP III definition failed to consider patients who were undergoing 
specific treatment for hypertension or dyslipidaemia as having these components of the 
definition. 
The American College of Endocrinology and American Association of Clinical 
Endocrinologist 2003 (ACE/AACE) definition of MetS (Grundy et al., 2004) used the same 
cut-off points as the ATP III definitions however, significantly, they modified the ATP III 
definition by including patients who were undergoing treatment for dyslipidaemia or 
hypertension but did not apply this criteria to abnormalities related to insulin resistance 
(Daskalopoulou et al., 2006). The ACE/AACE statement deliberately did not provide a 
specific definition of a syndrome but allowed the diagnosis to rely on clinical judgement 
(K. G. Alberti et al., 2006).  
In 2006 the International Diabetes Federation (IDF) published a new MetS 
definition that aimed to be globally applicable for the identification of people at high risk 
of T2D and vascular events (Alberti, Zimmet, Shaw, & Grundy, 2006). The consensus 
group who prepared the International Diabetes Federation definition intended the 
 19 
 
definition to be easy to apply in clinical practice by being based on clinical end-points and 
avoiding the need for measurements usually only available in research settings (K. G. 
Alberti et al., 2006). This definition attempted to incorporate the risk factors related to 
both CVD and T2D (Alberti et al., 2005). The International Diabetes Federation criteria for 
the clinic identification of MetS are shown in Table 2-1. 
The International Diabetes Federation definition defined obesity by using ethnic 
specific waist circumference values as shown in Table 2-2. The ethnic specific cut-off 
values for waist circumference include values for a number of ethnic groups, but the 
tables do not cater well for some ethnic groups including the Polynesian or other Pacific 
Island communities. It also states that if BMI is >30 then central obesity can be assumed 
and waist circumference does not have to be taken. This definition required a waist girth 
of 94 cm for men and 80 cm for women (for Europids) which equates roughly to a BMI of 
25 compared to the more liberal ATP III waist circumference measurements of 102 cm for 
men, and 85 cm for women which equates to a BMI of approximately 30. 
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Table 2-2 Ethnic specific values for waist circumference 
Ethnic group Waist circumference (as 
measure of central obesity) 
Europids 
 Men 
 Women 
 
≥ 94 cm 
≥ 80 cm 
South Asian 
 Men 
 Women 
 
≥ 90 cm 
≥ 80 cm 
Chinese 
 Men 
 Women 
 
≥ 90 cm 
≥ 80 cm 
Japanese 
 Men 
 Women 
 
≥ 90 cm 
≥ 80 cm 
Ethnic South and Central 
Americans 
Use European data until more 
specific data are available 
Sub-Saharan Africans Use European data until more 
specific data are available 
Eastern Mediterranean and 
Middle East (Arab populations) 
Use European data until more 
specific they are available 
       (K.G. Alberti et al., 2006) 
The International Diabetes Federation definition differed from the ATP III 
definition in that it required central obesity as one of the three factors needed for a 
diagnosis of MetS criteria and it allowed treatment for dyslipidaemia, diabetes or 
hypertension to be used as a diagnostic factor for MetS.  
Despite the publication of the International Diabetes Federation definition in 
2006, controversy remained as to the definition of MetS. The ATP III (2001) and 
International Diabetes Federation (2006) definitions were the most commonly used, 
however the fact that the IDF definition made it mandatory to include a threshold value 
for waist circumference while the ATP III definition did not, presented a major difference. 
In 2009 an initiative of the International Diabetic Federation and the American Heart 
Association/National Heart, Lung and Blood Institute was joined by the World Heart 
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Federation, the International Atherosclerosis Society and the International Association for 
the Study of Obesity to develop a Harmonized Definition of MetS.   
A report on this new definition was published in October 2009 (Alberti et al., 
2009). One of the most significant characteristics of the consensus document was the 
removal of the mandate for obesity to be present, thus allowing the diagnosis of MetS to 
be used with non-obese patients who met three of the other criteria. The criteria for the 
Harmonized Definition are shown in Table 2-1.  
A revised National Cholesterol Education Program Adult Treatment Panel (ATP IV) 
was expected to be published sometime in 2012 (Martin et al., 2012) which may include 
revisions to the definition of MetS. At the time of writing, this new definition has not yet 
been published. Unless otherwise noted, the Harmonized Definition of MetS is used in 
this dissertation. 
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2.4.1 Relevance of the Metabolic Syndrome 
There is compelling evidence that MetS has reached epidemic proportions in the 
Western world. Using 1999-2004 National Health and Nutrition Examination Survey Data, 
the age adjusted prevalence of MetS in adults was 35% based on the ATP III (2001) 
definition and 39% using the IDF definition (Cornier et al., 2008). Alberti et al  (2009) 
estimated the unadjusted prevalence of  MetS in the US adult population 20 years and 
over, using the IDF definition, to be 42% in males and 38% in females. 
The clinical relevance of MetS is that it identifies people who are at an increased 
long-term risk of CVD, stroke and T2D (Alberti et al., 2005; Chew, Gan, & Watts, 2006). 
All-cause mortality has been shown to be higher in individuals with MetS (Hu, Qiao, & 
Tuomilehto, 2004).  
The American Diabetics Association and the European Association for the Study of 
Diabetes (ADA/EASD) have raised a number of concerns regarding MetS. These concerns 
include perceived ambiguity and incompleteness of criteria for MetS, the fact that the 
rationales for the criteria are ill-defined and that there is no clear basis for the inclusion or 
exclusion of other CVD risk factors. They question the value of including diabetes in the 
definition of MetS and whether insulin resistance can be identified as a unifying aetiology. 
They also speculate that the risk of CVD associated with MetS as a syndrome is no greater 
than the risk associated with the individual components of MetS and that the treatment 
of the syndrome "MetS" is no different than the treatment of the individual criteria. 
These concerns led them to conclude that the medical value of diagnosing the syndrome 
is unclear (Kahn et al., 2005). 
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Numerous studies have shown that the relative risk of diabetes is significantly 
higher for individuals with MetS. The relative risk of diabetes for those with MetS is 3.5 - 
5.2 in the general population and as high as 33.6 if a population with zero abnormalities is 
used as reference (Bloomgarden, 2009; Ford, Li, & Sattar, 2008). Studies have also shown 
that patients diagnosed with MetS are at greater risk of developing CVD. The increase of 
risk of CVD ranges from 30 to 400%.(Kahn et al., 2005). Cornier et al (2008) concluded 
MetS approximately doubles CVD risk and the risk of T2D is more than five times higher 
for patients who have MetS than the general population that does not have MetS. It has 
been suggested that MetS accounts for the majority of CVD risk in the US population 
(Potenza & Mechanick, 2009). In addition MetS is associated with a number of other 
comorbidities such as non-alcoholic fatty liver disease, sleep disorders, reproductive tract 
disorders and microvascular disease (Cornier et al., 2008). 
In response to the claim that the risk of CVD associated with MetS is no greater 
than the risk associated with the individual components of MetS, Grundy (2006) and 
others adamantly argue that the risk of CVD associated with the MetS is greater than the 
sum of the components (Alberti & Zimmet, 2006; Grundy, 2006b).  
Some of the concerns raised above have been addressed by later definitions of 
MetS with the clarification of the criteria in the IDF and Harmonized Definition. The later 
definitions also allow the use of the diagnosis of MetS in non-diabetic patients. 
 While there is ongoing discussion as to whether there is a unifying aetiology for 
MetS, as discussed in the next section, Pladevall et al. (2006) concluded, using 
confirmatory factor analysis, that the concept of a single underlying factor is not only 
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plausible but best explains the observed correlations between the core components of 
MetS. 
There is a growing consensus that MetS has value in determining CVD and diabetic 
risk (Eckel et al., 2010). While there continues to be ongoing discussions as to exactly 
what risk factors should be included in the definition of MetS, a number of groups 
support MetS as a valuable tool (Alberti et al., 2005). Even the American Diabetics 
Association and the European Association for the Study of Diabetes statement in Diabetes 
Care concluded by acknowledging MetS has been a useful paradigm (Kahn et al., 2005).  
Overall, MetS appears to be a practical and useful means to identify individuals at 
increased risk of CVD and T2D (Alberti et al., 2009; Alberti & Zimmet, 2006). 
 
2.4.2 Aetiology of the Metabolic Syndrome 
When MetS was first proposed, insulin resistance was seen to be the root cause of 
the syndrome. Obesity, particularly central obesity, was viewed as a possible contributing 
factor. As mentioned earlier, Reaven (1988) did not include obesity in the original 
description of his "Syndrome X". However, over time, a shift from the traditional 
glucocentric understanding of MetS to an increasingly lipocentric viewpoint has occurred 
(Savage et al., 2005). This paradigm shift in the understanding of the causation of MetS is 
illustrated by two articles authored 12 years apart by the same authors. In 1998, Alberti 
and Zimmet, in their report for the WHO consultation, stated that "evidence is 
accumulating that insulin resistance could be the common aetiological factor for the 
individual components of the Metabolic Syndrome"(Alberti & Zimmet, 1998). In sharp 
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contrast, the same authors recently reported that "evidence now indicates that the 
metabolic syndrome all begins with excess central adiposity" (Eckel et al., 2010). 
Grundy (2006a) suggested that MetS begins insidiously with abnormal obesity. 
Initially the increased risk is only marginal however as obesity increases and other 
exacerbating factors become involved the risk factors increase significantly. This can 
eventually leads to diabetic complications. Meanwhile atherogenesis is also taking place 
causing atherosclerotic cardiovascular disease. Grundy (2006b) explains that increasing 
age can also act as a precursor to abdominal obesity.  
The pathophysiology of MetS has been summarised by Potenza and Mechanick  
(2009), with the undergirding of genetic predisposition, physical inactivity and an 
atherogenic western diet leading to increased central adiposity. The model proposes that 
visceral adipose tissue secretes inflammatory cytokines, adipokines and nonesterified 
fatty acids. These factors create insulin resistance at the level of skeletal muscles and the 
liver leading to hyperinsulinaemia that provokes atherogenesis, both directly and through 
compromised endothelial integrity. The increased blood fatty acid concentration also 
alters hepatic lipid production resulting in low high density lipoprotein (HDL), low-density 
library protein (LDL) changes and elevated triglycerides (TG).  
A limitation of this model is that not all people with MetS are overweight or obese 
(St-Onge, Janssen, & Heymsfield, 2004), and not all overweight and obese individuals 
have MetS. This would suggest that MetS has a multifactorial aetiology, involving complex 
interactions between factors including genetics, hormones and nutrition. Further, there is 
evidence to suggest an epigenetic component to MetS. Bruce and Hanson (2010) suggest 
that maternal obesity during pregnancy and gestational diabetes can often result in foetal 
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overgrowth which can lead to increased MetS susceptibility in adulthood. However, they 
point out that while this epigenetic ‘priming’ may be present, it requires the appropriate 
stimulus, such as an atherogenic diet combined with a sedentary lifestyle, to trigger MetS 
in the susceptible adult. 
Bays et al (2008) discussed a pathogenic form of fat which causes the symptoms of 
MetS. The pathogenic potential of adipose tissue appears to be effected by acquired 
and/or environmental factors. This pathogenic fat has been referred to as "sick fat" (Bays, 
2009) and can affect individuals regardless of body weight. In the underweight patient 
with lipodystrophy there is a lack of adipose tissue that results in impaired adipose tissue 
functionality. Inadequate adipose tissue stores may compromise the storage of free fatty 
acid which results in increased circulating free fatty acids causing lipotoxicity. This 
lipotoxicity is characterised by the depositing of ectopic fat in muscle, the liver and the 
pancreas, all of which can contribute to T2D and MetS (Bays et al., 2008). 
In the normal weight individual, during positive caloric balance where 
adipogenesis (Gregoire, Smas, & Sul, 1998; Roche, 1981) is impaired, the existing fat cells 
(adipocytes) must undergo hypertrophy (lipodystrophy), to store the excess energy 
(Gregoire, 2001). The hypertrophy of the adipocytes decreases their ability to function 
effectively leading to increased circulating levels of adiponectin and free fatty acids 
causing lipotoxicity. 
Regardless of whether an individual is underweight or overweight, during times of 
positive caloric balance the excess energy may be stored through fat cell hypertrophy 
rather than adipogenesis, leading to pathologic adipose tissue responses and MetS (Bays 
et al., 2008). 
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2.4.3 Treatment of the Metabolic Syndrome 
Arising from the above discussion, it appears that central obesity, exacerbated by 
sedentary lifestyle and the Western diet, are the primary cause of MetS (Hoerger & 
Ahmann, 2008; Pladevall et al., 2006). Accordingly, the treatment of choice for MetS 
involves lifestyle interventions targeting weight loss (Bays & Dujovne, 2006; Eckel et al., 
2010; Horton, 2009; Pereira et al., 2009) with appropriate drug treatment only used to 
treat the “residual” CVD risk once lifestyle treatment has been utilised (Eckel et al., 2010).  
Yet while lifestyle intervention is the preferred treatment strategy, 
pharmacological treatment of the individual abnormalities associated with MetS such as 
dyslipidaemia, hypertension and blood glucose abnormalities are mostly employed 
(Grundy, 2006a), despite being costly and often less effective than lifestyle intervention. 
For example, the projected Australian expenditure on statins, used to treat dyslipidaemia, 
for the period January 2009 to December 2019 exceeds $13 billion (Clarke & Fitzgerald, 
2010). This presents an average cost in excess of one billion dollars per year and while 
substantial savings could be made by the use of generic statins, it is still represents an 
enormous economic burden. Furthermore, statin therapy does not eliminate 
cardiovascular risk (Nabel & Braunwald, 2012).  
As well as being relatively expensive, pharmaceutical approaches for the 
treatment of MetS are often less effective than lifestyle modification. Ratner et al. (2005) 
found that in a three year follow up of MetS patients in the Diabetes Prevention Program, 
pharmacological treatment was 28% less effective for hypertension and 25% less effective 
for hyperlipidaemia than lifestyle intervention. The “Portfolio” diet that included 
cholesterol-lowering foods such as oatmeal, nuts, and soy was found to be as effective as 
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statins in the management of dyslipidaemia (D. J. Jenkins et al., 2003; Jenkins, Kendall, 
Marchie, Faulkner, Wong, et al., 2005). In reducing the absolute incidence of diabetes, 
lifestyle intervention was shown to “dominate” the pharmaceutical approach, with 
lifestyle intervention shown to be 20% more effective than a placebo in reducing the 
absolute incidence of diabetes compared to only 8% for Metformin (Herman et al., 2005). 
Lifestyle intervention was shown to reduce the incidence of MetS by 41% when compared 
to a placebo, while Metformin was shown to reduce the incidence of MetS by only 17% 
(Orchard et al., 2005).  
Morbidity and mortality from just CVD can be reduced by at least 50% by healthy 
lifestyle change (Slavicek et al., 2008). Lifestyle intervention using either a 
Mediterranean-style diet or a low-fat diet have been shown to deliver significantly better 
overall health outcomes and cardiovascular-event-free survival after first myocardial 
infarction than usual care. Patients receiving dietary intervention had better primary-
outcome-free survival after 24 months (85 of 101) than the usual-care control (61 of 101) 
(p <0.001) (Tuttle et al., 2008).  Lifestyle treatment has been shown to compare 
favourably with pharmaceutical treatment of hyperlipidaemia and hypertension 
(Liberopoulos, Tsouli, Mikhailidis, & Elisaf, 2006; Sacks & Katan, 2002). This was 
demonstrated in the Health Professionals Follow-up Study involving 42,847 men, leading 
to the researchers concluding “cardiovascular medication should be used as an adjunct, 
and not just a replacement for healthy lifestyle practices, especially in the setting of 
primary prevention”(Chiuve, McCullough, Sacks, & Rimm, 2006, p. 164). 
Despite the clear benefits of lifestyle modification for the management of MetS, a 
perception persists, in the medical community, that it is easier to prescribe drugs than to 
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change dietary habits of patients and a belief that patients will not change their lifestyle 
habits. However several studies have shown that significant change in lifestyle patterns is 
achievable and sustainable long-term. In the Lyon Diet Heart Study, researchers found 
that several years after randomisation most of the patients in the experimental group 
were still closely following the recommended diet. They suggest that provided the 
instruction and supervision of the diet was delivered in a professional manner and that 
the new dietary habits were financially achievable and acceptable from a taste 
perspective, then long-term adherence to the new diet was achievable for most of the 
study participants (de Lorgeril et al., 1999). Esselstyn had three quarters of his 
experimental group stay with a very low fat, plant based diet for 20 years (Esselstyn, 
2008). Furthermore, it is often overlooked that there are major problems with adherence 
to pharmaceutical treatments targeting the symptoms associated with MetS. Chapman et 
al., (2005) found that the percentage of patients adherent to both antihypertensive and 
lipid-lowering pharmacological therapy dropped rapidly following treatment initiation, 
with only 45% patients adherent at three months and 36% after six months.  
A key reason why lifestyle interventions are preferable to pharmaceutical 
interventions for the treatment of chronic disease is that lifestyle interventions treat the 
underlying cause of the disease (Esselstyn, 1999; Ornish, 2002). As a consequence, 
lifestyle interventions address all of the symptoms of MetS as compared to medication 
that typically only treats its individual components. For example, statins can be used for 
treating dyslipidaemia but do not improve fasting plasma glucose levels, hypertension or 
central obesity. Finally, lifestyle interventions have less negative side effects than 
medications (Sattar et al., 2010).  
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A number of lifestyle modification programs have shown to successfully improve 
the risk factors associated with MetS. These include the Lyon diet (de Lorgeril et al., 
1999), the Ornish Heart Disease Reversing Program (Aldana et al., 2003) and the Pritikin 
program (Barnard, 2007; Sullivan & Samuel, 2006).  
After reviewing the evidence from the three EUROASPIRE patient surveys 
conducted across 22 countries in Europe, Kotseva et al. (2009, p. 929) conclude that “to 
salvage the acute ischaemic myocardium without addressing the underlying cause of the 
disease is futile; we need to invest in prevention.” Alberti and Zimmet (2006, p. 261) 
concluded that for the treatment of MetS "at present there is only one magic bullet, and 
that is lifestyle management." However very few patients in usual primary care settings 
are offered the opportunity to participate in lifestyle interventions (Shurney, Hyde, & 
Hulsey, 2012), despite the fact that the current management paradigm for MetS, 
dominated by a heavy reliance on medication and surgery, is unable to cope with the 
increased burden of chronic disease that has occurred since the epidemiological 
transition (Campbell & Campbell, 2006, p. 327). It is in this climate that Lifestyle Medicine 
has emerged.  
Bariatric surgery has been used for the treatment of extremely obese patients and 
has been shown to have a positive impact on T2D (Schauer et al.) and to decrease overall 
mortality in severely obese patients (Kwok et al., 2014; Sjöström et al., 2007). However 
there seems to be significant variation in outcomes between the various types of bariatric 
surgery with gastric banding being less effective than other procedures (Inabnet, 
Winegar, Sherif, & Sarr). Bariatric surgery, alone, without intensive lifestyle intervention 
does not treat the underlying cause of the obesity and Mets and as a major surgical 
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procedure carries the associated risks of surgery (Arterburn, Johnson, Butler, Fisher, & 
Bayliss, 2014). 
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2.5 Lifestyle Medicine: an overview 
2.5.1 Introduction 
The first of the two research questions which forms the basis of this dissertation 
is: How effective is the Coronary Health Improvement Program (CHIP) lifestyle 
intervention for reducing the selected risk factors of chronic disease that constitute the 
Metabolic Syndrome, when delivered by volunteers to free-living participants in their 
community? In order to answer this question it is necessary to present an overview of the 
development of Lifestyle Medicine as a background to the CHIP intervention. 
Epidemiological studies that are foundational to Lifestyle Medicine which demonstrate 
the relationship between lifestyle and disease will be presented. This is followed by an 
exploration of the work of several pioneering researchers who attempted to use lifestyle 
interventions to treat some chronic diseases. Finally the limitations of Lifestyle Medicine 
are discussed. 
It has been long speculated that the way that we live has an impact on our health. 
Almost 2500 years ago Hippocrates advocated, "Let food be thy medicine and medicine 
thy food" (Smith, 2004). Yet by the 19th century, "food as medicine" had fallen into 
obscurity (Lucock, 2004). 
In the early to mid-19th century a number of "health reformers" postulated that 
diet could have a significant effect on health and behaviour. Sylvester Graham had 
concluded, by 1837, that wheat as a food could sustain American bodies and prevent 
"immoral behaviour", particularly masturbation and sexual excitement (Tompkins, 2009). 
In 1863 Ellen G White, taking a more holistic approach, proposed eight laws of health by 
asserting, "Pure air, sunlight, abstemiousness, rest, exercise, proper diet, the use of 
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water, trust in divine power – these are the true remedies" (White, 1905, p. 127). These 
have been developed into the acronym NEW START, representing nutrition, exercise, 
water, sunshine, temperance, air, rest and trust (Weimar, 2012). Inspired by White, John 
Harvey Kellogg, who with his brother Will Keith Kellogg invented the cornflakes breakfast 
cereal, established the Battle Creek Sanitarium in the mid 1800's and promoted a 
vegetarian diet, exercise and absence from alcohol and tobacco. Kellogg's clients included 
former president William Howard Taft, Amelia Earhart, Henry Ford and Thomas Edison 
among others (Bull & Lockhart, 2007, p. 12; Wikipedia, 2012). 
2.5.2 Epidemiological studies 
By the mid-20th century researchers examining the interaction between diet and 
health began to suspect a correlation between diet and heart disease, referred to as the 
diet-heart concept. One of the key leaders in this research, Ancel Keys, postulated that a 
“rich” diet, high in saturated fats, may contribute to higher plasma cholesterol levels and 
a tendency towards coronary health disease (Macini & Stamler, 2004). Keys first 
investigated this hypothesis in a group of 300 businessmen from Minnesota, aged 45 to 
55 years, who were recruited in 1947 for a prospective study that involved annual follow-
ups. Key observed that the incidence of CVD was higher among individuals with higher 
levels of relative weight, body fatness, blood pressure and serum cholesterol 
concentrations. Of the measures studied, serum cholesterol concentration showed the 
most significant association to CVD (Keys et al., 1963). Further studies by Keys and 
associates, involving controlled feeding protocols in male residents of psychiatric 
institutions, showed a clear correlation between dietary intake and blood lipid levels 
(Keys, Anderson, & Grande, 1959; Keys & Parlin, 1966). 
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As is the case with most novel postulates, the diet-heart hypothesis was met with 
subtle and not so subtle “agnosticism”(Macini & Stamler, 2004). At a World Health 
Organisation meeting in 1955 where Keys proposed the link between diet, cholesterol 
and heart disease, expecting to be accepted without argument, he was publicly 
challenged by Sir Gregory Pickering. Pickering is reputed to have said with disdain, “Yes, 
and Prof Keys, would you be kind enough to cite for us the principal piece of evidence 
that you think supports this diet-heart theory of yours?”(Ordovas, 2005, p. 919).  
Partly as an attempt to answer some of the criticism of the diet-heart theory Keys, 
along with prominent investigators from other countries, initiated the “Seven Countries 
Study” which was designed to be a 5-year prospective study of 12,770 men aged 49 to 59 
from Finland, Greece, Italy, Japan, the Netherlands, the United States and Yugoslavia. The 
findings of the study were first published as a supplement in Circulation in 1970 and 
clearly showed that the incidence of deaths due to coronary heart disease was related to 
the prevalence of hypertension, serum cholesterol values and dietary saturated fat intake 
(Aravanis, Corcondilas, Dontas, Lekos, & Keys, 1970; Buzina et al., 1970; Fidanza, Puddu, 
Imbimbo, Menotti, & Keys, 1970; Keys, 1970; Kimura & Keys, 1970).  
As a result of these findings, Keys became impressed with the benefits of the 
“Mediterranean diet”. The Mediterranean diet is mainly vegetarian and incorporates a 
variety of pasta, leaves sprinkled with olive oil, a wide variety of vegetables in season, 
fruit as the standard dessert, and wine in moderation (Keys, 1995). Together with his 
wife, Margaret, Keys published a book Eat Well and Stay Well in 1959 promoting the 
benefits of the Mediterranean diet for the prevention of CVD and general longevity. 
Research into the Mediterranean diet and its benefits in relation to CVD have continued 
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in the Lyon Diet Heart Study which continues to show the protective effects of this eating 
pattern (de Lorgeril et al., 1994; de Lorgeril et al., 1999). While the Mediterranean diet 
has its detractors, the fact that Keys lived to the age of 100 and his wife to the age of 97 
tended to lend credence to their hypothesis (VanItallie, 2005; Wright, 2011). 
Several other studies were initiated in the middle of the 20th Century that 
complimented the work of Keys. The landmark Framingham Study begun in 1948 as an 
ongoing cardiovascular study on the residents of Framingham, Massachusetts. The study 
involved 5,209 subjects and showed a clear correlation between diet, cholesterol levels 
and heart disease (Caroline, 2006; Castelli et al., 1986). The Ireland–Boston Diet–Heart 
Study, a 20 year mortality study tracking 1,001 middle-aged men of Irish descent living in 
Boston, also showed a correlation between diet and the development of coronary heart 
disease (Kushi et al., 1985). The results from the Framingham study were used to 
generate the Framingham Risk Score which is still used to predict an individual’s chance of 
having a heart attack in the next 10 years (National Cholesterol Education Program, 2002; 
Wilson et al., 1998).  
The Iowa Women’s Health Study which has followed 34,492 women since 1986 
(Cutler et al., 2008; Jacobs, Meyer, Kushi, & Folsom, 1999; Jacobs, Meyer, Kushi, & 
Folsom, 1998; Jacobs, Pereira, Meyer, & Kushi, 2000) and the Nurses’ Health Study which 
followed 121,700 women from 1976 (Hu, Manson, et al., 2001; Hu et al., 2000; Hu, 
Stampfer, et al., 2001; Oh, Hu, Manson, Stampfer, & Willett, 2005; Stampfer, Hu, Manson, 
Rimm, & Willett, 2000) have shown a clear correlation between lifestyle choices such as 
diet, exercise and smoking and chronic diseases such as CVD, T2D and some cancers.  
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The Adventist Health Studies began in 1960 with the Adventist Mortality Study 
and followed by Adventist Health Study One (AHS-1) 1974 – 1988, collected data on 
34,192 participants and indicated that Seventh-day Adventist’s had lower risk from 
cancers, CVD and diabetes than the general population. In 2002 the second Adventist 
Health Study (AHS-2) commenced, enrolling over 90,000 participants. These studies 
showed the advantages of lifestyle choices such as not smoking, a plant-based diet and 
exercise as being protective from certain types of cancer, T2D and CVD (Butler et al., 
2008; Fraser, 2005; Fraser, Lindsted, & Beeson, 1995; Fraser & Swannell, 1981; Rizzo, 
Sabate, Jaceldo-Siegl, & Fraser, 2011; Tonstad, Butler, Yan, & Fraser, 2009; Tonstad et al., 
2011). 
The Cornell China Study which was a comparative dietary and mortality study 
from 65 counties and 130 villages in rural mainland China found that the mortality rates 
from coronary artery disease and some cancers for both genders in rural China were very 
strongly correlated to diet. There was a positive association with the intake of animal 
protein and the frequency of meat intake for CVD and certain cancers, and an inverse 
association with plant protein, legume and light-coloured vegetable intake (Campbell, 
Parpia, & Chen, 1998). 
It is interesting that despite the findings of these large epidemiological studies 
clearly demonstrating a connection between diet and disease, some critics remain of the 
diet-disease connection, describing it as “quackery” (Le Fanu, 2000, p. 322). However 
there is a general consensus that a strong correlation exists between lifestyle practices 
and the prevalence of chronic disease. Nestle (1999, p. 216) concluded, “What does seem 
clear is that diets based largely on plant foods are most associated with health and 
 37 
 
longevity, at least under conditions of food abundance. Substantial and compelling 
evidence supports the idea that people in industrialised and industrialising economies 
could reduce the risk factors for chronic disease if they increased intake of fruits, 
vegetables and grains in proportion to animal foods.” Similarly, Fraser and Shavlik (2001) 
observed that lifestyle choices such as a adopting a plant-based diet, exercising, not 
smoking and maintaining a healthy body weight could influence the expected age of 
death by as much as a decade, and that these healthy choices also equate to a better 
quality of life at an older age.  
2.5.3 Interventional studies 
Following the evidence of the early epidemiological studies which showed that 
lifestyle choices, particularly relating to diet, smoking and exercise had an impact on 
health, several researchers began, in the 1970s, to investigate the possibility of using 
lifestyle change in an attempt to treat the risk factors associated with chronic diseases. 
Investigations were undertaken at both the societal level and individual level.  
At the societal level, the North Karelia Project in Finland was commenced in 1972 
with the aim of reducing smoking, salt intake and saturated dairy fat intake, and 
increasing the intake of vegetables in order to target high blood cholesterol and high 
blood pressure levels. Results published at 5 years, 10 years, 20 years and 30 years show 
reductions in population smoking rates, serum cholesterol and blood pressure levels in 
both male and female populations. Between 1969 to 2006, this resulted in a 62% 
reduction in all-cause mortality, and a 79% reduction in CVD mortality and a 65% 
reduction in all cancer mortality (Puska, 2008; Puska et al., 1985; Puska et al., 1983; 
Salonen, Puska, & Mustaniemi, 1979).  
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Researchers also began to look at the effects of implementing lifestyle 
interventions in small groups of individuals. Three of the pioneers of these group-based 
interventions were Nathan Pritikin, Dean Ornish and Caldwell Esselstyn. The contribution 
of these individuals is detailed below, followed by an examination of some large 
interventional studies including the Dietary Approach to Stop Hypertension (DASH), the 
Diabetes Prevention Program (DPP), the Look AHEAD Trial and the Portfolio diet. 
 Pritikin 
In 1958, curiosity led Nathan Pritikin to Lester Morrison who had begun an 
experiment in the late 1940s in which he took 100 patients with diagnosed 
atherosclerosis and randomised 50 of the patients to a low fat, low cholesterol diet while 
the remaining patients acted as controls and were given no specific treatment. After 12 
years, 19 of the 50 patients on the low fat, low cholesterol diet were still alive while all of 
the 50 control patients had died (Morrison, 1960). While visiting Morrison, Pritikin 
discovered that his own cholesterol levels were high (280 mg/dL) and a stress 
electrocardiogram resulted in a diagnosis of asymptomatic coronary insufficiency. He was 
advised, by expert cardiologists, not to exert himself and informed that there was nothing 
he could do about his elevated cholesterol levels (Hubbard, Inkeles, & Barnard, 1985; 
Withnell, 2003). Following this diagnosis, Pritikin adopted a diet high in complex 
carbohydrates and low in fat and cholesterol. Combined with daily vigorous physical 
exercise, the “Pritikin Diet” resulted in significant reductions in Pritikin’s blood cholesterol 
levels (155mg/dL) within six months and he experienced substantial improvement in his 
health (Hubbard et al., 1985).  
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In the early 70s, Pritikin in association with John Kern (Trowell, 1977) studied the 
“Pritikin Diet” in a six-month trial of 38 individuals suffering from severe peripheral 
vascular disease. The control group were given usual care treatment and ate a Western 
diet consisting of approximately 30% low fibre starch, 45% fat, 12% protein, 13% sugar 
and salt as desired. This group made no significant improvements in treadmill 
performance, lipid profile or arteriograms. Conversely, the experimental group, who 
exercised vigorously and ate a diet which consisted of 80% rich unrefined starchy foods, 
10% protein and 10% fat, and was low in cholesterol with no added sugar, salt and fat but 
fruits and vegetables as desired, made statistically significant improvements in their lipid 
profile, treadmill performance and arteriograms (Trowell, 1977).  
In 1976, Pritikin established the Pritikin Longevity Research Institute, in Santa 
Barbara, California. The Institute offered a 30-day residential lifestyle program 
incorporating the Pritikin diet and daily exercise. The Pritikin diet constituted less than 
10% fat, 10 to 15% protein and 75 to 80% complex carbohydrates, with less than 25 mg of 
cholesterol and 4 g of sodium chloride per day and 10 to 20 g per day of crude fibre. 
Protein was derived from plant sources with the exception of non-fat milk and a small 
amount of fish or poultry which was served once a week (Barnard, Lattimore, Holly, 
Cherny, & Pritikin, 1982; Pritikin, 1984).  
Participants at the Pritikin Longevity Research Institute experienced significant 
reductions in FPG, with a number of patients being able to come off oral hypoglycaemic 
medication and, in some cases, cease using insulin. Follow-up studies showed that 
patients were able to maintain the improvements in fasting plasma glucose levels 2 and 3 
years after participating in the program (Barnard, Massey, Cherny, O'Brien, & Pritikin, 
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1983). Participants also experienced significant improvements in serum triglyceride and 
cholesterol levels (Reddy et al., 1988; Weber, Barnard, & Roy, 1983).  
Pritikin died in 1985. An autopsy of his heart showed no sign of atherosclerosis 
despite the diagnosis of heart disease 30 years earlier (Hubbard et al., 1985). The Institute 
Pritikin established continued following his death, as the Pritikin Longevity Centre, and 
publications continue to show significant improvements in fasting plasma glucose levels, 
lipid profiles, blood pressure and weight loss (Barnard, 1990, 1991; Barnard, Jung, & 
Inkeles, 1994; Rosenthal et al., 1985). The research from the Pritikin Longevity Centre 
indicates that a residential lifestyle program can have a statistically significant effect on 
the risk factors associated with chronic disease as defined by MetS (Barnard, 2007; 
Barnard & Wen, 1994). 
More recent studies from the Pritikin Longevity Centre suggest that the Pritikin 
diet and lifestyle can also slow the progression of prostate cancer (Barnard, 2007; 
Barnard, Aronson, Tymchuk, & Ngo, 2002; Barnard, Kobayashi, & Aronson, 2008). 
The studies arising from the Pritikin Longevity Centre indicate that a low-fat, low-
protein, high-carbohydrate plant-based diet can be effective in reducing the risk factors 
associated with MetS and possibly even reversing heart disease (Withnell, 2003). The 
limitations of the studies from the Pritikin Longevity Centre were that the results were 
achieved in a controlled environment, namely a residential setting, using health 
professional presenters. Hence the program is relatively expensive making it inaccessible 
to many. Further, the sample size of the studies were small. 
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 Ornish 
Dean Ornish conducted his first clinical study on reversing heart disease between 
his second and third year at medical school, in 1977, after becoming convinced from the 
medical and scientific literature that diet and lifestyle choices had a significant impact on 
the underlying causes of coronary heart disease. In this first study Ornish took 10 patients 
who were considered inoperable because of cardiac disease, housed them in a hotel, and 
for 30 days worked with them using exercise, meditation, group activities and a low-fat 
vegetarian diet consisting predominantly of fruits, vegetables, grains and legumes in their 
natural forms. Fat comprised around 10% of calories in the diet and salt, alcohol and 
caffeine were not used. The study achieved a 91% reduction in the incidence of angina 
and using thallium scans showed improvement in myocardial perfusion (Ornish, 2002).  
In 1980, Ornish conducted a randomised controlled trial with 48 patients 
randomly assigned to either the intervention group or control. The intervention consisted 
of stress management training, meditation, exercise and a vegan diet excluding salt, 
alcohol and caffeine. The control group continued their normal routine. After 30 days, the 
intervention group increased their exercise tolerance by 40% compared to the control 
group. The intervention group showed a 20.5% reduction in total cholesterol (TC) while 
there was no change in the control group. Similarly, significant reductions in triglycerides 
(TG) were observed in the intervention group but not in the control. The frequency of 
angina decreased from 10.1 episodes per week to 0.9 by the end of the 30 days. 
Medication usage reduced significantly in the intervention group only, with a number of 
participants having to discontinue antihypertensive medication (Ornish et al., 1983). 
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In 1986, Ornish initiated the Lifestyle Heart Trial which used qualitative coronary 
arteriography and cardiac PET scans to examine the progression of heart disease. Twenty-
eight symptomatic patients were assigned to an experimental group and were asked to 
eat a low-fat vegetarian diet for at least 12 months. The diet included fruits, vegetables, 
grains, legumes and soya bean products without caloric restriction. No animal products 
were allowed except for egg white and 1 cup of non-fat milk or yoghurt per day. 
Cholesterol intake was limited to 5 mg per day or less. Approximate 10% of the calories in 
this diet were derived from fat, 15 to 20% protein and 70 to 75% complex carbohydrates. 
Caffeine was eliminated and alcohol consumption was discouraged and if consumed 
limited to no more than two units per day. Vitamin B12 supplementation was given. As a 
control, 20 patients were assigned to a usual-care group. The program also included 
exercise and stress management components. Compliance to the diet, exercise and stress 
management components was high in the experimental group.  
After 12 months the experimental group showed a significant regression in arterial 
stenosis from 40% to 37.8%, while the control group showed a progression of arterial 
stenosis from 42.7% to 46.1%. The experimental group also showed significant reductions 
in chest pain frequency and severity. The experimental group showed a 24.3% reduction 
in TC and a 37.4% reduction in low density lipoproteins cholesterol (LDL). High density 
lipoprotein cholesterol (HDL) levels did not change significantly in either group. A strong 
dose relationship was demonstrated, with those participants in the experimental group 
who showed the strongest compliance with the program achieving the greatest benefits 
(Ornish et al., 1990a, 1990b). 
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A follow-up to this study showed that after 5 years, the experimental group which 
continued to be treated with a low-fat plant-based diet, exercise, stress management and 
group support, had decreased stenosis and improved myocardial perfusion compared to 
increased stenosis and reduced perfusion in the control group treated with standard 
antianginal therapy. Interestingly, compliance to treatment was significantly higher in the 
experimental group than in the control group (Gould et al., 1995; Ornish et al., 1998). 
Ornish established the Preventive Medicine Research Institute in Northern 
California and conducted the Multicentre Lifestyle Demonstration Project. For this study, 
333 patients who had angiographically documented coronary artery disease severe 
enough to warrant revascularisation were selected to participate in the study. Patients 
were offered the option of undertaking extensive lifestyle modification or the 
revascularisation procedure. A total of 194 patients agreed to undergo the lifestyle 
modification program, forming the experimental group, with the remaining 139 patients 
who underwent the revascularisation procedure forming the matched-control group. 
Staff were trained at various centres to offer the lifestyle intervention to the patients in 
the experimental group, who then met three times per week for 12 weeks and then once 
a week for the remaining nine months of the year-long study. Most sessions were four 
hours in duration and consisted of exercise, stress management techniques, group 
support and a group meal. The experimental group and control group were tracked for 
three years despite the fact that the intervention was only conducted for 12 months. 
After three years, patients in the experimental group experienced a significant 
decrease in LDL cholesterol levels (122.9 mg/dL to 101.7 mg/dL) and TC (202 mg/dL to 
183.4 mg/dL). HDL cholesterol levels initially decreased from 36.7 mg/dL at baseline to 
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32.8 mg/dL after three months, but increased to 42.2 mg/dL at three years. Triglyceride 
(TG) levels initially increased insignificantly from 229.8 mg/dL at baseline to 235.7 mg/dL 
after three months, but reduced to 200.8 mg/dL after three years which was not 
significant (p = 0.339). Mean body weight decreased from 187.3 lb at baseline to 170 lb 
after three months (p <0.001) and was 179.9 lb after three years which was still 
significantly less than baseline (p = 0.007).  
Participants in the experimental group also showed significant improvement in 
psychosocial quality-of-life factors (Dansinger, Gleason, Griffith, Selker, & Schaefer, 2005; 
Koertge et al., 2003), depression scores (Pischke et al., 2010) and endothelial function 
(Dod et al., 2010). This study suggested that individuals affected by heart disease could 
avoid revascularisation procedures for at least three years by making comprehensive 
lifestyle changes. Further, the lifestyle intervention showed a cost saving, estimated 
conservatively to have been $30,000 per participant in the experimental group in the first 
year (Ornish, 1998a, 2009a). Subsequently, other researchers have shown the benefits of 
the Ornish program in Rockford, Illinois (Aldana et al., 2004; Aldana et al., 2003), and 
across 2974 participants from 24 different hospital sites (Silberman et al., 2010). A 
limitation of the Ornish program is that it is very time intensive for the participant, at 
least 3 four hour sessions per week over a 12 week period, and requires intensive input 
from professional facilitators. 
Recent studies from the Preventive Medicine Research Institute have shown 
positive changes in prostate gene expression in men undergoing intensive lifestyle 
intervention (Dewell et al., 2007; Ornish, Magbanua, et al., 2008; Ornish et al., 2005) and 
even increased telomerase activity (Ornish, Lin, et al., 2008; Skordalakes, 2008). 
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Furthermore, these positive effects may  cause beneficial changes in gene expression in a 
relatively short period of time (Ornish, 2009b). 
Ornish is adamant that in order to achieve reversal of coronary artery disease,  
aggressive fat reductions to around 10% of calories is appropriate and necessary (Ornish, 
2004; Ornish & Brown, 1993; Ornish & Denke, 1994). Indeed, several of his studies have 
shown a “dose-response” relationship to dietary fat, cholesterol intake and changes in 
arterial stenosis (Ornish, 1998b). Importantly, this diet has been found to be nutritionally 
adequate (Dunn-Emke et al., 2005). 
Ornish has met with considerable opposition from the medical establishment 
throughout the course of his career. He recounts the story of someone saying to him at 
the end of a lecture in Texas “Hey, your research is really pioneering. You know how we 
can tell pioneers here in Texas? By the arrows in their back”(Ornish, 2002, p. 273). 
Encouragingly, the Ornish Program for Reversing Heart Disease was awarded Medicare 
claimability in the United States in 2012.   
 Esselstyn 
Caldwell Esselstyn, a surgeon from the Cleveland Clinic in Ohio, was frustrated 
with simply treating the symptoms of heart disease and not the underlying cause of the 
disease (Esselstyn, 2008). He became convinced from examining the literature that heart 
disease could be arrested and even reversed by dietary intervention if total serum 
cholesterol levels were reduced to 150 mg/dL or below and that such reductions could be 
achieved by consuming a very low-fat plant based diet. Accordingly, in 1985 he enrolled a 
group of 22 participants who had angiographically documented evidence of severe 
coronary heart disease in a five-year study to test his hypothesis that reversal was 
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possible. The participants were asked to adhere to a diet where less than 10% of calories 
were derived from fat and to avoid all animal products except for skimmed milk and non-
fat yoghurt. Participants were also asked, but not required, to moderate their 
consumption of alcohol and caffeine. Low dose statins were used for some participants. 
Daily food diaries were kept, by the participants, and reviewed by Esselstyn every two 
weeks, during a one-on-one consult with each participant. Additionally, all participants 
were invited to a group-based support session four times per year. 
Follow-up angiograms conducted five years later showed a mean 7% reduction in 
stenosis. The mean TC level of the participants which was 246 mg/dL at baseline was 
132.4 mg/dL after five years (range = 109.9 to 149.9 mg/dL), showing that all participants 
could achieve a TC under 150 mg/dL (Esselstyn, Ellis, Medendorp, & Crowe, 1995). 
Five participants dropped out of the study and resumed their pre-study dietary 
habits. These five participants all reported new cardiac events. Of the participants who 
remained in the study, no new infarctions or clinical evidence of progression of 
atherosclerotic lesions occurred (Esselstyn et al., 1995). 
After 12 years, 17 patients remained compliant to the eating pattern prescribed in 
the study and none showed progression of the disease, new coronary events, or required 
any interventional procedures which is remarkable considering that they had collectively 
experienced 49 coronary events in the eight years before the study commenced. The 
mean TC of the 17 participants after 12 years in the study was 145 mg/dL (Esselstyn, 
1999).  
A 20-year follow-up of this cohort showed continued adherence by the 
participants to the lifestyle and successful arresting of the cardiac disease (Esselstyn, 
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2008). Rather than being unwilling to make drastic lifestyle changes Esselstyn has found 
that the majority of patients “rejoice” once they have been given a comprehensive 
understanding of the cause of the disease and how to halt its progression (Esselstyn, 
2010). 
Esselstyn states emphatically that the conventional medical treatment of coronary 
heart disease is not effective or efficient: “Our stop-gap, device-driven approach isn’t 
working because it doesn’t address our toxic food environment which is responsible for 
our epidemic”(Esselstyn, 2001, p. 41). In an editorial, in the American Journal of 
Cardiology, Esselstyn likened the current medical and surgical treatment of coronary 
artery disease to the radical mastectomy. While admitting that in a few acute cases stents 
and coronary artery bypasses may be lifesaving, Esselstyn asserts that none of the current 
medical therapies treat the cause: the Western diet (Esselstyn, 2010). 
While the outcomes of Esselstyn’s research have shown that dietary changes may 
be able to reverse coronary artery disease, it is limited by the small sample size of only 17 
participants. A further limitation is the requirement for intensive and time-consuming 
input from the caring physician. Esselstyn advocates a five hour initial patient interview 
followed by hourly interviews every two weeks. 
 Dietary Approach to Stop Hypertension (DASH) 
The Dietary Approach to Stop Hypertension (DASH) examined the effectiveness, in 
459 adults, of eight weeks on the “DASH” diet compared to a control. The DASH diet was 
rich in fruits, vegetables, and low-fat dairy products and with reduced saturated and total 
fat. The control diet that was low in fruits, vegetables and dairy products with a fat 
concentration typical of the average diet in the United States. Body weight and sodium 
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intake were maintained at a constant levels. Significant reductions were found in both 
SBP and DBP for those on the intervention diet compared to the control. The authors 
concluded that a diet rich in fruits, vegetables and low-fat dairy foods can substantially 
lower blood pressure (Appel et al., 1997). 
The DASH intervention was further explored in the PREMIER clinical trial which 
randomly assigned 810 adults with elevated BP to three groups: an “advice only” control 
group, a treatment group that implemented the “established” traditional 
recommendations for losing weight, reducing sodium intake, increasing physical activity 
and limiting alcohol intake, or the “established plus DASH” group which involved the 
recommendations for the “established” group as well as the DASH diet. The trial found 
both the “established” and “established plus DASH” group to show significantly greater 
reductions in BP than the control group after six months, but the “established plus DASH” 
group achieved the best outcomes (Appel et al., 2003; Elmer et al., 2006). The DASH 
intervention has also been shown to be effective for weight loss (Hollis et al., 2008). 
On the basis of these and other trials, the American Heart Association 
recommends dietary modification to treat hypertension (Appel et al., 2006). 
 Diabetes Prevention Program (DPP) 
The Diabetes Prevention Program Research Group (DPP) conducted a large, 
randomised clinical trial involving adults who were at high risk of developing T2D to 
determine whether lifestyle intervention could delay the onset of T2D. In the study, 3234 
individuals with elevated FPG who were still non-diabetic (i.e. pre-diabetes) were 
randomly assigned either to a placebo, treatment with Metformin, or a lifestyle-
modification program with the goal of at least 7% weight loss and a minimum of 150 
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minutes of physical activity per week. The primary outcome measure was the incidence of 
individuals developing T2D. Lifestyle intervention was almost twice as effective as 
Metformin for preventing the development of established T2D with a 58% reduction in 
the incidence of T2D in the lifestyle intervention group compared to the placebo group 
(Knowler et al., 2002). The Metformin group had a 31% reduction in the development of 
T2D compared to the placebo control. The lifestyle intervention also significantly reduced 
risk factors of CVD including BP and TC, and increased HDL, when compared to the 
placebo or Metformin  groups (Ratner et al., 2005).  In a cost analysis of the lifestyle and 
Metformin  interventions, lifestyle was said to “dominate”, costing $1,100 per QALY 
gained as opposed to $31,300 per QALY for the Metformin  intervention (Herman et al., 
2005). 
Following the initial findings of this study, 88% of the original participants enrolled 
for a long-term follow-up study. Due to the findings of the initial study, all participants 
were offered group-implemented lifestyle intervention. After 10 years, the incidence of 
diabetes was reduced by 34% in those participants initially randomised to the lifestyle 
intervention group and 18% in the group initially randomised to the Metformin group, 
when compared to the placebo group. This study indicated that the benefits of lifestyle 
intervention can persist for at least 10 years (Knowler et al., 2009).  
The DPP-based curriculum has been used in numerous interventions including a 
number of community-based, professionally-delivered programs, and has shown 
significant weight loss and reduction in symptoms of MetS (Jackson, 2009). It has also 
been found to be effective in a pilot study involving a church-based delivery of the DPP 
curriculum in rural African-American churches (Davis-Smith et al., 2007).  
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 Look AHEAD Trail 
Look AHEAD (Action for Health and Diabetes) included 5,145 overweight or obese 
men and women with T2D, from 16 sites throughout the US, who were randomly 
assigned to either an Intensive Lifestyle Intervention or the usual care of Diabetes 
Support and Education. The Intensive Lifestyle Intervention group met weekly for six 
months and then three times per month for the next six months and were prescribed a 
calorie goal of 1,200-1,800 kcal/day with 30% of the energy from fat and a physical 
activity goal of 175 minutes/week of moderate-intensity activity (Wing et al., 2011). 
After four years, the Intensive Lifestyle Intervention group had better overall 
levels of glycaemic control, BP, HDL and TG than did the control group, resulting in 
lowered CVD risk (Wing & Look, 2010). The Intensive Lifestyle Intervention group was 
associated with a greater remission of T2D (Gregg et al., 2012)  and was also shown to 
have more improvement in erectile function than the control group (Wing et al., 2010). In 
the Intensive Lifestyle Intervention group attendance at appointments was better than 
80% and significant weight loss was achieved at one year across all categories of 
overweight and obese participants (Unick et al., 2011). 
Funding for this study was stopped by the National Institute of Health in October 
2012 as no difference in the number of cardiovascular events was noted between the two 
groups after 11 years (Despres & Poirier, 2013). It has been observed that several 
confounding factors could have contributed to the lack of difference in cardiac events 
between the two groups including: exclusion from the trial of participants unable to 
perform a maximal graded exercise test, the higher level of lipid-lowering and 
antihypertensive medication used in the control group, and the emphasis on calorie 
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restriction in the Intensive Lifestyle Intervention group (Despres & Poirier, 2013). The 
Intensive Lifestyle Intervention diet consisted of 30% of calories from fat and there was 
no emphasis on fruit and vegetables which are quite different from that advocated by 
studies discussed earlier which have been shown to alleviate and reverse CVD. Despite 
these limitations this study still showed significant advantages in the risk factors for MetS 
for the Intensive Lifestyle Intervention group. 
 Portfolio Diet 
The Portfolio Diet is a low-fat vegetarian diet with the addition of “portfolio” foods 
and nutrients purported to reduce blood cholesterol levels, including plant sterols, 
viscous fibre, soy protein and almonds. In one study, 46 individuals with elevated 
cholesterol levels, but otherwise healthy, were randomised into either: (1) a control diet 
which was a very low saturated fat diet, (2)the control diet plus statin medication, or (3) 
the control diet plus portfolio foods. Significant and comparable reductions were 
observed in LDL and C-reactive protein levels in both the group treated with statins and 
the portfolio diet (Jenkins, Kendall, Marchie, Faulkner, Josse, et al., 2005; D. J. Jenkins et 
al., 2003; Jenkins, Kendall, Marchie, Faulkner, Wong, et al., 2005). A larger study, 
involving 345 participants, showed the Portfolio Diet to be effective in reducing LDL when 
compared to a control at six-months follow-up (Braun, 2012; Jenkins et al., 2011).The 
Portfolio diet has also shown benefits for the treatment of T2D (David JA Jenkins et al., 
2003).   
 Other studies 
A number of smaller studies have also shown benefits of dietary and lifestyle 
interventions for the management of chronic diseases and MetS. These include the Daniel 
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Diet (Bloomer et al., 2010), the NORDIET study (Adamsson et al., 2011) and a study 
conducted by the Physicians Committee for Responsible Medicine (Barnard et al., 2009). 
The studies showed positive outcomes for a plant-based diet but were limited by small 
sample sizes. 
 The Daniel Diet, involved a 21-day plant-based diet devoid of animal products and 
preservatives but including fruits, vegetables, whole grains, legumes, nuts and seeds. The 
43 subjects enrolled in this study showed a 98.7% compliance with the diet and significant 
reductions in TC, LDL, HDL, SBP and DBP (Bloomer et al., 2010). Significant improvements 
in antioxidant status and oxidative stress markers were also observed (Bloomer, Kabir, 
Trepanowski, Canale, & Farney, 2011). This study was also limited by the short duration of 
only 21 days. 
The NORDIET study analysed the benefits of the more traditional Nordic eating 
pattern which was primarily plant-based with a low intake of meat products, dairy 
products, sweets, deserts and alcoholic beverages, compared to the current Scandinavian 
diet (Adamsson et al., 2012). A randomised controlled trial of 88 mildly 
hypercholesterolaemic participants were assigned to either a typical Scandinavian diet or 
the NORDIET. Those participants on the NORDIET showed improved lipid profile, insulin 
sensitively and BP (Adamsson et al., 2011). 
In a study that randomly assigned 99 participants to either an experimental group 
(n =49) assigned to total plant-based diet consisting of fruits, vegetables, grains and 
legumes with unrestricted portion size and energy intake (approximately 10% of energy 
from fat) and compared them with a control group (n = 50) assigned to the diet 
recommended by the 2003 American Diabetes Association, individuals consuming the 
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plant-based diet showed greater reductions in LDL, TC, and HbA1c through 74 weeks. 
When controlled for weight loss, the plant-based diet improved blood sugar control and 
plasma lipids more than the conventional diet (Barnard et al., 2009). The 74 weeks length 
of the study showed good long-term outcomes however it is limited by the relatively 
small sample size. 
 Exercise interventions 
Most of the above studies have focused primarily on diet, however, the second 
pillar of Lifestyle Medicine is exercise and numerous studies have shown that exercise is 
an important component of lifestyle interventions for the management of chronic 
diseases and MetS. It is well established that improving cardiovascular fitness is an 
essential component of a lifestyle intervention targeting T2D and BP (Totsikas et al., 
2011), reversing risk factors of MetS (Tjonna et al., 2008) and chronic inflammation 
(Mathur & Pedersen, 2008).  
While trials focusing on exercise are not as common as those focused on overall 
lifestyle modification, there are several studies that show the benefits of exercise in 
isolation. A Canadian study randomly assigned a group of 216 participants with T2D but 
not on insulin therapy, to one of four groups: aerobic training, resistance training, 
combined aerobics and resistance training or a control group. Both aerobic and resistance 
training improved glycaemic control, however, the greatest improvements were achieved 
when both aerobic and resistance training were combined (Sigal et al., 2007). A Finnish 
study which randomised 56 men with type I diabetes into an exercise program or control 
found that exercise training improved lipid profiles, especially HDL/LDL ratios (Laaksonen 
et al., 2000). A meta-analysis of 12 studies looking at the effect of exercise found that 
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aerobic exercise when combined with dietary intervention had a beneficial effect on the 
lipid profile of overweight and obese adults for TC, LDL, TC/HDL ratio and TG but not HDL, 
but was unable to identify the independent effect of exercise or diet on the lipid profile 
(Kelley, Kelley, Roberts, & Haskell, 2012). 
 Definition of Lifestyle Medicine 
The epidemiological studies reviewed earlier indicated that there was a link 
between lifestyle, MetS and chronic diseases such as T2D, CVD and some cancers. The 
interventional studies reviewed in this section show that for many individuals, it is 
possible to halt the progression of, and in some cases reverse the effects of, these 
diseases using aggressive lifestyle modification therapy. These studies, among others, 
have lead to the emergence of a discipline referred to as Lifestyle Medicine (Egger, Binns, 
& Rossner, 2009). It is a growing discipline that is now represented by the American 
College of Lifestyle Medicine (ACLM, 2013), the European Society of Lifestyle Medicine 
(ESLM, 2014) and the Australian Lifestyle Medicine Association (ALMA, 2013). Lifestyle 
Medicine has been defined as: 
“The application of environmental, behaviour, medical, and motivational 
principles to the management of lifestyle-related health problem in a clinical setting … 
including self-care and self-management.” (Egger et al., 2011) or simple as “the use of 
lifestyle interventions in the treatment and management of disease.” (ACLM, 2013).   
2.5.4 Limitations of Lifestyle Medicine 
While we have seen that lifestyle can be effective in combating Mets and 
associated chronic diseases, it should be noted that there are some limitations with 
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Lifestyle Medicine. These limitations include environmental issues, study design issues, 
measurement issues and the wide variety of recommended interventions. 
Lifestyle interventions tend to focus on the individual. The majority of lifestyle 
interventions attempt to get an individual to make significant changes in their lifestyle. 
While encouraging individuals to take responsibility for their own health can be seen as a 
positive move the downside of focusing on the individual is that for those individuals who 
for whatever reason struggle to comply with the intervention there can be a tendency to 
“shame and blame” (Larsen, 2012). Focusing on the individual rather than the 
environment and focusing on the individual level devoid of social context can in some 
cases lead to an ideology of individual responsibility and victim blaming (Korp, 2010). 
While individual lifestyle adaption is important there also needs to be a societal 
approach incorporating multiple segments of society for intervention including the 
transport and infrastructure sector, the media and the food sector (Swinburn & Egger, 
2002). Walls, Peeters, Proietto, and McNeil (2011) suggest that it is the obesogenic 
environment that is the primary cause of the exploding epidemic of obesity and this 
environment is best treated by enacting high-level policy and legislative changes to alter 
the environment rather than targeting individuals in lifestyle modification programs.  
Lifestyle interventions do not lend themselves well to randomised controlled trials 
(RCT) because lifestyle interventions usually affects several diseases and the people who 
undergo lifestyle interventions also have an impact on their immediate environment as a 
result of undergoing the intervention which makes it difficult to measure exactly what has 
changed (Rosén, 1989). Also, given that there is no placebo for lifestyle, it is not possible 
to use blind or double-blind methodology in RCTs of Lifestyle Medicine (Tarasuk & 
 56 
 
Brooker, 1997). When randomisation is attempted in studying lifestyle interventions it is 
usually done by randomly assigning participants to either a control group or to a lifestyle 
modification group however due to the prominence given to “healthy choices” promoted 
in the media it is not uncommon for members of the control group to make lifestyle 
changes independent of the research project which adds complications to the study 
(Merrill, Aldana, Greenlaw, Diehl, et al., 2008). 
In evaluating lifestyle interventions obtaining accurate measures of compliance 
can be difficult. While some of the earlier researchers in lifestyle interventions used 
captive populations, such as psychiatric institutions (Keys et al., 1959), where lifestyle 
variables could be more easily controlled such studies are no longer considered ethical. In 
a free living populations it is “notoriously” difficult to accurately measure dietary intake 
(Tarasuk & Brooker, 1997). This makes it very difficult to accurately measure compliance 
and also to identify exactly what is responsible for the changes that may have taken 
place. 
Another limitation in the analysis of Lifestyle Medicine interventions is the 
variability of the lifestyle interventions published in the literature (Yamaoka & Tango, 
2012). There is still a lot of discussion as to what is considered to be appropriate lifestyle 
intervention and the information which the public receives is often incomplete and 
confusing (Weinberg, 2004; Yancy, Westman, French, & Califf, 2003).  
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2.6 The Coronary Health Improvement Program (CHIP) 
While the epidemiological and interventional studies looking at Lifestyle Medicine 
showed promise, the evidence for the effectiveness of community-based lifestyle 
interventions, on the other hand, was initially disappointing. A meta-analysis of 
community-based lifestyle intervention programs delivered to free-living individuals 
concluded that these programs were only modestly effective, reducing cholesterol levels 
by about 3% (Tang et al., 1998). The editors of the British Medical Journal concluded that 
general population health education programs were of limited effectiveness in impacting 
lipid profile (Smith & Ebrahim, 1998). However, in the same year, Hans Diehl (1998) 
published a paper in the American Journal of Cardiology which showed significantly 
greater reductions in cholesterol levels and the risk factors of MetS through a community-
based lifestyle intervention than those published in the British Medical Journal meta-
analysis. This was the first peer-reviewed article relating to the Coronary Health 
Improvement Program (CHIP). 
2.6.1 The Coronary Health Improvement Program (CHIP): a description 
The CHIP program was developed in 1986 by Hans Diehl, after working for a 
period as the research director at the Pritikin Longevity Centre (Gidley, 2008). Diehl was 
impressed by the outcomes achieved by participants in the residential programs at the 
Pritikin Longevity Centre but recognised that the expense of the program was prohibitive 
to many individuals. Further, he observed that the lifestyle prescriptions the participants 
practiced in the residential program were more likely to be difficult to sustain when the 
participants returned to their home environment. In response, Diehl developed CHIP as a 
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community-based lifestyle intervention based on the lifestyle principles promoted at the 
Pritikin Longevity Centre. 
CHIP was developed as a 30-day lifestyle intervention that encouraged 
participants to move towards what is referred to as the “Optimal Diet”, engage in at least 
30 minutes a day of aerobic exercise, and reduce stress. The Optimal Diet is defined as a 
whole-food plant-based diet, emphasising fruits, grains, legumes and vegetables ad 
libitum, with little or no animal products. This eating pattern recommended that no more 
than 15% of calories be derived from fat, and a daily intake of less than 10 teaspoons of 
added sugar, 5 g of salt and 15 mg of cholesterol. The consumption of 2 to 2.5 L of water 
each day was also recommended (Englert, Diehl, & Greenlaw, 2004).  
The primary goals of CHIP were to substantially improve blood lipid levels, blood 
pressure and blood sugar levels. Secondary goals were to decrease weight, eliminate 
smoking, enhance daily exercise, improve stress coping strategies and decrease 
medication used for hypertension, diabetes and heart disease (Diehl, 1998).  
The program delivery was in 16 two hour sessions over a four or five week period, 
and focused on developing intelligent self-care through a clearer understanding of the 
nature and aetiology of CVD and T2D, their epidemiology and risk factors (Englert et al., 
2004).  
CHIP incorporated accountability measures with a “health screen” conducted at 
the beginning and at the end of the intervention. The health screen included 
measurement of height, weight, BP, lipid profile and FPG. The results of the health screen 
were used to motivate participants to maintain lifestyle changes and to improve health-
related self-efficacy through the intervention. Following the completion of the initial 
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intervention participants were encouraged to join a “CHIP Alumni” which meet on a 
monthly basis to provide ongoing support for the lifestyle changes initiated during the 
intervention. 
The first program was conducted in British Columbia, Canada in 1988. This 
program consisted of a risk assessment of factors pertaining to MetS which included a 
brief medical history, BP, height, weight, food frequency and fasting blood drawn to 
measure TC, LDL, HDL, TG and FPG. The program involved participants meeting four 
nights a week for four weeks. Following the four-week program a further health appraisal 
was conducted. The final health appraisal showed a decrease in BP, resting heart rate, TC, 
LDL, TG, FPG and body weight (Gidley, 2008). 
Following the success of the initial program numerous other programs were 
conducted in North America. In 1997 the program series was videotaped in front of a live 
audience at the Borgess Medical Center, Kalamazoo, Michigan, USA. A curriculum 
package was then built to support these recordings (Gidley, 2008). The results of CHIP 
programs in Kalamazoo, Michigan were published by Hans Diehl in 1998 in the American 
Journal of Cardiology (Diehl, 1998).  
In 1999 CHIP was established in Rockford, Illinois at the invitation of Dr. Roger 
Greenlaw, Medical Director of the Centre for Contemporary Medicine attached to the 
Swedish-American Hospital, after he read Diehls’ paper in the American Journal of 
Cardiology. Rockford has since become the business centre for CHIP (Diehl, 2003; Gidley, 
2008) where the program is delivered by health professionals. There have been a number 
of articles published on the results obtained from the Rockford programs (Aldana, 2001; 
Aldana et al., 2002; Aldana et al., 2008; Aldana, Greenlaw, Diehl, Salberg, Merrill, & 
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Ohmine, 2005; Aldana, Greenlaw, Diehl, Salberg, Merrill, Ohmine, et al., 2005; Aldana, 
Greenlaw, et al., 2006; Englert, Dieh, Greenlaw, & Aldana, 2012; Englert et al., 2004; 
Englert et al., 2007; Gidley, 2008; Merrill & Aldana, 2008, 2009; Merrill, Aldana, Greenlaw, 
& Diehl, 2008; Merrill, Aldana, Greenlaw, Diehl, & Salberg, 2007; Merrill, Aldana, 
Greenlaw, Diehl, et al., 2008; Merrill, Massey, et al., 2008; Merrill, Taylor, & Aldana, 2008; 
Thieszen et al., 2011). 
Subsequent to the success of the professional delivery of CHIP, Hans Diehl further 
developed CHIP so that it could be delivered by volunteers who were non-health 
professionals, to members of their local community, outside the confines of a recognised 
medical establishment. The program was made available to volunteer directors by 
supplying them with the recorded presentations on DVD, curriculum material for 
participants and with 2 days of training. To date approximately 50,000 people have 
completed the CHIP program in their communities under the guidance of volunteer 
directors. The researcher has been unable to find published research that has reported on 
the effectiveness of these volunteer directed programs. 
CHIP has been delivered using paid professional facilitators and using community 
volunteers as facilitators. In a number of cases the volunteer facilitators delivering CHIP 
were health professionals however as volunteers they donated their time to facilitate the 
CHIP programs. The literature published to date examining CHIP is based on programs 
using paid health professionals as facilitators. The purpose of this dissertation is to look at 
the effectiveness of CHIP interventions delivered by volunteers.  In this dissertation 
volunteer means that individual is not receiving payment or remuneration remuneration 
and donated their time when facilitating the CHIP programs.  
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2.6.2 Coronary Health Improvement Program publications 
To date there have been 17 peer review articles published examining the 
effectiveness of the CHIP lifestyle intervention when delivered by professional facilitators. 
The first paper, mentioned above, arose from data collected by Hans Diehl in a CHIP 
intervention he personally presented (Diehl, 1998). Another 15 papers examined the 
effectiveness of CHIP using professional facilitators in clinical, workplace or community 
settings in Rockford, Illinois. In 2012, a paper was published documenting the 
effectiveness of CHIP in treating patients with T2D in a workplace setting (Shurney et al., 
2012). An overview of these papers is presented below. 
 Diehl 
In 1998 Hans Diehl published an article in the American Journal of Cardiology 
presenting the results from his CHIP program (Diehl, 1998). This article reports on a 
hospital-based educational program (n=288) aimed at substantially decreasing the risk of 
coronary artery disease and associated diseases such as T2D, essential hypertension and 
obesity through appropriate lifestyle change, delivered in Kalamazoo, Michigan, USA. 
The pre-and post-health screen showed highly significant changes in lipid 
screen, blood pressure, weight and body mass index except for total-to-HDL cholesterol 
ratio and triglyceride levels in women as shown in Table 2-3. 
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Table 2-3 Change, by gender, in coronary disease risk factors over four weeks in CHIP participants from Diehl 1998 
  Means               
  Men (n = 123)  Women(n = 165) 
 Before SD After SD Change SD % Change  Before SD After SD Change SD % Change 
Age 54.9 11       54.6       
Weight (lb) 202.5 38 195.7 35 -6.80 3 -3.4  172.1 43 166.9 41 -5.2 4 -3.0 
BMI (kg/cm2) 29.4 5 28.4 5 -1.00 1 -3.4  29.8 7 28.9 7 -0.9 0 -3.0 
SBP (mmHg) 132.1 17 127.5 17 -4.60 16 -3.4  130.5 21 122.1 19 -8.3 14 -6.4 
DBP (mmHv) 83.7 10 77.8 9 -6.00 8 -7.1  78.7 10 73.2 9 -5.5 9 -7.0 
TC (mg/dL) 222.2 42 180.9 31 -41.30 33 -18.6  227.3 42 205.8 40 -21.6 28 -9.5 
HDL (mg/dL) 35.9 9 32 8 -3.80 4 -10.6  48.9 12 42.3 11 -6.6 7 -13.5 
TC /HDL 6.5 2 5.9 1 -0.60 1 -9.2  5 2 5.2 2 0.2 1 4.0 
LDL (mg/dL) 149.8 34 116.1 28 -31.90 26 -21.3  147.2 38 131.1 34 -16.3 26 -11.1 
TG (mg/dL) 190.5 116 163.2 84 -27.20 94 -14.3  159.4 87 164.1 101 4.8 77 3.0 
FPG (mg/dL) 111.3 34 99.5 23 -11.80 2 -10.6  104.3 42 97.7 45 -6.7 26 -6.4 
P <0.001 for all change except TG for women and total TC/HDL for women       
(Diehl, 1998) 
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Diehl (1998) also stratified the participants according to their risk level at 
program entry.  Table 2-4 shows the change in lipid profile and Table 2-5 show the change 
in FPG. In general, participants who were at the greatest risk experienced the greatest 
improvements. While triglycerides did not show a significant change in the aggregated 
data, participants with triglyceride levels greater than 200 mg/dL, particularly men, 
experienced significant reductions. Diehl (1998) identified that these reductions in 
triglyceride levels were not consistent with other studies that had shown increases in 
triglyceride levels with a very low-fat, high-carbohydrate diet. Some participants were 
able to decrease or discontinue antidiabetic, hypolipidaemic and antihypertensive 
medication as a result of the intervention. 
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Table 2-4 Changes in serum lipid levels degree of risk Diehl 1998 
Change in Serum Lipid Levels by Degree of Risk and Gender in 
Chip Participants 
   Change (%) 
   Men  Women 
Total cholesterol (mg/dL)    
 <200  -11  -7 
 200 - 239  -17  -9 
 240 - 279  -21  -11 
LDL cholesterol (mg/dL )%    
 <100  -19  -6 
 100 - 129  -15  -6 
 130-159  -17  -9 
 160-189  -22  -14 
Total/HDL cholesterol    
 4.0-5.9  +2*  ND 
 6.0-7.9  -11   
 >7.9  -15   
Triglycerides (mg/dL)    
 <100  +21  +25 
 100-199  0*  +9 
 200-299  -18  -11 
 300-399  -25  -14* 
 400-599  -39  -20* 
      
* p<0.05 change if not marked with asterisk 
ND = No Data     (Diehl, 1998) 
 
Table 2-5 Changes in FPG levels degree of risk Diehl 1998 
Change in Fasting Plasma Glucose Levels by Baseline Degree of 
Risk for Participants not Taking Antidiabetic  Agents 
Category n Baseline  After %Change 
<101 (mg/dL) 64 91 88 -3 
101-110(mg/dL) 59 105 97 -8 
111-139(mg/dL) 25 116 98 -18 
≥140*(mg/dL) 19 135 117 -18 
* or by history of Diabetes    
p<0.001 for all changes   
(Diehl, 1998) 
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The study demonstrated that measurable clinical improvements could occur 
within 30 days through a community-based lifestyle intervention at a relatively low cost 
compared to residential programs.  
Diehl acknowledged several limitations of the study including its short duration 
and lack of a control group, and urged for a randomised control trial to further explore 
the short and longer term effectiveness of the CHIP intervention.  
 Rockford based studies 
Following the publication of Diehl's 1998 article in the American Journal of 
Cardiology, Roger Greenlaw introduced CHIP to Rockford, Illinois. This project, working 
with the Swedish American Health System, aimed to enrol, within a seven-year period 
7000 residents over the age of 40 years which represented 10% of the Rockford 
population, in a CHIP intervention (Englert et al., 2004). To date, 15 papers have been 
published in peer-reviewed journals examining different cohorts from the Rockford 
project. Some of the interventions were delivered in workplace settings and others in the 
community. In all cases the programs were delivered by professional facilitators.  
Seven of the papers focused on the same cohort of 348 participants who were 
randomised to a treatment group who commenced a CHIP intervention immediately or a 
delay-control group who were stalled for six months before receiving the intervention. In 
all cases the intervention groups were shown to achieve significantly better outcomes 
than the control group (Aldana, Greenlaw, Diehl, Salberg, Merrill, & Ohmine, 2005; 
Aldana, Greenlaw, Diehl, Salberg, Merrill, Ohmine, et al., 2005; Aldana, Greenlaw, et al., 
2006). 
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Of the Rockford papers, seven provided an analysis of changes in biometric data 
from baseline to post-intervention (Aldana et al., 2002; Aldana et al., 2008; Aldana, 
Greenlaw, Diehl, Salberg, Merrill, & Ohmine, 2005; Aldana, Greenlaw, Diehl, Salberg, 
Merrill, Ohmine, et al., 2005; Englert et al., 2004; Englert et al., 2007; Merrill & Aldana, 
2008). A summary of these analyses is shown in Table 2-6. Several of these publications 
observed that the reductions in the biometrics were among the largest reported in the 
literature for a community-based lifestyle intervention  (Aldana et al., 2002); (Aldana, 
Greenlaw, Diehl, Salberg, Merrill, Ohmine, et al., 2005; Aldana, Greenlaw, et al., 2006).  
Significant improvements were observed in all biometrics, except for triglycerides 
in three of the papers (Aldana et al., 2008; Aldana, Greenlaw, Diehl, Salberg, Merrill, 
Ohmine, et al., 2005; Englert et al., 2007). These studies showed that participants in the 
highest risk category at baseline achieved the greatest results (Aldana et al., 2002; Aldana 
et al., 2008; Englert et al., 2004; Englert et al., 2007). Further, males were observed to 
achieve significantly better outcomes through the program than women in all biometric 
measures except for fasting plasma glucose (Aldana et al., 2002), a pattern also observed 
by Diehl (1998). Gender differences were particularly noteworthy for weight reduction, 
TC and TG. Several studies also reported significant reductions in medication usage 
(Aldana, Greenlaw, Diehl, Salberg, Merrill, Ohmine, et al., 2005; Diehl, 1998) by the end of 
the CHIP intervention. Merrill, Massey, et al. (2008) found that CHIP did not have a 
significant impact on C-reactive protein levels. 
One initially concerning observation of these studies was a significant drop in HDL 
levels. While high levels of HDL are considered cardioprotective (Navab et al., 2006) , it 
was suggested that low HDL levels are only a problem in the context of high TC and LDL 
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levels, as typically found in Western society. In societies where TC and LDL levels are low, 
such as the Tarahumara Indians in Mexico, HDL levels are very low but there is virtually no 
CVD (Englert et al., 2004). Hence, it was asserted in these studies that the lowered HDL 
observed as a result of the CHIP intervention was not of concern due to the greater 
reduction in TC and LDL. The slight increase in TG observed in those participants with low 
baseline TG, was also not considered clinically significant (Diehl, 1998; Englert et al., 
2004). 
A number of the papers showed that the CHIP interventions had a positive impact 
on sleep, stress disorders, depression and mental health (Merrill, Aldana, Greenlaw, & 
Diehl, 2008; Merrill, Taylor, et al., 2008; Thieszen et al., 2011). It was also found that 
overall health and functional status improved for participants in the CHIP intervention 
(Merrill & Aldana, 2009). 
Several studies followed the CHIP participants beyond the 30-day intervention. A 6 
month follow up of 348 participants showed that continued improvement in weight, BMI, 
systolic and diastolic blood pressures and fasting plasma glucose levels were recorded 
after six months, but there was decay in the lipid measures (Aldana, Greenlaw, et al., 
2006). An 18 month follow-up of this cohort showed that improvements in nutrition and 
physical activity health behaviours were still significant at 18 months although there was 
some decay following the end of the intervention (Merrill, Aldana, Greenlaw, Diehl, et al., 
2008). A 12 month follow-up, of 1,712 participants, showed significant improvement for 
TC, HDL, LDL, TG, FPG, BMI and BP after 4 weeks and 12 month however 49% of the 
participants were lost to follow-up at 12 months (Merrill & Aldana, 2008). 
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Table 2-6 Summary of percentage mean change baseline vs post-intervention for various CHIP programs reported in literature 
Percentage Change in Biometrics    
Reference Diehl 1998  
Aldana 
2002  Englert 2004  
Adana 
2005 
A  
Adana 
2005 
B  Englert 2007  
Aldana 
2008  Merrill 2008    
Gender Male Female  Mixed  Male Female  Mixed  Mixed  Male Female  Mixed  *     
n 123 165  442  88 164  64  167  400 649  714  862 841    
Age 54.9 54.6  52.1  57 52  46.1  50.4  57.00 52.00  ND  55.2 55.2    
Weight -3.36 -3.02  -4.43  -3.79 -3.62  -3.25  -3.67  -4.42 -3.59  -4.01  ND ND    
BMI 3.40 -3.02  -4.38  -3.96 -3.72  -3.43  ND  -3.13 -3.03  -3.91  -3.85 -3.44    
BP systolic -3.48 -6.36  -5.41  -2.91 -2.14  -5.69  -5.56  -6.38 -5.67  -4.76  -4.64 -4.83    
BP diastolic -7.17 -6.99  -6.02  -3.63 -2.71  -6.31  -6.42  -5.81 -5.95  -4.02  -4.44 -5.08    
Total cholesterol -18.59 -9.50  -13.20  -14.27 -7.96  -8.02  -7.52  -16.00 -9.30  -10.89  -11.63 -10.19    
HDL -10.58 -13.50  -13.31  -10.20 -10.38  -6.77  -7.54  ND ND  -14.19  -11.84 -11.81    
LDL -21.30 -11.07  -13.66  -15.66 -7.97  -9.58  -9.28  -18.55 -9.38  -12.22  -12.03 -10.9    
Triglycerides -14.28 3.01  -9.76  -22.37 -4.67  -2.53  2.63  -10.39 -1.96  -7.39  -9.27 -7.434    
Glucose -10.60 -6.42  -5.06  -8.53 -2.33  -4.00  -3.99  -7.02 -4.55  -6.52  -4.40 -5.301    
                        
                        
* Merrill gives data for two groups: the first group is those who were followed up after 12 months the second group is those who were lost to follow-up 12 months  
 All figures are data after four weeks                  
                        
Diehl 1998 p< 0.001 except for female triglycerides and female Cholesterol/HDL ratio            
Merrill 2008 p< 0.0001 for all factors                    
Aldana 2005 A p< 0.0001 for weight and BMI, p< 0.02 for systolic and diastolic BP, p< 0.005 for total cholesterol HDL LDL and p< 0.05 for triglycerides and FPG 
Aldan 2005 B p< 0.0001 for all factors except for FPG = 0.003 and triglycerides 0.9513        
Aldana 2008 p< 0.001 except for  triglycerides=0.0284                 
Englert 2004 p<0.05 for Female blood pressures and female  triglycerides, p<0.01 for male and female glucose and female HDL, all other factors p<0.001   
Englert 2007 p<0.0001 except for female triglycerides where p=0.113               
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 Other CHIP publications 
Recently, Shurney et al. (2012) enrolled 28 employees of Vanderbilt University 
with diagnosed T2D in a CHIP intervention delivered by health professionals. Participants’ 
biometrics and health care expenditure were tracked for 26 weeks. Positive changes were 
observed in HBA1C, TC, LDL, HDL and TG.  Approximately one quarter of the participants 
were able to eliminate one or more of their medications by the 26 week follow-up. 
Significant cost reductions were reported in the study with a total net saving of $67,582 
within the initial six months for the 28 employees. Significant improvements were also 
recorded in the participants’ Well-Being Indices. 
The authors conclude that the CHIP intervention can improve well-being and 
health outcomes for individuals suffering with T2D and is capable of generating 
measurable savings with a meaningful return-on-investment within a relatively short time 
period of six months. 
 Summary of CHIP publications 
These 17 published papers clearly showed that using paid health professionals as 
facilitators in workplace and community settings, the CHIP intervention can produce 
significant reductions in the risk factors associated with MetS. Further, the benefits of 
these reductions can still be seen through 18 months (Merrill, Aldana, Greenlaw, Diehl, et 
al., 2008). These papers also showed that CHIP can deliver significant improvements in 
quality of life, and psychological factors such as stress, sleep disorders and depression. 
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2.7 Volunteer delivery  
The objective of this dissertation was to explore the effectiveness of the CHIP 
lifestyle intervention when delivered by volunteer facilitators in a community setting. In 
this dissertation the term volunteer is taken to mean a person who does not receive 
payment for the service they are delivering, the volunteer has donated his or her time. As 
demonstrated above, there is substantial evidence showing the effectiveness of lifestyle 
interventions, including CHIP, using professional facilitation. It has been suggested that 
more well-trained professionals achieve the best health care outcomes (Alter, 2007). 
Volunteers, in most cases, do not have the same training or experience as trained 
healthcare professional and because remuneration cannot be used as an inducement it 
can be more difficult to motivate and control volunteers. While these limitations affect 
volunteers, there is evidence in the literature that adequately resourced volunteers have 
been effectively utilised in the delivery of community programs.  
Volunteers from Faith in Action groups were successfully used to deliver the 
Strong for Life program to elderly people and it was found that these trained volunteers 
could safely deliver programs to a wider community group of frail older persons (Etkin, 
Prohaska, Harris, Latham, & Jette, 2006). Further, Schneider et al (2007) concluded that 
volunteers can successfully deliver health promotion programs which allows for wider 
program dissemination than is possible using only professional leaders. 
An obvious advantage of utilising volunteer facilitators is the cost saving when 
compared to utilising paid facilitators; however, there may be other advantages in the 
utilisation of volunteer community-based facilitators. In order for a community program 
to be successful, at least one person must champion the program. Indeed, a passionate 
  71 
volunteer can incite his peers to action (Kong, 1997). Volunteers have relationships with 
individuals in the community and these relationships can be utilised to encourage 
members of that community to be proactive about their health and to make and sustain 
positive lifestyle changes (Kong, 1997).  
While the ability to utilise volunteers depends on the availability and commitment 
of the volunteers, the utilisation of volunteers maximises the use of social and human 
capital. Yuasa et al (2007) observe that if a significant initial investment is made in social 
and human capital, other forms of capital, such as financial, physical and natural, are not 
always necessary. This may mean that the utilisation of voluntary facilitators can 
dramatically increase the scope and efficacy of lifestyle modification programs while 
keeping costs to a minimum.  
In order to explore the effectiveness of volunteers in the delivery of a lifestyle 
modification program targeting the risk factors associated with the Metabolic Syndrome, 
this dissertation analyses the results achieved by 178 volunteer-facilitated, community-
based CHIP interventions involving 5070 participants between 2006 and 2009 in multiple 
locations in the United States and Canada. 
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2.8 Conclusion 
There is abundant evidence from the literature that lifestyle intervention can 
effectively reduce the risk factors associated with MetS and improve chronic disease 
status. The CHIP lifestyle intervention has been shown to be effective when delivered by 
professional facilitators, but its effectiveness when delivered by volunteers has not been 
examined. Further, there is a need for an understanding of how participant 
demographics, including age, gender and marital status, influence their responsiveness to 
lifestyle interventions. Presently, there is little work published in this area, yet this will be 
critical to the future designing of lifestyle interventions to be most efficacious. 
The remainder of this dissertation examines the effectiveness of volunteer-
delivered, community-based CHIP interventions in over 5000 CHIP participants and 
explores factors that influence the outcomes of these CHIP interventions.  
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Chapter 3 Methodology 
 
3.1 Introduction 
In this chapter the methodology used to address the research questions is 
presented. The study design is defined. An overview of the CHIP lifestyle intervention is 
presented, and the data collection and collation process is explained. The author’s 
experience with, and contribution to, the CHIP intervention, as well as his role in the data 
collection process is also outlined. The measures analysed in this study are explained and 
an overview of the statistical analyses is presented.  
3.2 Study Design 
The study design that forms the basis of this dissertation was a pre-test post-test 
cohort design involving 5070 individuals who participated in one of 178 community-based 
CHIP interventions delivered by volunteers between 2006 to 2009 in the United States 
and Canada 
3.3 Research Questions 
The two research questions that form the basis of this dissertation are: 
1. How effective is the Coronary Health Improvement Program (CHIP) 
lifestyle intervention for reducing the selected risk factors of chronic 
disease that constitute the Metabolic Syndrome, when delivered by 
volunteers to free-living participants in their community? 
 
  74 
2. What is the impact of selected participant factors, including age, 
gender, marital status, religious affiliation, previous history, family 
history and body weight on the outcomes achieved by participants in 
the CHIP intervention? 
 
3.4 The CHIP intervention 
To answer these research questions question a large cohort (n = 5070) of 
individuals who participated in 178, volunteer-delivered, community-based, CHIP 
interventions between 2006 and 2009 in the United States of America and Canada has 
been analysed.  
The CHIP interventions which provided the participants for this study were 
delivered by community based volunteer directors. In all cases the volunteer facilitators 
donated their time to conduct the CHIP interventions analysed in this dissertation. These 
volunteer directors were not required to be health professionals, although some were, 
and underwent a two-day training workshop at the cost of $250 per team of 3, during 
which they received instruction and detailed manuals regarding the programs philosophy, 
content and method. They were then provided with a comprehensive resource package 
that included all the materials required to deliver the program.  
The majority of these CHIP interventions were conducted through local Seventh-
day Adventist churches. Although detailed data is not available on how participants were 
recruited, in general, participants were recruited from the local community by word of 
mouth, advertising in local print and radio media and some cases physician referral. 
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Participants were charged to participate in the CHIP intervention and the normal fee was 
$250 per participant. 
The CHIP intervention begins with an initial health appraisal which is then 
followed by an intensive education program consisting of 16 two and a half hour sessions 
delivered over a four or five week period. The focus is on developing a greater measure of 
intelligent self-care involving a clearer understanding of the nature and aetiology of CVD 
and T2D, their epidemiology and risk factors. The potential for prevention, arrest and 
reversal through better lifestyle choices in the areas of smoking, sedentary living, diet and 
stress management is outlined and participants are shown how to implement positive 
lifestyle change. 
 
The CHIP curriculum includes the following topics:  
 modern medicine its accomplishments and limitations 
 atherosclerosis 
 chronic disease risk factors 
 smoking 
 exercise 
 dietary fibre 
 cholesterol 
 the optimal diet 
 obesity 
 diabetes 
 hypertension 
 hyperlipidaemia 
 lifestyle and health 
 behavioural change 
 self-worth  
(Englert et al., 2004).  
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Each session typically includes a 60 minute DVD presentation, a cooking 
demonstration, group discussion and encouragement to exercise. Also included is a 
shopping tour. 
At the conclusion of the program a post-intervention health appraisal is 
conducted. Following a graduation ceremony participants are encouraged to join a CHIP 
Alumnus, which meets on a monthly basis to encourage the preservation of lifestyle 
changes. 
The CHIP program encourages participants to move towards what is referred to as 
the Optimal Diet which is a whole-food, plant-based diet with little or no animal products. 
The recommendation is that on a daily basis: less than 15-20% of calories be derived from 
fat; less than 10 teaspoons of added sugar, 5 grams of salt and 15 mg of cholesterol be 
ingested; and 2 to 2.5 L of water be consumed (Diehl & Ludington, 2005, p. 197; Englert et 
al., 2004). CHIP recommends at least 30 minutes of moderate intensity aerobic exercise 
or 10,000 steps a day. The program also recommends the cessation of smoking and the 
implementation of strategies to reduce stress. 
Diehl states that the primary goals of this comprehensive educational program are 
to substantially improve blood lipid levels, blood pressure and blood sugar levels. 
Secondary goals are to decrease weight, eliminate smoking, enhanced daily exercise, 
adopted better stress-coping strategies and decrease medication for hypertension, 
diabetes and heart disease (1998). 
3.5 Theoretical framework of CHIP: A Theory of Planned Behaviour 
CHIP builds off a number of behaviour change strategies but leans heavily on the 
Theory of Planned Behaviour (TPB). TPB was first proposed by Ajzen in 1985 as an 
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extension of the Theory of Reasoned Action published by Ajzen and Fishbein in 1975 
(Ajzen, 1985).  
Ajzen’s theory was developed in an attempt to improve health education 
(Nutbeam, 2000) and has become one of the most frequently cited and influential models 
for the prediction of human behaviour (Ajzen, 2011). TPB has been successfully used to 
predict and explain a wide range of health behaviours and intentions including: smoking, 
drinking, health services utilization, breast-feeding and substance abuse (Glanz, Rimer, & 
Viswanath, 2008, p. 68). 
The TPB is based on several assumptions including the assumption that the 
majority of an individual’s everyday behaviours are under volitional control. The theory 
also assumes that most human behaviour is goal directed (Ajzen, 1985).  
A schematic of the TPB is shown in Figure 2. As illustrated, the TPB suggests that 
behaviours, or actions, are premeditated by intentions for the behaviour. TPB suggests 
that between these beliefs and behaviours is the intentions that are formed by the 
individual to perform a given behaviour at a specific time and place (Ajzen, 2011). In 
essence TPB views an individuals’ beliefs as predictors of their intentions or motivation 
which in turn predict their behaviour or actions. The theory acknowledges, however, that 
not all intentions are carried out. 
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Figure 2 Theory of Planned Behaviour 
 
The theory suggests that there are three determinants of an individual’s 
intentions: 
1. Attitude - the individual’s positive or negative evaluation of the value of 
performing the behaviour. Typically a person would ask questions like: “What will be the 
result of performing this behaviour?” and “What is the consequence of performing this 
behaviour?” Driving a person’s attitude are beliefs associated with that particular attitude 
which Ajzen refers to as behavioural beliefs. The stronger a person’s attitude, the more 
likely that attitude is to drive intentions and ultimately drive behaviour (Ajzen, 2001). 
2. Subjective Norms - the individuals’ perception of the social pressure to 
perform or not perform a behaviour. It is in this category that an individual assesses the 
expectation of friends, family and society in performing a particular behaviour. Typically 
individuals would ask themselves: “Do the people in my sphere of influence approve, or 
disapprove of this behaviour?” Ajzen suggest that decisions are not always based just on 
an individual’s judgement but can be significantly influenced by the judgement of 
significant others. The beliefs associated with subjective norms are called normative 
beliefs. In developing normative beliefs an individual makes a determination as to 
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whether social pressures from significant others or peers are valid. If the individual 
believes that the social pressures are valid, they are more likely to adopt the opinions of 
those around them. 
3.  Perceived Behavioural Control - the individuals’ perception as to whether 
or not they will succeed or fail in the behaviour. Ajzen divides perceived behavioural 
control into two components: how much control a person has over the behaviour and 
how confident a person feels about being able to perform a particular behaviour. An 
individual’s behaviour is strongly influenced by their confidence in their ability to perform 
a task, also referred to as self-efficacy. The person who is confident in their ability to 
master a skill is more like to succeed than one who doubts their ability to succeed, even if 
they have an equal capability of learning (Ajzen, 1991). The beliefs that influence 
perceived behavioural control are called control beliefs. These behavioural beliefs 
determine whether or not an individual believes that they are able to successfully 
perform a task. 
In summary, according to TPB, an individual’s beliefs drive their attitudes, 
subjective norms and perceived behavioural control which in turn predicts their 
intentions and subsequent behaviours. 
Ajzen’s theory has been criticised for not taking sufficient account of affective and 
emotional processes that are known to strongly influence intentions and behaviours 
(Armitage & Conner, 2001; Rapaport & Orbell, 2000). Ajzen (2011) has responded by 
suggesting that affect and emotions serve as background factors that influence beliefs 
which ultimately drive intentions and thus behaviour. 
  80 
While CHIP is influenced by a number of well-established health behaviour 
theories including the Health-Belief Model (Rosenstock, 1974), the Social-Cognitive theory 
(Bandura, 2001), the Transtheoretical Model (also known as the Stages of Change) 
(Prochaska, Norcross, & DiClemente, 2013), the TPB is the most important theoretical 
framework for CHIP. CHIP deliberately impacts the three sets of beliefs, as proposed by 
TPB, that impact intentions and thus action in order to encourage and enable the 
participants to make positive changes to their lifestyle. 
3.6 Data collection 
The CHIP intervention incorporates a health assessment at baseline and the 
second health assessment postintervention. This health assessment includes measuring 
of height weight, blood pressure and blood samples taken to measure TC, HDL, LDL, TG 
and FPG. Where possible trained health professionals, normally nurses, were used for the 
measuring of blood pressure and blood samples were collected by trained phlebotomists 
from the local pathology laboratory services.  
Once the results from the health assessment have been received by the volunteer 
director they are entered into a Microsoft Access™ based software package called the 
CHIP Assistant, which was provided to all directors of the CHIP interventions. The CHIP 
Assistant software package is used for the purpose of generating a basic report which is 
given to the CHIP participants to provide feedback on their health status, particularly in 
relation to lipid levels, blood pressure and BMI, compared to optimal levels. 
The CHIP Assistant software package has provision for the data entered by the 
facilitators to be forwarded to a central collection point, managed by Dr John Gobble, as 
Microsoft Excel™ spreadsheets. The data thus collected records the name of the director, 
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the location, date and duration of the CHIP program but all participant data is 
anonymous. 
3.7 The authors’ involvement with CHIP 
From January 2006 through December 2011, Paul Rankin (the author), was 
employed as the Health Director for the New Zealand Pacific Union Conference of the 
Seventh-day Adventist Church. As part of this role he oversaw the introduction and 
rollout of the CHIP program in New Zealand. During this period, the author facilitated the 
training of over 150 volunteer CHIP directors leading to over 100 CHIP interventions being 
offered in New Zealand, involving over 1000 participants. The author was responsible for 
the collection of the participant’s biometric data from the pre-and post-intervention 
health appraisals.  
The author supervised an extensive rewrite and reprint of the books and materials 
provided to the CHIP participants in New Zealand and Australia. This rewrite was 
necessary to contextualise the program into the Australasian context including utilising 
units of measurement that are familiar to Australian and New Zealand audiences, the 
adaptation of recipes for the Australasian market and localisation of spelling and 
grammar. He also supervised the production of an Australasian CHIP recipe book "Simple, 
Tasty, Good" providing CHIP recipes that taste good and use ingredients that are readily 
available in New Zealand supermarkets. 
In 2009, the author was interested to determine the effectiveness of CHIP as 
delivered by volunteers and decided to undertake Ph.D. research to address this issue. His 
initial intention was to use the data that he had collected from New Zealand CHIP 
programs. He contacted Dr John Gobble to request any additional New Zealand data that 
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was available. 
On requesting the data for New Zealand the author was informed that there was 
also a large amount of data from American participants, in the community-based, 
volunteer delivered CHIP interventions which has not been analysed. Following 
discussions with the custodians of this data, Dr Hans Diehl, Dr John Gobble, Dena Guthrie 
and Harold Burden an agreement was entered into to make this data available for use in 
this research project. The use of these data were provided to a large extent in recognition 
of the extensive contribution by the author to the development of the CHIP program in 
New Zealand and the substantial contribution he had made to the database.  
While this dissertation focuses on the North American data set, the author has 
been involved in the publication of two papers examining the New Zealand data (Kent, 
Morton, Hurlow, Rankin, & Hanna, 2013; Morton et al., 2013). 
3.8 Ethics consent 
All participants in this study signed a form entitled “Request to Participate in the 
Coronary Health Improvement Program” at the time of enrolling in CHIP. This form 
included the following paragraph “I agree to my results being included as part of group 
analyses and publication of the program’s results and understand that my particular 
results will not be disclosed to anyone without my express permission.” Confidentiality of 
the participant data were protected by providing only anonymous data to the 
researchers. These data were only accessible to the research team and only aggregated 
data were presented in publications and public presentations. 
Appropriate application forms were completed and submitted to the Avondale 
College of Higher Education Human Research Ethics Committee for permission to analyse 
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and publish this data in October 2009. Based on the consent form completed by the 
participants before the collection of this data, Avondale College Human Research Ethics 
Committee, on Monday, January 25, 2010, gave retrospective ethics approval for the use 
of this data (Approval number 20:10:07). 
3.9 Collation of data  
The extent of this data were some 7000 datasets collected since 2007 in North 
America, Australia and New Zealand from around 300 different CHIP programs. Because 
of the large size of the data set and to get a more homogenous sample a decision was 
made to concentrate on the North American data for this dissertation. The New Zealand 
and Australian data from this data set and the New Zealand data collected by Paul Rankin 
has been analysed independent of this research project and the results of the analysis 
were published in the New Zealand Medical Journal in February 2013 (Morton et al., 
2013). 
The data consisted of 183 separate Microsoft Excel™ spreadsheets containing 
5581 datasets. As the data had been produced by different versions of the CHIP Assistant 
software the spreadsheets were in different formats so they had to be converted into a 
single format. The separate spreadsheets were combined into a single spreadsheet with 
all of the data appropriately aligned and formatted. 
The data had been collected in both the United States and in Canada. The US data 
were in American units with TC, HDL, LDL, TG and FPG being in milligrams per decilitre 
(mg/dL) and height being in feet and inches with weight being in pounds while the 
Canadian data were in international units with TC, HDL, LDL, TG and FPG being in 
millimoles per litre (mmol/L), height in metres and weight in kilograms. Because the 
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majority of the data were from the US and the aim was to publish in US journals all of the 
Canadian data were converted to American units.  
Once the data had been collated and converted into an appropriate format it was 
entered into the PASW Statistics 18 (for Microsoft Windows™) version of SPSS.  
3.10 Measures analysed  
The CHIP program commences with a health appraisal. Participants are asked to 
present themselves having fasted for at least eight hours, and a blood sample is taken and 
analysed for cholesterol levels (TC, HDL, LDL and TG) and FPG levels. This blood was 
collected by professional phlebotomists and analysed by professional laboratories. 
Participants’ height, weight and blood pressure were measured by the trained volunteers. 
Participants were then requested to complete a lifestyle evaluation form which includes 
details of self-reported, exercise habits, past exposure to smoking, obesity, diabetes, high 
blood pressure and cardiac events as well as age, gender and religious affiliation. The 
lifestyle evaluation form also collects information pertaining to family histories of 
diabetes, cancer and coronary events. The health appraisal is performed again at the 
conclusion of the intervention.  
The various measures, analysed in this dissertation, from this data are: 
3.10.1 Body Mass Index (BMI) 
BMI was used as a measure of obesity in this study as data were available on 
height and weight but no data were collected on waist circumference (WC) or on hip 
weight ratio (HWR). BMI is determined by the formula (weight in kilograms/height in 
metres2) where (BMI units = kg/m2). As imperial units were recorded for this dataset the 
BMI calculation was (weight in pounds/height in inches2 X 703). Height and weight were 
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measured at the baseline and post-intervention health screens which were performed at 
the same time of day. Weight and height was measured with shoes removed and 
participants were asked to wear the same clothing for both health screens. The same 
instruments were used at baseline and post-intervention.  
Participants were categorised by BMI at program entry according to the WHO BMI 
categories of underweight (< 18.5), normal (18.5 – 24.99), overweight (25 - 29.99), obese I 
(30 - 34.99), obese II (35 - 39.99) and obese III (> 40) (WHO, 2000).  
BMI has been routinely used in clinical and public health practice to identify 
individuals and populations at risk of developing CVD and T2D for decades (Taylor et al., 
2010). However in recent times BMI has been criticised as a measure of risk because it 
does not specifically identify abdominal adiposity (Mason, Craig, & Katzmarzyk, 2008). 
Waist circumference (WC) and waist-hip ratio (WHR) have been suggested as alternative 
measures to BMI with some studies finding these measures superior to BMI for predicting 
the onset of CVD andT2D (Dobbelsteyn, Joffres, MacLean, & Flowerdew, 2001; Yusuf et 
al., 2004). The Harmonized definition of MetS uses waist circumference to measure 
obesity (Alberti et al., 2009).   
However Dalton et al. (2003) suggest that WC, BMI and WHR identify different 
portions of the population, as measures of both prevalence of obesity and CVD risk 
factors and Freiberg et al. (2008) found that BMI and WC were nearly identical in 
predicting the onset of the first cardiovascular event. Weight or BMI has been found to be 
correlated to waist circumference with a reduction of 1 cm in waist circumference being 
equivalent to approximately ¾ kilogram weight loss (Egger & Dobson, 2000). An analysis 
of 14,924 participants in the Third National Health and Nutrition Examination Survey 
  86 
found that waist circumference cut-off points did not provide any greater prediction of 
health risk beyond that already predicted by BMI (Janssen, Katzmarzyk, & Ross, 2002). 
After examining the data from four large cohort studies to compare the association of 
BMI, WC and WHR for identifying persons at risk of future disease, Taylor et al. (2010) 
conclude that no strong evidence supports replacing BMI in clinical or public health 
practice with other adiposity measures. 
The IDF definition of MetS stated that if the BMI was > 30 then central obesity 
could be assumed (K.G. Alberti et al., 2006). 
3.10.2 Lipid Profile 
Participants lipid profile was measured from fasting (> 8 hours) blood samples. 
Blood samples were collected by trained phlebotomists and analysed by local pathology 
laboratories to determine TC, HDL, LDL and TG. Units used for the lipid profile was 
milligrams per decilitre (mg/dL). 
LDL levels are routinely calculated using the Friedewald formula which is LDL = TC - 
HDL - (TG/5) provided that TG levels are not greater than 400 mg/dL (Friedewald, Levy, & 
Fredrickson, 1972; National Cholesterol Education Program, 2002). 
The National Cholesterol Education Program Adult Treatment Panel III 
classification system (National Cholesterol Education Program, 2002) was used to 
categorize LDL, HDL and TG (Table 3-1).  
The Framingham Risk Classification (Wilson et al., 1998) was used for 
stratification of the TC data, because it includes 5 categories compared to only 3 in the 
National Cholesterol Education Program Adult Treatment Panel III classification system 
and thus allowing a more detailed analysis of the effect of the intervention on the highest 
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risk participants (Table 3-1).  
Table 3-1 Lipid profile categories 
3.10.3 Fasting Plasma Glucose (FPG) 
FPG levels were measured using the same blood samples collected for the lipid 
profile. FPG levels were categorised according to National Cholesterol Education Program 
Adult Treatment Panel III classification system. These categories were < 110, 110-125, > 
125 and the units used were milligrams per decilitre (mg/dL) (National Cholesterol 
Education Program, 2002). 
3.10.4 Blood Pressure 
Systolic and diastolic blood pressures were measured using Sphygmomanometry 
and reported as millimetres of mercury (mmHg). BP was categorised according to the risk 
factor categories outlined by the National Cholesterol Education Program Adult 
Treatment Panel III classification system. For SBP the categories were ≤120, 121-139, 140-
160 and >160. For DBP the categories were ≤80, 81-89, 90-100 and >100. (National 
Cholesterol Education Program, 2002). 
TC categories  LDL categories HDL categories TG categories 
<160 <100 <40 <100 
160 – 199 100 – 129 42 – 60 100 – 199 
200 – 239 130 – 159 >60 200 – 500 
240 – 280 160 – 190  >500 
>280 >190   
All units mg/dL 
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There are several challenges with the measurement of blood pressure. Firstly 
blood pressure is notoriously labile and can change simply because it has been measured, 
a phenomenon referred to as white coat syndrome (Den Hond, Celis, Vandenhoven, 
O'Brien, & Staessen, 2003; Owens, Atkins, & O’Brien, 1999). Secondly, the indirect 
measurement of blood pressure using an occluding cuffs, stethoscope and manometer 
(Sphygmomanometry) has many possible causes of error and inaccuracy (Perloff et al., 
1993). However it has been found that trained lay people can take accurate blood 
pressure readings (Kong, 1997). In this study the use of trained personnel, normally 
nurses, for the measurement of blood pressure and the large sample size, (4,560 for 
systolic blood pressure and 4,552 for diastolic blood pressure) should ameliorate some of 
the measurement errors.  
3.10.5 Metabolic Syndrome status 
MetS status was calculated using the Harmonized Definition (Alberti et al., 2009). 
In order to calculate MetS status participants BMI, BP, HDL, TG and FPG were categorised 
as either 0 if they did not meet the criteria for MetS or 1 if they did. If the total of the five 
MetS scores was three or more the participants was considered to be categorised as 
having MetS. The Harmonized Definition (Alberti et al., 2009) defined MetS as: 
Any three (3) of 
 Increased Waist Circumference   
o population-specific and countries-specific definitions as per IDF 
 Raised Triglycerides  
o ≥ 150 mg/dL (1.7 mmol/L)  
o or specific drug treatment for this lipid abnormality 
 Reduced HDL-cholesterol  
o < 40 mg/dL (1.03 mmol/L) in males 
o < 50 mg/dL (1.29 mmol/L) in females 
o or specific drug treatment for this lipid abnormality 
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 Raised Blood Pressure 
o Systolic BP≥ 130 or diastolic BP≥ 85mmHg 
o or specific drug treatment for previously diagnosed hypertension 
 Raised Fasting Plasma Glucose 
o (FPG) ≥ 100 mg/dL (5.6 mmol/L)  
o or drug treatment for increased glucose. 
(Eckel et al., 2010) 
 As waist circumference data were not available on this dataset a BMI of 30 or 
greater was used as the classification for BMI as per the IDF definition (K.G. Alberti et al., 
2006). 
3.10.6 Framingham Risk Score 
The Framingham Risk Score is a widely used reference tool that estimates the 10-
year risk of an individual developing coronary heart disease. This score was calculated 
using participants’ age, TC, HDL, BP, FPG and self-reported smoking with points being 
assigned in each category as per the formula developed by Wilson et al. (1998) and 
published in the National Cholesterol Education Program Adult Treatment Panel III 
(National Cholesterol Education Program, 2002). The total points were then totalled to 
provide a raw Framingham Risk Score which could then converted to percentage risk of 
coronary heart disease within the next 10 years as also outlined by Wilson et al. (1998) 
(Table 3-2, Table 3-3). 
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Table 3-2 10-year risk estimates for men (Framingham risk score) (National Cholesterol Education Program, 2002) 
Age Points  Total 
Cholesterol 
(mg/dL) 
Points at 
Ages 20-
39 
Points at 
Ages 40-
49 
Points at 
Ages 50-
59 
Points at 
Ages 60-
69 
Points at 
Ages 70-79 20-34 -9 
35-39 -4  <160 0 0 0 0 0 
40-44 0  160-199 4 3 2 1 0 
45-49 3  200-239 7 5 3 1 0 
50-54 6  240-279 9 6 4 2 1 
55-59 8  ≥280 11 8 5 3 1 
60-64 10        
65-69 11   Points at 
Ages 20-
39 
Points at 
Ages 40-
49 
Points at 
Ages 50-
59 
Points at 
Ages 60-
69 
Points at 
Ages 70-79 70-74 12 
75-79 13  Nonsmoker 0 0 0 0 0 
   Smoker 8 5 3 1 1 
         
HDL 
(mg/dL) 
Points  Systolic BP 
(mmHg) 
If Untreated If Treated 
≥60 -1  <120 0 0 
50-59 0  120-129 0 1 
40-49 1  130-139 1 2 
<40 2  140-159 1 2 
   ≥ 160 2 3 
      
 
Point Total 10-Year Risk Point Total 10-Year Risk 
<0 <1% 11 8% 
0 1% 12 10% 
1 1% 13 12% 
2 1% 14 16% 
3 1% 15 20% 
4 1% 16 25% 
5 2% ≥ 17 ≥30% 
6 2%   
7 3%   
8 4%   
9 5%   
10 6%   
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Table 3-3 10-year risk estimates for women (Framingham risk score) (National Cholesterol Education Program, 2002) 
Age Points  Total 
Cholesterol 
(mg/dL) 
Points at 
Ages 20-
39 
Points at 
Ages 40-
49 
Points at 
Ages 50-
59 
Points at 
Ages 60-
69 
Points at 
Ages 70-
79 
20-34 -7 
35-39 -3  <160 0 0 0 0 0 
40-44 0  160-199 4 3 2 1 1 
45-49 3  200-239 8 6 4 2 1 
50-54 6  240-279 11 8 5 3 2 
55-59 8  ≥280 13 10 7 4 2 
60-64 10        
65-69 12   Points at 
Ages 20-
39 
Points at 
Ages 40-
49 
Points at 
Ages 50-
59 
Points at 
Ages 60-
69 
Points at 
Ages 70-
79 
70-74 14 
75-79 16  Nonsmoker 0 0 0 0 0 
   Smoker 9 7 4 2 1 
         
HDL 
(mg/dL) 
Points  Systolic BP 
(mmHg 
If Untreated If Treated 
≥60 -1  <120 0 0 
50-59 0  120-129 1 3 
40-49 1  130-139 2 4 
<40 2  140-159 3 5 
   ≥ 160 4 6 
      
Point Total  10-Year Risk Point Total 10-Year Risk 
<9 <1%  20 11%  
9 1%  21 14%  
10 1%  22 17%  
11 1%  23 22%  
12 1%  24 27%  
13 2%  ≥25 ≥30%  
14 2%     
15 3%    
16 4%    
17 5%    
18 6%    
19 8%    
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3.10.7 Gender 
Gender was reported by participants as either male or female. 
3.10.8 Age 
Participant’s age was calculated from the date of birth. Participants were grouped 
into decadal age groups.  
3.10.9 Marital status 
Marital status was reported by participants as either single, married, divorced or 
widowed. A limitation of the data collection on marital status was that data were not 
collected on de facto relationships as participants were only given the above four options 
to select for marital status. 
3.10.10 Religious affiliation 
As the majority of the programs analysed in this study were conducted under the 
auspices of Seventh-day Adventist churches, participants were asked to identify whether 
or not they were members of the Seventh-day Adventist Church. Using this information 
participants were categorised as either Seventh-day Adventists (SDA) or non-Seventh-day 
Adventists (non-SDA). 
3.10.11 Family history and previous history  
In the initial health appraisal participants were asked to complete a question 
relating to the participants’ family medical history and another question relating to the 
participants’ previous medical history. These two questions were analysed in order to 
assess the impact of family history and previous history on the outcomes of the CHIP 
intervention.  
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The first question related to family medical history and was:- 
One or both of your parents died before age 60:  of heart disease?  □Yes □No  of diabetes? □Yes □No 
The second question related to participants’ own medical history and was:- 
Check (X) if you have ever been told by a physician that you have any of the following: 
Angina  (Yr)? 
__________ 
Abnormal EKG (last 3 
yrs)  
Gall bladder trouble  Ulcers 
Heart attack (yr)? 
______ 
Irregular heartbeats Gout Osteoarthritis 
Angioplasty (Yr)? 
_______ 
Stroke (Yr)? ________ Kidney disease Rheumatoid arthritis 
Bypass (Yr)? ________ High blood pressure Chronic bronchitis Overweight 
Heart failure (Yr)? ____ High cholesterol Emphysema Gout 
Blood clotting problem High triglycerides Thyroid disorder Cancer 
 
3.10.12 Dietary intake and smoking 
Unfortunately, while some data were collected on dietary intake at the health 
appraisal, the data were not entered into the CHIP Assistant Software and so we were 
unable to use it in this research project. Data were also collected with regard to 
participants’ smoking history however the categories for smoking on the health screen 
questionnaire provided to participants were confusing and consequently the data 
collected was unreliable and was not suitable for use in this analysis. 
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3.11 Statistical analyses 
Prior to analysis duplicates were removed and outliers were identified and 
eliminated from the data and the distribution of the change was tested for normality by 
means of graph construction and calculation of skewness and kurtosis. The distribution, 
for all biometrics was found to be near normal though due to the large sample size 
violations of the assumption of normality are of little concern (Coakes & Steed, 2010, p. 
73; Lumley, Diehr, Emerson, & Chen, 2002). Once outliers and duplicates had been 
removed from the data set the clean dataset consisted of data on 5,070 participants from 
178 CHIP interventions. 
Detailed analysis of the data to address the research questions included, where 
appropriate, descriptive techniques, comparison of means, multivariate analysis and 
linear regression. Where necessary Bonferroni’s post hoc analysis was used to perform 
pairwise comparisons following a significant overall test result. The effect size of any 
change was determined using Cohen’s d. An effect size of 0.2 or less is considered a small 
change, an effect size > 0.2 but < 0.8  is considered a moderate change and an effect size 
of > 0.8 is considered large (Cohen, 1988, pp. 285-287).  
Chapter 4 presents the results of the analyses that were performed to answer the 
first research question: “How effective is the Coronary Health Improvement Program 
(CHIP) lifestyle intervention for reducing selected risk factors of chronic disease 
associated with the metabolic syndrome, when delivered by volunteers to free-living 
participants in their community?” 
In order to answer this research question the data from all the participants were 
grouped together independent of their respective demographic and initial health status. 
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Using this grouping, the change in each biometric, from baseline to post-intervention, was 
analysed, using t-tests to determine whether this change was significant and, if 
significant, to identify the extent of this change. The effect size was calculated using 
Cohen's d. 
The effect of the intervention on the various risk factors was further analysed 
by stratifying the participants according to their risk factor status at baseline. 
Conventional risk factor categories were used to stratify the participants.  
A paired t-test was used to determine if there was a significant change within each 
of the risk factor categories from baseline to post-intervention. Additionally, changes in 
the distribution of the number of participants within the risk categories from baseline to 
post-intervention was examined using appropriate the Chi square test. 
Chapter 5 addresses the second research question: “What is the impact of 
selected participant factors, including age, gender, marital status, religious affiliation, 
previous history, family history and weight on the outcomes achieved by the CHIP 
intervention?” In order to answer this question the impact of selected participant factors 
on the participants’ outcome in relation to lipid profile, BMI, FPG and BP were examined. 
The participant factors that were examined are age, gender, gender differences across 
age range, marital status, religious affiliation, BMI, family history and previous history. 
For each of the factors, differences in the biometrics at baseline between the 
categories were assessed using appropriate t-testing or ANOVA. Next the change in 
biometrics from baseline to post-intervention within the same category was examined 
using paired t-tests.  If the change in biometrics was found to be significant within 
categories, the difference in change between categories was examined using appropriate 
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t-tests or ANOVA. When a significant difference between the categories was identified, 
Bonferroni’s post hoc analyses were performed to identify where the differences 
occurred. Cohen’s d was calculated to show the effect size where appropriate.  
3.12 Summary 
In brief, the following analysis steps were employed: each variable was examined 
for accuracy of data entry, variables were categorized as outlined above, and various 
statistical methods were used to identify differences in the data at baseline and then to 
analyse any changes in participants’ biometrics from baseline to post-intervention. The 
results of these analyses are presented and discussed in the next two chapters. 
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Chapter 4 Results part 1: The effectiveness of the volunteer-
delivered community-based CHIP interventions 
 
4.1 Introduction 
In this chapter the first research question, “How effective is the Coronary Health 
Improvement Program (CHIP) lifestyle intervention for reducing selected risk factors of 
chronic disease associated with the Metabolic Syndrome, when delivered by volunteers 
to free-living participants in their community?”, is addressed.  
To answer this question, this chapter presents the analysis of a large cohort (n = 
5070) of individuals who participated in 178, volunteer-delivered, community-based, CHIP 
interventions between 2006 and 2009 in the United States of America and Canada. The 
chapter begins by examining the overall changes, from baseline to post-intervention (30-
days), in the biometric scores for the participants in the CHIP interventions delivered by 
volunteers to free-living participants in their community. To assess the clinical significance 
of these results, the change in MetS status and Framingham Risk Score is shown. The 
results from the volunteer-delivered, community-based interventions included in this 
study are then compared with the published results of professionally delivered CHIP 
interventions. Thirdly, the participants are stratified according to their risk categories at 
baseline and the change in biometric scores from baseline to post-intervention are 
analysed. The key finding from these analyses are then discussed with reference to the 
literature before concluding. 
The biometric measures analysed include: height and weight from which body 
mass index (BMI) was calculated, total cholesterol (TC), low density lipoprotein 
cholesterol (LDL), high density lipoprotein cholesterol (HDL), triglycerides (TG), fasting 
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plasma glucose (FPG), systolic blood pressure (SBP) and diastolic blood pressure (DBP). 
The ratios of TC to HDL and LDL to HDL have been calculated. Metabolic Syndrome (MetS) 
status of the participants and Framingham Risk Score was also calculated. The significance 
or otherwise of changes in these biometrics from baseline to post-intervention were 
assessed using paired t-tests and the impact factor is showing using Cohen’s d.  
4.2 Overall changes in the biometric scores from baseline to post-
intervention 
In this section the overall change in the participant’s biometric scores (BMI, TC, 
HDL, LDL, DG, FPG, and BP) from baseline to postintervention is presented. This data set 
consisted of 5070 individuals who participated in one of 178 CHIP interventions. The 
mean age of the participants was 57.2 ± 12.9 years with 1690 (33.5%) males (57.86 ± 
12.97 years) and 3353 (66.5%) females (56.9 ± 12.9 years). Using this grouping, the 
change in each biometric, from baseline to post-intervention, was analysed to determine 
whether this change was significant and, if significant, to identify the extent of this 
change.  
The postintervention scores were lower than the baseline scores for all of the 
biometrics analysed at a significance of <0.001. The effect size ranged from small for TG 
and body weight to moderate for TC (Table 4-1). 
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Table 4-1 Overall change in biometrics post-intervention 
Factor N Baseline 
Post-
intervention Mean  Percent t  p value Cohen’s  
  Mean   (SD) Mean   (SD) change change statistic  d 
Weight (kg)  4,579 192.21 50.2 186.14 48.11 6.07 3.2% 80.36 <0.001 0.12 
Body mass index (kg/m2) 4,508 31 7.28 30.02 7 0.98 3.2% 82.35 <0.001 0.14 
Total cholesterol (mg/dL) 4,642 193.23 41.26 172.16 37.8 21.07 10.9% 55.90 <0.001 0.53 
Low density lipoprotein (mg/dL) 4,539 130.67 61.18 113.7 54.35 16.97 13.0% 43.34 <0.001 0.29 
High density lipoprotein (mg/dL) 4,638 54.71 25.49 49.97 23.06 4.74 8.7% 40.47 <0.001 0.20 
Triglycerides (mg/dL) 4,628 141.24 83.48 131.49 72.59 9.75 6.9% 13.28 <0.001 0.12 
Fasting plasma glucose (mg/dL L) 4,511 99.52 24.37 94.26 19.71 5.26 5.3% 26.69 <0.001 0.24 
Systolic blood pressure (mmHg) 4,560 133.35 19.1 126.34 16.52 7.0 5.3% 31.54 <0.001 0.39 
Diastolic blood pressure (mmHg) 4,552 79.86 11.1 75.69 9.89 4.2 5.2% 28.37 <0.001 0.40 
Framingham score 3,670 12.18 9.29 10.38 7.84 1.8 14.8% 17.34 <0.001 0.21 
SD – Standard deviation           
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4.2.1 Changes in Framingham Score and Metabolic Syndrome Status 
To examine the clinical significance of these changes, the Framingham Risk Score (FRS) 
(National Cholesterol Education Program, 2002; Wilson et al., 1998) and Metabolic Syndrome Status 
was calculated at baseline and post-intervention and the differences compared. Data were available 
to calculate the FRS on 3,670 participants. The mean reduction of 1.8 in the Framingham Risk Score 
(Table 4-1) from baseline to post-intervention for the study cohort would be predicted to prevent 
approximately 70 coronary incidents over the next decade. 
Data were available to determine the MetS status, at baseline and post-intervention, on 
4,391 participants. A higher percentage of male participants (54.4%) could be categorised as having 
MetS at baseline than female participants (45.6%) [χ2 = 19.417, p < 0.001]. There was a significant 
reduction (Mantel-Haensizel chi squared score = 1474.619, df =1, p <0.001) between the number of 
participants who were categorised as having MetS at baseline (N= 2111, 48.1%) and post-
intervention (N=1891, 43.1%). This represents a 10.4% reduction in the incident of MetS.  
Table 4-2 Number of participants meeting the criteria for the MetS risk factors at program entry and post-intervention 
Risk Factor Baseline  
(N) 
Post-intervention 
(N) 
Change 
(N) 
BMI 2170 1980 190 
BP 2761 1994 767 
FPG 1553 1113 440 
TG 1523 1350 173 
HDL 2050 2608 +558 
MetS (≤3) 2111 1891 130 
 
Table 4-2 shows that this overall reduction in MetS occurred because of the improved 
results for BMI, BP, FBG and TG, however during the intervention overall HDL levels dropped by 
8.7%. This meant that an additional 558 participants met the MetS criteria for HDL at the end of the 
intervention (Table 4-1 and Table 4-2). By the end of the program 257 participants who were not 
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classified as having MetS at program entry acquired this status however, 157 of these individuals 
(61%) only did so because of reduced HDL levels.  For these individuals, the TC: HDL and LDL: HDL 
ratios increased significantly from baseline to post-intervention (3.56 versus 4.12, p<0.001; 2.31 
versus 2.44, p=0.006, respectively) as both TC (12%, p<0.001) and LDL (15%, p<0.001) did not 
decrease as much as HDL (21%, p<0.001).  
4.2.2 Comparison with professionally delivered CHIP interventions 
Table 4-3 shows a comparison of baseline to post-intervention change presented in seven 
papers published from the Rockford CHIP project andDiehl (1998) , outlined in chapter 2, with the 
results from this study. These eight papers, when aggregated, show the results for 4669 CHIP 
participants at the completion of the four week intervention where professional facilitators were 
used. This table shows that the outcomes achieved by the volunteer delivered programs, presented 
in this dissertation, are not dissimilar from those achieved by the professionally delivered. 
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Table 4-3 Comparison of volunteer facilitated CHIP interventions with professionally facilitated CHIP interventions 
Percentage Change in Biometrics 
Reference 
 Professionally Facilitated  
Volunteer 
Facilitated 
 
Diehl 
1998 ++ 
Merrill 2008* 
Aldana 
2002 
Adana 
2005 
A 
Adana 
2005 
B 
Aldana 
2008 
Englert 
2004 ++ 
Englert 
2007++ 
 Professionally 
Facilitated 
Aggregated 
 
n  288 862 841 442 64 167 714 242 1049  4669  5042 
Age  54.73 55.2 55.2 52.1 46.1 50.4  54.14 54.14  54.12#  57.29 
Weight  3.17 ND ND 4.43 3.25 3.68 4.01 3.68 3.91  3.89#  3.16 
BMI  3.18 3.85 3.44 4.38 3.43 ND 3.91 3.82 3.07  3.47#  3.16 
SBP  5.2 4.6 4.8 5.4 5.7 5.6 4.8 2.5 6.0  5.0#  5.3 
DBP  7.0 4.4 5.4 6.0 6.3 6.4 4.0 3.1 5.9  5.2#  5.2 
TC  13.36 11.63 10.19 13.20 8.02 7.52 10.89 10.66 12.16  11.29#  10.90 
HDL  12.37 11.84 11.81 13.31 6.77 7.54 11.85 10.30 ND  9.05#  8.66 
LDL  15.87 12.03 10.90 14.66 9.58 9.28 12.22 11.26 13.29  12.45#  12.99 
TG  4.43 9.27 7.43 9.76 2.53 0.26 7.39 12.23 5.56  7.30#  6.90 
FPG  8.15 4.40 5.30 5.06 4.00 4.00 6.52 4.98 5.60  5.46#  5.26 
All figures are data after four weeks 
* Merrill gives data for two groups the first group is those who were followed up after 12 months the second group is those who were lost to 
 follow-up at 12 months but were followed up at 4 weeks 
++ Data were presented for Male and Female for comparison purposes this has been combined using weighted means 
# Average of the Professionally Facilitated Programs calculated using weighted means 
Volunteer Facilitated  p< 0.0001 for all factors 
Diehl 1998 p< 0.001 except for triglycerides  Merrill 2008 p< 0.001 for all factors 
Aldana 2002 Weight and BMI p<0.001, SBP p=0.0197, DBP p = 0.0175, TC p=0.0021, HDL p=0.0006, LDL p=0.0022, Tri p=0.0446 and FPG p=0.0263 
Aldana 2005 A p< 0.0001 for weight and BMI, p< 0.02 for systolic and diastolic BP, p< 0.005 for TC HDL LDL and p< 0.05 for triglycerides and FPG 
Aldan 2005 B p< 0.0001 for all factors except for FPG p= 0.003 and triglycerides p=0.9513 
Aldana 2008 p< 0.001 except for  triglycerides where p=0.0284 
Englert 2004 p<0.05 for blood pressures and triglycerides, p<0.01 for glucose and HDL, all other factors p<0.001 
Englert 2007 p<0.0001 except for triglycerides where p=0.113 
 
  103 
These results clearly show that the volunteer delivered, community-based CHIP intervention 
can achieve significant improvements in selected chronic disease risk factors. Biometric changes 
from baseline to post-intervention are however more pronounced among the participants with 
higher risk profiles at program entry, as shown in the following section. 
4.3 Results stratified for initial risk factor classification  
The effect of the intervention on the various risk factors was further analysed by stratifying 
the participants according to their risk factor status at baseline. Conventional risk factor categories 
were used to stratify the participants. The National Cholesterol Education Program Adult Treatment 
Panel III classification system (National Cholesterol Education Program, 2002) was used to 
categorize the participants for all risk factors, except TC, for which the Framingham Risk Score 
Classification was used, and BMI, for which the WHO classification was used (WHO, 2000). The 
Framingham Risk Classification (Wilson et al., 1998) was used for stratification of the TC data, 
because it includes 5 categories compared to only 3 in the National Cholesterol Education Program 
Adult Treatment Panel III classification system, thus allowing a more detailed analysis of the effect 
of the intervention on the highest risk participants. The stratified analyses are shown in Table 4-4 
and Table 4-5. 
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Table 4-4 Changes in risk factor levels within 30 days according to initial risk factor classification BMI and Lipid Profile 
Risk 
Factor 
N N  
χ2* (p)  
Baseline  
Post-
intervention  
Mean  % Mean  
t p Cohen's d 
Baseline 
Post-
intervention 
Mean  (SD) Mean  (SD) Change Change 
Body mass index (kg/m2)                    
< 18.5 27 33 
 (<0.001) 
17.6 0.9 17.5 0.8 -0.1 0.8% 1.50 0.144 -0.12 
18.5 - 24.9 884 1,086 22.7 1.6 22.3 1.7 -0.5 2.1% 17.78 <0.001 -0.24 
25 – 30 1,470 1,539  27.5 1.4 26.6 1.5 -0.9 3.1% 51.08 <0.001 -0.62 
> 30 2,242 1,965  36.6 6.1 35.4 6 -1.3 3.4% 59.56 <0.001 -0.20 
Total cholesterol (mg/dL)            
< 160 631 1,862 
1,950 (<0.001) 
132.1 13.8 126.0 22.4 -6.1 4.6% 7.545 <0.001 -0.34 
160 – 199 2,116 1,781 176.1 13.8 160.7 23.8 -17 8.8% 33.198 <0.001 -0.82 
200 – 239 1,261 756  217.6 11.3 189.6 25.63 -27.1 12.7% 40.624 <0.001 -1.49 
240 – 280 478 183  254.7 10.7 215.2 30.7 -39.5 15.5% 28.679 <0.001 -1.91 
> 280 126 30  306.6 27.2 245.9 43.4 -60.7 19.8% 15.037 <0.001 -1.72 
Low density lipoprotein (mg/dL)           
< 100 1,453 2,115 1,008 (<0.001) 80.6 15.1 75.3 209.1 -5.3 6.6% 10.928 <0.001 -0.29 
100 - 129 1,345 1,326  114.6 8.3 102.1 20.2 -12.5 10.9% 23.794 <0.001 -0.88 
130 - 159 905 588  142.4 8.5 120.1 21.8 -22.3 15.7% 31.843 <0.001 -1.47 
160 - 190 377 197  172 8.2 141.6 27.1 -30.4 17.7% 22.486 <0.001 -1.72 
> 190 488 342  273.9 67.9 229.8 73.1 -44.1 16.1% 20.218 <0.001 -0.63 
High density lipoprotein (mg/dL)           
< 40 1,316 1,814 539 (<0.001) 34.2 4.8 33.2 7 -1 3.0% 6.15 <0.001 -0.17 
40 - 60 2,097 1,912  48.9 5.3 45 7.8 -3.8 7.8% 27.29 <0.001 -0.60 
> 60 1,261 948  86.3 29.8 76.2 28.5 -10.1 11.8% 30.15 <0.001 -0.35 
Triglycerides (mg/dL)           
<100 3,053 3,232 109 (<0.001) 95.5 29.7 99.7 41.8 4.2 4.4% -6.64 <0.001 0.12 
100 - 199 753 765  171.9 13.9 158.1 53 -13.8 8.1% 7.17 <0.001 -0.41 
200 - 500 820 663  270.5 62.4 220.1 81.8 -50.3 18.6% 18.995 <0.001 -0.70 
> 500 45 11  634.7 114.2 354.8 158.5 -279.9 44.1% 10.431 <0.001 -2.05 
 * McNemar chi-square test. SD – Standard deviation.   
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Table 4-5 Changes in risk factor levels within 30 days according to initial risk factor classification FPG and BP. 
Risk 
Factor 
N N  
χ2* (p)  
Baseline  
Post-
intervention  
Mean  % Mean  
t p Cohen's d 
Baseline 
Post-
intervention 
Mean  (SD) Mean  (SD) Change Change 
Fasting plasma glucose (mg/dL)            
< 110 3,716 4,026 265 (<0.001) 90.7 9.9 88.6 10.9 -2.1 2.3% 12.698 <0.001 -0.20 
110 - 125 390 304  116.1 15.5 106 15.5 -10.1 8.7% 13.55 <0.001 -0.65 
> 125 525 301   164 42.2 131.4 34.5 -32.6 19.9% 20.745 <0.001 -0.85 
Systolic blood pressure (mmHg)            
≤ 120 1,279 1,866 
662 (<0.001) 
111.8 9 114.5 27 2.7 2.4% -3.51 <0.001 0.15 
121 - 139 1,719 1,788 129.9 5.1 125.2 27 -4.7 3.6% 7.28 <0.001 -0.29 
140 - 160 1,127 743  147.2 5.8 134.3 13.1 -12.9 8.7% 31.82 <0.001 -1.37 
> 160 454 182  170.7 11.9 147.3 17.6 -23.3 13.7% 27.49 <0.001 -1.59 
Diastolic blood pressure (mmHg)           
≤ 80 2,619 3,364 
560 (<0.001) 
72.4 6.9 71.8 8.9 -0.7 0.9% 3.604 <0.001 -0.08 
81 - 89 1,060 822 84.8 2.3 78.3 7.7 -6.4 7.6% 27.277 <0.001 -1.30 
90 - 100 688 322  92.9 3.0 82.7 8.4 10.2 10.9% 31.608 <0.001 -1.79 
> 100 210 69  106.2 13 87.7 10.3 -18.5 17.4% 16.963 <0.001 -1.59 
 * McNemar chi-square test. SD – Standard deviation. 
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While the overall group data presented in Section 4.2 shows significant changes in 
each of the biometrics, the stratified analyses present a more comprehensive picture. As 
shown in Tables 4-3 and 4-4, significant reductions were recorded in all risk categories for 
each of the biometrics at p < 0.001 with the exception of BMI < 18.5 where the change 
was not significant (p = 0.144) and the < 100 category for TG where there was a 4.4% 
increase (p < 0.001).  
In general participants in the highest risk categories at baseline experienced the 
greatest change. For all biometrics the change was smallest in the lowest risk category 
and progressively increased as the level of risk increased, except for LDL where the 
second highest risk category (160 - 190 mg/dL) showed a slightly higher percentage mean 
reduction than the highest risk category (>190 mg/dL). The greatest variation of 
percentage mean change between categories was for TG where there was a 4.4% mean 
increase in the lowest risk category (< 100) and a 44.1% mean decrease in the highest risk 
category (> 500). 
A similar trend was observed for effect size, as shown by Cohen’s d, with the 
lowest risk categories experiencing the smallest effect size and the higher risk categories 
the largest effect size. In the higher risk categories, the effect sizes for the change from 
baseline to post-intervention were large. Interestingly, for all biometrics except for SPP 
and TG, where the highest category showed the largest effect size, the effect size was 
lower in the highest risk category than the second highest risk category. This may be 
explained by the fact that the standard deviations were large in the highest categories 
because there was no upper limit for these categories. Large effect sizes were observed in 
the higher risk categories for all biometrics except for HDL where the effect sizes were 
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moderate, and BMI where only the 25-30 risk category showed a moderate effect size 
with the other categories showing a small effect size. 
There were significant reductions in the number of participants categorised as 
belonging to the highest risk categories from baseline to post-intervention. The change in 
the number of participants in the respective FPG categories is especially noteworthy. At 
baseline 525 participants recorded a FPG of >125 mg/dL which is indicative of diabetes, 
but this had reduced to 301 by the end of the program (Table 4-5), representing a 42.7% 
(N = 224) reduction.  
The results of the stratified analyses indicate that the CHIP intervention is most 
effective for participants who exhibited the greatest risk level, at baseline, and therefore 
had the greatest need. 
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4.4 Discussion 
In order to answer the first research question: “How effective is the Coronary 
Health Improvement Program (CHIP) lifestyle intervention for reducing the selected risk 
factors of chronic disease that constitute the Metabolic Syndrome, when delivered by 
volunteers to free-living participants in their community?” this chapter has examined the 
overall changes in the biometric scores from baseline to postintervention for the 5070 
participants in this study and then the participants have been stratified according to 
baseline risk factor for further analysis. The key finding in this chapter is that the results 
of the overall and stratified analyses indicate that the CHIP intervention, when delivered 
by volunteer facilitators to free-living individuals in their community, effectively reduces 
risk factors associated with MetS. The stratified analyses showed that the CHIP 
intervention is most effective for those who need it most. Other findings are discussed 
below. 
4.4.1 Metabolic Syndrome  
In this study a 10.4% reduction in the number of participants being categorised as 
having MetS, from baseline to post-intervention was observed. Other studies, both 
human and animal studies, have shown that a low-fat plant-based diet and exercise can 
prevent and control MetS (Barnard & Wen, 1994). In a meta-analysis of lifestyle 
interventions Yamaoka and Tango (2012) concluded that long-term regular lifestyle 
modification programs reduce the prevalence of MetS and of the abnormalities 
associated with MetS.  
The percentage of participants classified as having MetS in this study (52.6% of 
male participants and 45.6% of female participants) is higher than the prevalence 
reported within the general US population which has been estimated between 24 - 42% 
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for males and 23 - 38% for females (Alberti et al., 2009; Ford, Giles, & Dietz, 2002). The 
higher percentage of participants classified as having MetS in the present study than the 
general population may be explained by the CHIP intervention attracting participants who 
were more compromised in their health which is unremarkable given the intervention is 
marketed to individuals with elevated chronic disease risk factors. The prevalence of 
MetS has also been observed to rise with age, although attenuating in the over 70 years 
population (Hu et al., 2004). Given that the average age of participants in this study was 
57.2 years which is substantially older than the average US population of 38.5 years 
(Howden & Meyer, 2010), age could also explain the high prevalence of MetS in this 
study. 
In this study a 10.4% reduction in the number of participants being categorised as 
having MetS, from baseline to post-intervention was observed. Other studies, both 
human and animal studies, have shown that a low-fat plant-based diet and exercise can 
prevent and control MetS (Barnard & Wen, 1994). In a meta-analysis of lifestyle 
interventions Yamaoka and Tango (2012) concluded that long-term regular lifestyle 
modification programs reduce the prevalence of MetS and of the abnormalities 
associated with MetS.  
4.4.2 Body Mass Index 
The changes in BMI observed in this study were substantive given they were 
achieved in only 30 days. The mean 6.1 lb reduction in weight, equating to a 3% decrease 
in BMI, and a 3.4% reduction among those participants categorised as obese at program 
entry, might in itself be clinically significant.  
Purposeful weight loss has been shown to improve exercise capacity, BP and lipid 
profile, as well as behavioural factors and quality of life (Aucott et al., 2005; Lavie, Milani, 
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Artham, Patel, & Ventura, 2009). While the benefits of weight loss are well recognised it is 
still frequently stated that lifestyle approaches to weight loss are ineffective (Goodpaster 
et al., 2010; Monkhouse, Morgan, Bates, & Norton, 2009). Surgical intervention is 
becoming increasingly popular. While weight loss can be achieved from surgical 
intervention, weight loss through lifestyle change has been found to be more effective in 
reducing blood pressure than equivalent weight loss from surgical intervention (Aucott et 
al., 2005) and successful maintenance of  weight loss, even when achieved by surgical 
means, requires lifestyle change (Douketis, Macie, Thabane, & Williamson, 2005). Further 
weight loss by lifestyle seems to show greater reduction in risk factors associated with 
CVD and T2D than does weight loss from surgical means (Douketis et al., 2005). 
The decrease in BMI observed in this study, of 3.2%, were substantive given they 
were achieved in only 30 days. Even modest weight loss can produce substantive health 
benefits (Goodpaster et al., 2010). It has been observed that in combating MetS and 
associated coronary vascular disease (CVD), a 10% reduction in body mass is the goal 
during the first year, and that 5% can be helpful (McClendon, Dunbar, Clark, & Coverson, 
2010; Wing et al., 2011). The participants in the present study made good progress 
toward this goal within just 30 days.  
Significant weight loss within the initial period of a weight loss program has been 
shown to be an important factor in successful weight maintenance (Elfhag & Rössner, 
2005), as it may indicate greater compliance with the program (van Baak et al., 2003). The 
3% mean weight loss in just 30 days, achieved by participants in this study may be 
beneficial long-term. 
CHIP recommends a low-fat diet and increased exercise. Other studies have found 
that the lowering of fat intake in the diet can increase the effectiveness of a weight loss 
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program (Carmichael, Swinblirn, & Wilson, 1998) with the inclusion of physical exercise 
being particularly beneficial for weight loss (Goodpaster et al., 2010; Mekary, Feskanich, 
Hu, Willett, & Field, 2010). 
4.4.3 Lipid Profile 
The results of this study showed significant reductions in only 30 days in TC 
(10.9%), LDL (13.0%), HDL (8.7%) and TG (6.9%) (Table 4-1). These results are comparable 
to the published outcomes of the residential lifestyle interventions that promote a low-
fat, plant-based eating pattern, such as the Ornish and Pritikin programs (Barnard, 1991; 
Beard, Barnard, Robbins, Ordovas, & Schaefer, 1996; Ornish et al., 1983), as well as the 
professionally delivered CHIP interventions (Aldana et al., 2002; Aldana et al., 2008; Diehl, 
1998). Further, these changes in blood lipid profile compared favourably to those 
achieved with statin medication (Gould, Davies, Alemao, Yin, & Cook, 2007). 
 Low-Density Lipoprotein  
A key target in coronary heart disease prevention is reduction of LDL levels, 
particularly very low density LDL (VLDL) (National Cholesterol Education Program, 2002). 
Participants in this study experience significant reductions in LDL, in only 30 days, with an 
overall mean reduction of 13% and greater reductions among those participants with 
elevated levels of LDL (Table 4-4). While changes in the size of LDL particles was not 
measured in this study, similar low-fat, plant-based interventions combined with exercise, 
have been shown to significantly increased the particle diameter of LDL (Beard et al., 
1996). 
It has been suggested that a 1 mmol/L (38.67 mg/dL) drop in LDL equates to a 40-
50% reduction in coronary heart disease risk (Huxley, Lewington, & Clarke, 2002). The 
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overall mean decrease of 17 mg/dL observed in this study translates to an approximate 
20% reduction in coronary heart disease risk. In those participants with the highest LDL 
classification (>190 mg/dL) at program entry, the mean reduction of 44.1 mg/dL 
represents an approximate 50% reduction in coronary heart disease risk. In conclusion, 
clinically significant reductions in LDL cholesterol levels were achieved by participants 
enrolled in the volunteer-delivered, community-based CHIP lifestyle interventions 
examined in this study. 
 Triglycerides  
Two of the five criteria for MetS are related to lipid profile: elevated TG and 
lowered HDL. However, low-fat, plant-based diets, as advocated by CHIP, have been 
reported to elevate TG and lower HDL (Clevidence et al., 1992; Garg et al., 1994; 
McDougall, Litzau, Haver, Saunders, & Spiller, 1995). Consequentially, concern has been 
expressed by some authors as to the suitability of such diets for the prevention and 
management of MetS and associated T2D and CVD (Grundy et al., 2005; Lichtenstein et 
al., 2006; Lichtenstein & Van Horn, 1998; Weinberg, 2004).  
The findings from this study show that TG levels increased marginally (4.4%) only 
for those participants who had the lowest level of TG (<100) at program entry which is 
well below the cut-off of 150 for a diagnosis of MetS. The effect size was small (0.12) and 
such minor changes in a healthy population are probably of minor clinical significance 
(Diehl, 1998). Conversely, overall the mean TG levels reduced by 6.9%, and participants in 
the highest risk category (>500) showed a 44.1% reduction with a very large effect size (-
2.05) (Table 4-4). Of the 1523 participants who had a TG level above the MetS threshold 
at baseline, 173 participants fell below the threshold by the end of the intervention (Table 
4-2). It would seem that a low-fat, plant-based diet, as recommended by the CHIP 
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intervention, can effectively reduce participants’ TG levels for those with elevated TG 
levels. The findings of this study therefore support the recommendation of several 
authors who advocate a low-fat eating pattern for reducing TG levels (Barnard et al., 
2009; Barnard et al., 2008; Beard et al., 1996; Daubenmier et al., 2007; Diehl, 1998; 
Englert et al., 2007; D. J. Jenkins et al., 2003; Ornish et al., 1983). 
 High-Density Lipoprotein 
It is interesting that significant improvements in the risk factors that constitute 
MetS were observed in this study, except for HDL which significantly decreased (Table 
4-2). Clearly, the change in the number of individuals meeting the HDL criteria for MetS 
demonstrated an opposing trend to the other 4 MetS risk factors, BMI, FBG, BP and TG.  
Low levels of HDL, on a population level, are considered to be an important 
cardiovascular risk factor (Gordon & Rifkind, 1989). A strong inverse association between 
low HDL levels and the risk of cardiovascular events has been consistently observed in 
epidemiological studies (Brinton, Eisenberg, & Breslow, 1990; Rader, 2006). Low levels of 
HDL are included in the criteria for MetS. HDL has been shown to exhibit several potential 
anti-atherogenic properties, the most important of which is reverse cholesterol transport 
or cholesterol efflux which is the removal of cholesterol from peripheral tissues to the 
liver for catabolism (von Eckardstein, Nofer, & Assmann, 2001). More recently HDL has 
been shown to have many anti-atherogenic properties which include anti-inflammatory, 
anti-apoptotic, nitric oxide promoting, prostacyclin-stabilizing, and platelet-inhibiting 
functions.(Jensen, Rimm, Furtado, & Sacks, 2012; Leite & Fernandez, 2010) Indeed, it has 
been postulated that the anti-inflammatory properties of HDL and its ability to protect 
LDL from oxidation may be just as important as its role in reverse cholesterol 
transport.(Roberts, Ng, Hama, Eliseo, & Barnard, 2006)  
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However, HDL has been described as a “chameleon-like” lipoprotein as in its 
normal state it is anti-inflammatory but it can become pro-inflammatory during acute 
inflammatory responses. In its anti-inflammatory state the enzymes contained in HDL 
exhibit anti-atherogenic properties by destroying the oxidised lipids derived from LDL. In 
its pro-inflammatory state HDL, rather than inhibiting LDL oxidisation, enhances LDL 
oxidisation (Ansell et al., 2003; Navab et al., 2006; Navab, Van Lenten, Reddy, & 
Fogelman, 2001). 
The result of this study which suggests that HDL levels may not be helpful for 
predicting cardiovascular risk in individuals consuming a low-fat, plant-based diet, is 
supported by other epidemiological and clinical studies. Over 30 years ago, Connor 
observed that the Tarahumara Indians of Mexico, who consumed a largely plant-based 
diet comprising approximately 12% fat, 13% protein (predominantly from corn and beans) 
and 85% carbohydrate, had very low rates of vascular disease and blood lipids, including 
HDL (Connor et al., 1978). However, blood lipids, including HDL, were observed to 
significantly increase after only five weeks when their traditional diet was changed to a 
Western diet (McMurry, Cerqueira, Connor, & Connor, 1991). It was argued that the 
increase in HDL was the “normal response to a high-fat diet” and that low-HDL in concert 
with low-LDL in a low-fat diet are associated with a low risk of coronary disease.  
Other epidemiological findings also show that individuals who consume a plant-
based diet are at lower risk of CVD and T2D, despite having lowered HDL levels 
(Ferdowsian & Barnard, 2009; Roberts et al., 2006). In addition, the Lifestyle Heart Trial, 
(Ornish et al., 1998) which incorporated a plant-based diet with less than 10% fat, showed 
a 7.9% improvement in measured coronary artery percent diameter stenosis after five 
years despite a 13% reduction in HDL. Similarly, individuals with diagnosed CVD and a 
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recommendation for bypass surgery who participated in the Pritikin residential program 
which recommends a plant-based diet (< 10% fat), experienced a 16% reduction in HDL 
but decreases in symptomatic angina (Barnard, Guzy, Rosenberg, & O'Brien, 1983). These 
patients averted surgery for more than five years after program entry despite sustained 
lowered HDL levels.   
Lifestyle interventions that promote a plant-based diet have been shown to 
decrease HDL cholesterol levels despite concomitant reductions in atherosclerotic plaque 
and cardiac events (Esselstyn et al., 1995; Ornish, 1998b; Ornish et al., 1990a). This may 
be understood from the perspective that when all cholesterol subfractions are lowered 
there is not the demand for reverse cholesterol transport. In this study, there was a mean 
reduction in TC of 10.9% and LDL of 13.0% which means that the ratios of TC/HDL (3.53 at 
baseline to 3.45 post-intervention) and LDL/HDL (2.39 at baseline to 2.28 post-
intervention) have actually improved.  
Meta-analysis of the role of HDL in cardiovascular disease has indicated that 
increasing the levels of circulating HDL does not reduce the risk of coronary disease 
events, coronary heart disease deaths, or total deaths (Briel et al., 2009; Despres, 2013). 
In a review of published randomised clinical trials and observational studies Ferdowsian 
and Barnard (2009) found that decreased HDL associated with low-fat plant-based diets is 
not associated with poor cardiovascular health. Individuals who follow a plant-based 
eating pattern that is free from exogenous cholesterol typically have lower blood 
concentrations of all cholesterol subfractions, including HDL cholesterol. However, these 
individuals do not have compromised cardiovascular health and are not at increased risk 
of T2D (Ferdowsian & Barnard, 2009). Further in countries where a low-fat complex-
carbohydrate diet is typically consumed population levels of HDL are low when compared 
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to countries consuming a typical Western diet however the rate of atherosclerosis is also 
very low (Barnard & Wen, 1994; Brinton et al., 1990) 
There is also growing evidence that lifestyle interventions may be able to 
modulate the inflammatory or anti-inflammatory properties of HDL. In patients at risk of 
CVD, the anti-inflammatory properties of HDL improved following lifestyle modification, 
despite reductions in HDL (Roberts & Barnard, 2005). In another study, the HDL shifted 
from pro-inflammatory to anti-inflammatory in obese men, with MetS, who underwent a 
three-week intervention involving a low-fat, high- fibre diet and exercise (Roberts et al., 
2006). More specifically, consumption of saturated fat reduces the anti-inflammatory 
potential of HDL, but consumption of polyunsaturated fat has been shown to increase it 
(Nicholls et al., 2006). The regulation and function of HDL appears more complex than 
originally thought, although high HDL levels are associated with reduced CVD at a 
population level, at an individual level HDL function may be more important than the 
actual HDL levels. (Khera et al., 2011). 
Given the findings of this study, with regard to HDL and the literature mentioned 
above it would seem appropriate to challenge the inclusion of HDL as part of the MetS 
assemblage, especially when applied to vegetarian populations and when assessing the 
effectiveness of plant-based interventions targeting chronic disease. It may be more 
appropriate for the guidelines for diets targeting a reduction in atherosclerosis to 
emphasise the lowering of LDL rather than being concerned about HDL reduction (Brinton 
et al., 1990). 
4.4.4 Fasting Plasma Glucose 
In this study, significant reductions in mean FPG levels for all risk categories were 
observed. This was most clearly seen with those participants who had an FPG levels 
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indicative of T2D at program entry (>125 mg/dL) as this group showed a 19.9% reduction 
over the 30-day period of the intervention. Of the 525 participants who had an FPG 
indicative of T2D at baseline, 30 days later this number had reduced to 301 participants 
who had an FPG indicative of T2D , a 42.7% reduction.  
The Finnish Diabetes Prevention Study Group showed that a lifestyle intervention 
emphasising a low-fat, high-fibre diet and exercise significantly reduced the incidence of 
T2D, particularly in participants in the highest risk categories (Tuomilehto et al., 2001). 
Similarly, the Diabetes Prevention Program Research Group found that for people with 
pre-diabetes, lifestyle intervention was twice as effective as Metformin for preventing 
progression to established diabetes. Compared to a placebo, lifestyle intervention 
resulted in a 58% reduction in the incidence of T2D as compared to only 31% for 
Metformin (Knowler et al., 2002). Another randomised controlled trial also showed a low-
fat, plant-based diet to be more effective than a conventional diabetic treatment diet 
(2003 American Diabetes Association guidelines) for improving glycaemic control 
(Barnard et al., 2009; Barnard, Joshua, David, Gabrielle, & et al., 2006).  
Significant reductions in FPG have been observed in professionally delivered CHIP 
interventions (Aldana, Greenlaw, Diehl, Salberg, Merrill, Ohmine, et al., 2005; Diehl, 1998; 
Englert et al., 2007), in the Multicentre Lifestyle Demonstration Project (Pischke et al., 
2006) and in residential programs offered at the Pritikin Longevity Centre (Barnard et al., 
1994; Barnard et al., 1982; Barnard, Massey, et al., 1983). The results of this study 
indicate that CHIP interventions delivered by volunteers can also effectively reduce FPG 
levels, particularly in those participants in the highest risk categories. 
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4.4.5 Systolic and Diastolic Blood Pressure 
This study showed significant reductions in BP in just 30 days. These reductions 
were particularly noteworthy for those participants who had the highest blood pressures 
at baseline. Those participants who had a SBP of > 160, at baseline, experienced a 14% 
reduction in SBP, while those participants with a DBP of > 100, at baseline, experienced a 
17% reduction in DBP with very large effect sizes. Similar results have been observed in 
reducing BP in the professional delivery of the CHIP intervention (Table 4-3). 
Elevated BP is widely recognised as an important risk factor for strokes(Goldstein 
et al., 2011) and CVD (Lieb et al., 2013) and hence is included as a factor in the criteria for 
the MetS (Alberti et al., 2009) and as a component in calculating in the Framingham Risk 
Score (National Cholesterol Education Program, 2002; Wilson et al., 1998). 
As discussed in the previous chapter there are a number of challenges in obtaining 
accurate BP measurement, however in this study the use of trained personnel, normally 
nurses, for the measurement of blood pressure and the large numbers of participants, 
(4,560 for SBP and 4,552 for DBP) should ameliorate some of the measurement errors.  
The finding from this study that the lifestyle intervention can significantly reduce 
BP is reflected in a number of other lifestyle interventions including the PREMIER clinical 
trial (Appel et al., 2003), the McDougall program (McDougall et al., 1995), the Daniel diet 
(Bloomer et al., 2010; Trepanowski, Kabir, Alleman, & Bloomer, 2012), the Nordic diet 
(Adamsson et al., 2011) and the DASH diet (Appel et al., 2006). Significant reductions in 
blood pressure have also been observed in residential programs involving low-fat, plant-
based diets such as the Pritikin Longevity Centre (Roberts, Vaziri, & Barnard, 2002; Weber 
et al., 1983) and the Ornish Program (Ornish et al., 1983).  
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4.4.6 Behaviour change 
The results presented above show that participants in CHIP demonstrate 
improved biometrics post-intervention. The aim of the CHIP intervention is to improve 
health behaviour. Merrill, Aldana, Greenlaw, Diehl, et al. (2008) have shown that CHIP 
interventions can significantly improve nutrition and physical activity behaviours for up to 
18 months. That use of the principles of the Theory of Planned Behaviour (TPB), in the 
development of CHIP may explain some of this improvement. TPB suggests that a 
person’s intentions and subsequent behaviours are dictated by three sets of beliefs: 
behaviour beliefs leading to attitudes, normative beliefs leading to subjective norms and 
control beliefs leading to perceived behaviour control (Ajzen, 2011). CHIP attempts to 
influence all of these beliefs. 
With regards to behavioural beliefs, the CHIP intervention endeavours to influence 
the participant’s attitudes through education. Participants come away from CHIP well-
informed about health and how to achieve it. Aldana, Greenlaw, Diehl, Salberg, Merrill, 
Ohmine, et al. (2005) showed that CHIP participants significantly improved their health 
knowledge during CHIP interventions. The answer the question “What is the consequence 
of performing this behaviour?” is presented with support from current research, using 
pre-recorded video presentations delivered by trustworthy presenters. Initially 
participants are presented with the negative consequences of an unhealthy lifestyle but 
they are then presented with the positive consequences of adopting a healthy lifestyle. 
The presentation of this information impacts the participants’ behavioural belief and 
attitudes. 
The CHIP intervention is presented in a group setting. The group dynamics of CHIP 
create a socially supportive environment as people journey together, problems solved 
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together overcome obstacles together, become accountable to each other and celebrate 
with each other. As observed earlier one of the reasons that male participants get better 
results than female participants could be that they are more likely to participate in the 
CHIP intervention with their partner. This group support influences participants 
Subjective Norms.  
The health assessment performed at baseline and postintervention provide the 
CHIP participants with feedback on the changes in their biometric scores. The majority of 
the CHIP participants in these biometric scores improve during the intervention helping 
participants to realise that they can make a significant difference to their own health in as 
little as 30 days. This helps to increase the participant’s belief that they can succeed in 
making lifestyle changes. CHIP encourages participants to believe that they can take some 
measure of control over their own health and the 30 days is pitched as a “self-
experiment” in which the participant is challenged to give it a go and then observe the 
results. Participants in CHIP have been shown to experience improved biometrics but also 
experience improved sense of well-being, quality of life (Aldana, Whitmer, et al., 2006) 
and psychological health (Thieszen et al., 2011). These factors may have a positive impact 
on the participants Perceived Behavioural Control. 
The fact that CHIP impacts the three sets of beliefs, as proposed by the Theory of 
Planned Behaviour, that impact intentions and thus action may contribute to the 
biometrics changes demonstrated in this study. More research is need to determine the 
factors that influence the behavior change that lead to the changes observed in the CHIP 
studies. 
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4.4.7 Volunteer vs. professional facilitators 
A major focus of this dissertation is the efficacy of volunteer delivery CHIP 
interventions. This chapter has shown that volunteers, individuals who donate their time, 
can be effective in the delivery of CHIP interventions. Alter (2007) asserted the common 
perception that lifestyle modification programs that are intensely supported by trained, 
experienced health care professionals can be expected to have greater efficacy than 
those delivered by volunteers. However a comparison between the results from this 
study and the results obtained from published articles examining CHIP delivered by paid 
professional facilitator’s shows similar outcomes (Table 4-3).  
While no study of the effectiveness of the CHIP lifestyle intervention when 
delivered by volunteers had been published prior to this dissertation, there is evidence in 
the literature that the volunteers have been effectively utilised in the delivery of other 
community-based lifestyle modification programs. Volunteers, from Faith in Action 
groups, were successfully used to deliver the Strong for Life program to elderly people. It 
was found that these trained volunteers could safely deliver programs to a community 
group of frail older persons (Etkin et al., 2006). Further, Schneider et al (2007) concluded 
that volunteers can successfully deliver health promotion programs which allows for 
wider program dissemination than is possible using only professional leaders. 
An obvious advantage of utilising volunteer facilitators is the cost saving when 
compared to utilising paid facilitators (Parkin & McKeganey, 2000). However, there may 
be other advantages in using volunteer, community-based facilitators to deliver health 
programs. It has been observed that for a community program to be successful, at least 
one person must champion the program (Steckler & Goodman, 1989). Volunteers, who 
are members of the local community, already have relationships with individuals in the 
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community and these relationships can be utilised to encourage members of that 
community to be proactive about their health and make necessary life changes (Kong, 
1997). This means that they are often better placed than paid professionals to champion 
a program. As Kong (1997) suggests: a passionate volunteer can incite his peers to action. 
In addition, friendship and social networks which are tapped into by peer volunteers, 
have been shown to be protective when contributing towards positive health behaviour 
(Milburn, 1995). 
Volunteering has also been shown to have significant benefits for those who 
volunteer (Grossman & Furano, 1999). A study of older volunteers reported that they felt 
they were “a great deal better off” for having volunteered and that the benefits of 
volunteering were also felt by their families (Morrow-Howell, Hong, & Tang, 2009). 
Volunteering in peer educational programs has been found to be a positive and rewarding 
experience (Karwalajtys et al., 2009). It has been found that volunteers in peer 
educational programs, targeting drug and sexual behaviour, make many positive lifestyle 
changes as a result of the information they learn while volunteering (Parkin & 
McKeganey, 2000).  
Klein, Sondag, and Drolet (1994) found that the motivations for volunteering in 
university student peer health educators ranged from altruistic motives such as wanting 
to help others to self-efficacy beliefs, and the need to satisfy personal health goals.  The 
motivation of volunteers in this study was probably similarly varied. 
Yuasa et al (2007) observe that if a significant initial investment is made in social 
and human capital, other forms of capital, such as financial, physical and natural, are not 
always necessary. Using volunteers can maximise the use of social and human capital 
(Gratton & Ghoshal, 2003). The utilisation of voluntary facilitators can dramatically 
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increase the scope and efficacy of lifestyle modification programs while keeping costs to a 
minimum. 
This study indicates that volunteers can be effective in the facilitation of lifestyle 
intervention programs. 
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4.5 Conclusion 
The overall and stratified results outlined in this chapter provide evidence that the 
CHIP intervention, when delivered by volunteers to free-living participants in their 
community, can effect statistically significant reductions in chronic disease risk factors. 
The clinical significance of the results are indicated by the significant reductions observed 
in the Framingham Risk Score and MetS status from baseline to post-intervention. The 
results observed in this study showed similar outcomes to those reported in the literature 
for CHIP interventions delivered by paid, professional facilitators.  
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Chapter 5 Results part 2: The influence of selected participant 
characteristics on the effectiveness of the CHIP lifestyle 
interventions 
5.1 Introduction 
In the previous chapter, the first research question of this study which focused on 
the effectiveness of the volunteer-delivered, community-based CHIP lifestyle 
intervention, was addressed. In this chapter, the second research question: “What is the 
impact of selected participant factors, including age, gender, marital status, religious 
affiliation, previous history, family history and body weight on the outcomes achieved by 
participants in the CHIP intervention?” is examined. 
To address the second research question, this chapter presents an analysis of the 
impact the selected participant factors including age, gender, marital status, religious 
affiliation, previous history, family history and body weight on changes in the outcome 
measures of lipid profile, BMI, FPG and BP. This chapter is presented in six sections which 
commences with this introduction. The second section presents an overview of the 
statistical methods used in this chapter. The third section examines the impact of the 
selected participant factors on the outcome measures. In the fourth section all the 
participant factors are included in regression models to determine their relative 
influences on the outcome measures and to control for the influence of selected factors 
on the outcomes of other factors. The fifth section presents a discussion of the key 
findings with reference to the literature and the chapter ends with a concluding 
statement.  
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5.2 Statistical analyses 
In order to analyse participant factors, the participants in the study were grouped 
into appropriate categories:  
Gender   Male, Female 
Age    Decadal age groups 
Marital Status   Single, Married, Divorced, Widowed 
Religious Affiliation  Seventh-day Adventist, non-Seventh-day Adventist 
Body Mass Index  WHO BMI Categories 
Family History   family history, no family history  
Previous History  previous history, no previous history 
For each of the factors, differences in the biometrics at baseline between the 
categories were assessed using appropriate t-testing or ANOVA. Next the change in 
biometrics from baseline to post-intervention within the same category was examined 
using paired t-tests.  If the change in biometrics was found to be significant within 
categories, the difference in change between categories was examined using appropriate 
t-tests or ANOVA. When a significant difference between the categories was identified, 
Bonferroni’s post hoc analyses were performed to identify where the differences 
occurred. Cohen’s d was calculated to show the effect size where appropriate.  
5.3 Participant factors  
5.3.1 Gender  
Of the 5043 participants, who provided their gender, 1690 (33.5%) were male and 
3353 (66.5%) were female. The age of male participants (57.86 ± 12.97) was slightly older 
than the female participants (56.98 ± 12.91) [t (5040) = 2.240, p = 0.025].  
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 Gender differences in biometrics at baseline 
At baseline, the male participants had significantly lower TC (10.8%), HDL (28.2%) 
and LDL (5.5%) but significantly higher TG (10.4%), FPG (12.5%), SBP (2.6%) and DBP 
(3.1%) than the female participants. There was no significant difference between the 
male and female participants’ BMI at baseline (Table 5-1). 
Table 5-1 Baseline biometric by gender 
  Biometric by Gender   
  At Baseline   
  Male Female % Diff      
  N Mean SD N Mean SD  t df Sig Cohen's d 
TC 1672 180.2 40.8 3316 199.7 41.00 -10.8 -15.86 4986 <0.001 -0.48 
HDL 1671 46.0 21.4 3316 58.9 26.38 -28.2 -18.63 4024 <0.001 -0.54 
LDL 1630 123.5 60.4 3270 133.7 61.51 -8.2 -5.45 4898 <0.001 -0.17 
TG 1670 153.2 102.6 3312 137.3 82.16 10.4 5.52 2776 <0.001 0.17 
FPG 1655 105.4 32.2 3275 92.2 26.82 12.5 6.75 2839 <0.001 0.45 
BMI 1672 31.1 6.7 3247 31.0 7.62 0.1 0.17 3761 0.867 0.01 
SBP 1667 135.4 19.0 3295 131.9 19.66 2.6 6.13 4960 <0.001 0.18 
DBP 1667 81.5 11.0 3291 79.0 11.65 3.1 7.31 4956 <0.001 0.22 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 Changes baseline to post-intervention for male and female participants 
There were significant (p<0.001) reductions from baseline to post-intervention in all eight 
biometric risk factors for both the male and female participants (Table 5-2 and Units: TC, 
HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Table 5-3). 
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Table 5-2 Changes in biometrics for male participants 
 Baseline to Post-Intervention Changes for Male Participants  
 Baseline Post-intervention        
 N Mean SD N Mean SD % Diff  Change t df Sig Cohen’s d 
TC 1563 180.80 40.80 1563 157.03 32.22 13.2 23.8 34.82 1562 <0.001 0.65 
HDL 1561 46.13 1.54 1561 42.63 19.84 7.6 3.5 16.65 1560 <0.001 0.33 
LDL 1512 124.61 61.32 1512 104.28 50.82 16.3 20.3 28.02 1511 <0.001 0.36 
TG 1560 153.84 102.24 1560 136.31 80.40 11.4 17.5 9.90 1559 <0.001 0.19 
FPG 1547 105.54 32.36 1547 96.87 22.27 8.2 8.7 16.20 1546 <0.001 0.32 
BMI 1541 31.04 6.73 1541 29.96 6.36 3.5 1.1 44.88 1540 <0.001 0.17 
SBP 1542 135.72 18.61 1542 128.23 16.07 5.5 7.5 19.55 1541 <0.001 0.43 
DBP 1542 81.59 10.98 1542 76.79 9.98 5.9 4.8 19.53 1541 <0.001 0.46 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Table 5-3 Changes in biometrics for female participants 
 Baseline to Post-Intervention Changes for Female Participants  
 Baseline Post-intervention        
 N Mean SD N Mean SD  % Diff Change t df Sig 
Cohen’s 
d 
TC 3090 200.0 40.74 3090 179.7 36.81 10.1 20.3 42.44 3089 <0.001 0.52 
HDL 3091 59.2 26.59 3091 53.8 23.80 9.2 5.4 32.98 3090 <0.001 0.22 
LDL 3036 134.3 62.10 3036 118.9 56.18 11.5 15.5 31.62 3035 <0.001 0.26 
TG 3088 138.1 82.70 3088 130.3 71.36 5.6 7.8 7.83 3087 <0.001 0.10 
FPG 3038 99.1 26.79 3038 93.8 20.24 5.3 5.3 17.81 3037 <0.001 0.22 
BMI 2974 31.0 7.58 2974 30.6 7.32 1.4 0.4 56.90 2973 <0.001 0.06 
SBP 3016 131.9 19.56 30.16 126.0 29.18 4.5 6.0 11.41 3015 <0.001 0.24 
DBP 3014 79.1 11.64 3014 75.2 9.87 5.0 3.9 20.10 3013 <0.001 0.36 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
 Difference in change of biometrics from baseline to post-intervention between 
male and female participants 
The males experienced significantly greater reductions in TC, LDL, TG, FPG, BMI 
and BP than the female participants, but a significantly lower reduction in HDL. However 
the effect size, as shown by Cohen’s d, was small (Table 5-4). 
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Table 5-4 Difference in change pre- to post-intervention between male and female 
 Change baseline to post-intervention between male and female   
 Male Female        
 N Mean SD N Mean SD  Difference   % Diff t df Sig 
Cohen's 
d 
TC 1563 23.78 27.00 3090 20.29 26.57 3.49 14.7 4.21 4651 <0.001 0.13 
HDL 1561 3.50 8.30 3091 5.41 9.13 -1.91 -54.6 -7.19 3406 <0.001 -0.22 
LDL 1512 20.36 28.26 3036 15.46 26.93 4.90 24.1 5.70 4546 <0.001 0.18 
TG 1560 17.53 69.94 3088 7.79 55.26 9.74 55.6 4.80 2568 <0.001 0.16 
FPG 1547 8.68 21.08 3038 5.29 16.38 3.39 39.1 5.54 2519 <0.001 0.18 
BMI 1540 1.08 0.93 2972 0.93 0.80 0.15 13.9 5.45 2723 <0.001 0.17 
SBP 1542 7.49 10.79 3016 5.95 31.61 1.54 20.6 1.97 4556 0.049 0.07 
DBP 1542 4.80 12.01 3014 3.90 13.49 0.90 18.8 2.70 4554 0.007 0.07 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
 Summary  
At baseline, the male participants had lower TC, HDL and LDL but higher TG, FPG, 
SBP and DBP than the female participants. There was no difference between male and 
female participants in baseline BMI. Both male and female participants achieved 
significant changes during intervention in all biometric scores but males achieved greater 
improvements in risk factor status with greater reductions in TC, LDL, TG, FPG, BMI, SBP 
and DBP but less reduction in HDL. 
5.3.2 Age  
Age data were available on 5042 participants. The mean age was 57.29 + 12.91 
years (range = 10 – 100 years). 
The participants were grouped into decadal age categories. However, due to low 
numbers, all participants under the age of 30 were grouped into a single category, as 
were those over the age of 80 (Table 5-5).  
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Table 5-5 Age categories used for analysis 
Age Range Frequency Percent 
0 – 29 158 3.1 
30-39 283 5.6 
40-49 799 15.8 
50-59 1549 30.7 
60-69 1429 28.3 
70-79 680 13.5 
>80 144 2.9 
Total 5042 99.9 
 
 Biometrics by age category at baseline 
Using one-way ANOVA, significant differences between the participants in various 
age categories at baseline were identified: TC [F(6, 4980) = 25.90, p < 0.001], LDL [F(6, 
4892) = 9.66, p < 0.001], TG [F(6, 4974) = 7.22, p < 0.001], for FPG [F(6, 4922) = 16.04, p < 
0.001] BMI [F(6, 4911) = 20.56, p < 0.001] SBP [F(6, 4954) = 92.67, p < 0.001] and DBP 
[F(6, 4950) = 1608, p<0.001] and HDL [F(6, 4979) = 2.70, p < 0.013]  
(Figure 5-3 and Figure 5-4).  
Post Hoc analysis identified that baseline TC, LDL, TG, FPG, BMI and DBP was lower 
in the younger and older age groups, peaking in the 50-59 age group. HDL levels rose with 
age peaking in the 70-79 age group. SBP continued to rise with age. 
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*Sig at p= 0.05, ** Sig at p = 0.01, ***significant at p <0.001 
 
Figure 5-1 Lipid profile at baseline by age 
 
 
*Sig at p= 0.05, ** Sig at p = 0.01, ***significant at p <0.001 
 
Figure 5-2 Distribution of baseline FPG, BMI and BP by age 
 
TC *** HDL * LDL *** TG ***
0-29 166.56 50.66 109.8 110.7
30-39 180.05 51.14 121.56 134.03
40-49 193.33 53.7 132.29 139.29
50-59 199.14 54.99 136.07 149.07
60-69 195.4 54.9 131.36 145.96
70-79 189.52 56.84 125.31 140.76
80+ 177.31 52.89 109.92 119.3
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 Baseline to post-intervention changes within age groups 
With the exception of TG and FPG in the 0-29 age category significant change, was 
observed, baseline to post-intervention, for all age groups in all biometrics, at better than 
p = 0.05. Effect size ranged from small to moderate with the largest effect size for all age 
groups being for TC and the smallest effect sizes being for BMI and TG (Table 5-6 to Table 
5-12). 
 
Table 5-6 Biometric changes from baseline to post-intervention for the 0-29 age group 
 Baseline to Post-Intervention Change 0-29 Age Category  
 Baseline Post-intervention       
 Mean SD Post SD Change % t df p Cohen's d 
TC 166.8 30.64 151.5 30.72 15.3 9.2 7.51 143 <0.001 0.50 
HDL 50.3 23.98 48.1 23.86 2.2 4.4 2.52 143 0.013 0.09 
LDL 109.9 46.37 95.7 37.03 14.3 13.0 6.63 139 <0.001 0.34 
TG 109.6 68.14 107.2 63.91 2.4 2.2 0.85 143 0.398 0.04 
FPG 86.3 11.05 84.3 13.80 2.0 2.3 1.90 141 0.06 0.16 
BMI 28.7 8.06 27.9 7.65 0.8 2.6 9.17 137 <0.001 0.10 
SBP 118.7 15.15 114.0 12.55 4.7 4.0 4.58 137 <0.001 0.34 
DBP 74.1 13.10 70.9 9.04 3.3 4.4 3.32 137 0.001 0.30 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Table 5-7 Biometric changes from baseline to post-intervention for the 30-39 age group 
 Baseline to Post-Intervention Change 30-39 Age Category  
 Baseline Post-intervention       
 Mean SD Post SD Change % t df p Cohen's d 
TC 182.3 40.33 163.4 37.69 19.0 10.4 12.21 254 <0.001 0.49 
HDL 52.0 24.49 47.6 22.86 4.4 8.4 7.84 254 <0.001 0.18 
LDL 124.5 57.56 110.1 52.57 14.4 11.6 9.23 251 <0.001 0.26 
TG 135.9 97.30 121.8 70.63 14.1 10.4 3.11 254 0.002 0.17 
FPG 92.9 26.85 87.8 15.60 5.1 5.5 4.55 252 <0.001 0.24 
BMI 31.9 8.90 30.9 8.51 1.0 3.3 15.17 247 <0.001 0.12 
SBP 122.4 17.19 117.9 13.25 4.5 3.6 5.78 251 <0.001 0.29 
DBP 79.1 10.85 75.9 9.17 3.2 4.1 5.84 251 <0.001 0.32 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
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Table 5-8 Biometric changes from baseline to post-intervention for the 40-49 Age Group 
 Baseline to Post-Intervention Change 40-49 Age Category  
 Baseline Post-intervention       
 Mean SD Post SD Change % t df P Cohen's d 
TC 193.5 39.10 169.4 33.90 24.1 12.5 24.24 720 <0.001 0.66 
HDL 53.6 24.45 48.4 20.78 5.3 9.8 15.25 719 <0.001 0.23 
LDL 132.3 60.99 112.8 51.28 19.5 14.7 18.23 699 <0.001 0.35 
TG 141.1 97.78 128.0 78.74 13.1 9.3 5.41 720 <0.001 0.15 
FPG 97.6 26.37 92.4 19.65 5.2 5.3 8.13 709 <0.001 0.23 
BMI 31.4 8.00 30.3 7.71 1.0 3.3 30.09 705 <0.001 0.13 
SBP 126.5 16.51 119.9 14.91 6.6 5.2 13.42 715 <0.001 0.42 
DBP 81.1 11.26 76.6 9.95 4.5 5.6 12.28 714 <0.001 0.43 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Table 5-9 Biometric changes from baseline to post-intervention for the 50-59 Age Group 
 Baseline to Post-Intervention Change 50-59 Age Category  
 Baseline Post-intervention       
 Mean SD Post SD Change % t df P Cohen's d 
TC 200.0 40.96 175.6 37.31 23.4 11.8 32.10 1442 <0.001 0.60 
HDL 55.0 25.78 50.0 23.36 5.0 9.1 22.64 1441 <0.001 0.20 
LDL 136.3 62.81 117.7 56.21 18.6 13.6 24.82 1402 <0.001 0.31 
TG 149.0 95.18 136.1 75.93 12.9 8.7 7.32 1439 <0.001 0.15 
FPG 103.7 32.44 96.3 22.38 7.5 7.2 13.82 1412 <0.001 0.27 
BMI 31.9 7.58 30.9 7.29 1.1 3.3 46.59 1407 <0.001 0.14 
SBP 131.5 18.24 126.3 33.18 5.3 4.0 5.13 1412 <0.001 0.20 
DBP 81.2 11.13 77.0 9.69 4.2 5.2 15.25 1411 <0.001 0.40 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Table 5-10 Biometric changes from baseline to post-intervention for the 60-69 Age Group 
 Baseline to Post-Intervention Change 60-69 Age Category  
 Baseline Post-intervention       
 Mean SD Post SD Change % t df P Cohen's d 
TC 196.1 42.92 174.9 39.49 21.2 10.8 29.17 1315 <0.001 0.51 
HDL 55.5 25.84 50.6 23.03 4.9 8.9 20.44 1316 <0.001 0.20 
LDL 132.8 69.92 115.8 58.88 17.0 12.8 22.30 1296 <0.001 0.26 
TG 146.7 86.33 136.7 73.87 10.0 6.8 6.14 1314 <0.001 0.12 
FPG 103.3 28.48 96.2 20.49 7.1 6.9 15.02 1301 <0.001 0.29 
BMI 31.0 6.64 30.0 6.36 1.0 3.2 44.33 1267 <0.001 0.15 
SBP 137.3 18.93 129.8 16.13 7.5 5.5 16.94 1277 <0.001 0.43 
DBP 79.84 10.84 75.5 9.85 4.3 5.4 15.00 1278 <0.001 0.42 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
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Table 5-11 Biometric changes from baseline to post-intervention for the 70-79 Age Group 
 Baseline to Post-Intervention Change 70-79 Age Category  
 Baseline Post-intervention       
 Mean SD Post SD Change % t df p Cohen's d 
TC 190.1 43.35 171.4 39.20 18.6 9.8 17.78 636 <0.001 0.45 
HDL 57.0 28.84 52.6 26.19 4.4 7.7 11.82 636 <0.001 0.16 
LDL 126.5 62.74 112.0 56.16 14.5 11.5 13.08 619 <0.001 0.24 
TG 141.9 82.34 133.7 71.40 8.2 5.8 4.49 636 <0.001 0.11 
FPG 103.0 27.29 96.8 22.58 6.3 6.1 8.74 628 <0.001 0.25 
BMI 29.6 5.91 28.8 5.68 0.9 2.9 30.52 614 <0.001 0.15 
SBP 141.8 19.43 133.6 16.46 8.1 5.7 12.33 626 <0.001 0.45 
DBP 78.7 12.99 74.0 10.31 4.7 6.0 10.32 626 <0.001 0.40 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Table 5-12 Biometric changes from baseline to post-intervention for the >80 Age Group 
 Baseline to Post-Intervention Change >80 Age Category  
 Baseline Post-intervention       
 Mean SD Post SD Change % t df p Cohen's d 
TC 177.7 38.12 164.0 36.05 13.7 7.7 6.63 136 <0.001 0.37 
HDL 53.1 18.54 49.8 16.96 3.3 6.2 4.34 136 <0.001 0.18 
LDL 110.2 47.68 100.1 46.75 10.1 9.1 5.57 135 <0.001 0.21 
TG 121.0 70.80 112.8 65.61 8.2 6.8 2.24 136 0.027 0.12 
FPG 98.8 25.86 95.3 18.78 3.5 3.6 2.76 135 0.007 0.16 
BMI 26.6 4.64 26.0 4.50 0.6 2.1 8.94 128 <0.001 0.12 
SBP 143.7 21.09 137.4 20.19 6.2 4.3 3.79 133 <0.001 0.30 
DBP 74.9 10.38 72.6 10.00 2.3 3.0 2.63 132 0.01 0.22 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
 
 Differences in change from baseline to post-intervention in biometric measures 
between age categories 
As shown in Figure 5-3  and Figure 5-4 there were significant differences between 
the various age categories in the change in TC [F(6, 4646) = 7.24, p <0.001, LDL, F(6, 4541) 
= 4.64, p < 0.001], HDL [F(6, 4645) = 3.50, p= 0.002], FPG, [F(6, 4578) = 3.89, p = 0.001] 
and BMI [F(6, 4505) = 12.80 p = 0.01]. There was no difference between age categories 
for change in TG, SBP and DBP. 
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*Sig at p= 0.05, ** Sig at p = 0.01, ***significant at p <0.001 
 
 
Figure 5-3 Comparison of percent change in lipid profile by age 
  
*Sig at p= 0.05, ** Sig at p = 0.01, ***significant at p <0.001 
Figure 5-4 Comparison of percent change in FPG, BMI and BP by age category 
 TC *** HDL ** LDL *** TG
0-29 9.20 4.36 13.00 2.17
30-39 10.40 8.41 11.56 10.39
40-49 12.46 9.79 14.71 9.13
50-59 11.76 9.11 13.63 8.66
60-69 10.82 8.87 12.81 6.79
70-79 9.81 7.71 11.45 5.76
80+ 7.69 6.16 9.13 6.78
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Post hoc analyses found that largest change in TC, LDL and HDL was achieved in 
the 40-49 age category. The greatest change in FPG and BMI occurred in the 50-59 age 
category, although these changes were not significantly higher than the 40-49 age 
category.  
 Summary 
Baseline mean TC, LDL, TG, FPG levels, BMI and DBP tended to be lower in the 
younger and older age groups, peaking in the 50-59 age group. HDL levels rose with 
increasing age, peaking in the 70-79 age group. SBP continued to rise with age. Significant 
changes were observed from baseline to post-intervention in all biometrics in all age 
categories, except for TG and FPG in the 0-29 age categories. The largest changes in TC, 
LDL and HDL occurred in the 40-49 age category, and in the 50-59 age category for FPG 
and BMI, although these changes were not significantly higher than the 40-49 age group.  
5.3.3 Gender differences across age ranges 
Having observed that there were significant differences in the biometric baseline 
and change data in age and gender, this section compares the male and female 
participants across the different age categories.  
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The number of males and females in each age category is shown in Table 5-13. 
Table 5-13  Age range by gender 
 Male Female 
Age Range 
(years) 
Frequency Percent Frequency Percent 
0 – 29 56 3.3 102 3.0 
30-39 83 4.9 200 6.0 
40-49 249 14.7 550 16.4 
50-59 504 29.8 1045 31.2 
60-69 508 30.1 921 27.5 
70-79 240 14.2 440 13.1 
80+ 50 3.0 94 2.8 
Total 1690 100 3352 100 
 
There were only slight differences in the number of male and female participants 
in each age category, however, these differences are significant [t (5040) = 2.19, p = 
0.034]. 
 
 Differences in the change between baseline and post-intervention biometric 
measures by age categories and gender 
Two-way ANOVA analysis to examine the combined effect of age and gender, on 
change baseline to post-intervention, found that there were significant interaction effect 
between these variables for TC [F(6, 4639) = 2.91, p = 0.008], HDL [F(6, 4639) = 2.25, p = 
0.036], LDL [F(6, 4639) = 2.25, p = 0.036], TG [F(6, 4634) = 5.10, p = <0.001] and FPG [F(6, 
4634) = 5.10, p = <0.001].  
Independent t-tests indicated that change in TC was significantly greater for males 
in 30-39, 40-49 and >80 age groups (Figure 5-5), change in HDL was significantly lower for 
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males in the 0-29, 40-49, 50-59 and 60-69 age groups (Figure 5-6). Males demonstrated 
significant greater change in LDL for all age groups except for the 70-79 category (Figure 
5-7) and for TG the change was greater for males in the 30-39, 40-49 and 50-59 age 
groups (Figure 5-8). Males also showed greater change in FPG in the 0-29, 40-49, 50-59 
and 60-69 age groups (Figure 5-9). 
There was no significant interaction effect for BMI [F(6, 4498) = 0.472, p = 0.830] 
and the mean effect for both gender [F(1, 4498) = 16.44, p = <0.001] and age was 
significant, [F(6, 4498) = 12.84, p = <0.001]. Males exhibited greater change in BMI than 
did the females and at a younger age than did the females (Figure 5-10).  
There was no significant interaction effect for either SBP [F(6, 4544) = 0.39, p = 
0.89] or DBP [F(6, 4542) = 1.33, p = 0. 24].  However neither of the mean effects for 
gender, SBP [F(1, 4544) = 0.88, p = 0.35], DBP [F(1, 4542) = 3.28, p = 0.07] or age SBP [F(6, 
4544) = 1.55, p = 0.16] DBP [F(6, 4542) = 1.79, p = 0.098] were significant. (Figure 5-11 & 
Figure 5-12). 
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Figure 5-5 Change in TC by age and gender 
 
Figure 5-6 Change in HDL by age and gender  
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Figure 5-7 Change in LDL by age and gender 
 
 
 
Figure 5-8 Change in TG by age and gender 
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Figure 5-9 Change in FPG by age and gender 
 
  
 
 
Figure 5-10 Change in BMI by age and gender 
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Figure 5-11 Change in SBP by age and gender 
 
 
Figure 5-12 Change in Diastolic BP by age and gender 
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 Summary 
The preceding sections of this chapter have shown that significant reduction in risk 
factors for chronic disease can be achieved by both male and female participants at any 
age.   In this section it has been demonstrated that the greatest reduction in risk factors 
occurs at a younger age for the male participants than the female participants with the 
greatest improvements occurring at least 1 decadal age category earlier in the male 
participants than in the female participants (Table 5-14). 
 
Table 5-14 Age category at which greatest reduction in risk factor occurs by gender 
 Age Category 
 Male Female 
TC (mg/dL) 40-49 50-59 
HDL (mg/dL) (smallest reduction) 0-29 40-49 
LDL (mg/dL) 40-49 60-69 
TG (mg/dL) 30-39 60-69 
FPG (mg/dL) 50-59 60-69 
BMI (kg/cm2) 30-39 50-59 
SBP (mmHg) 60-69 70-79 
DBP (mmHg) 40-49 70-79 
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5.3.4 Marital status 
Marital status was captured on 4375 participants, as shown in (Table 5-15). 
Table 5-15 Frequency table, mean age and gender for marital status 
Marital status Frequency Percent Mean Age Male (%) Female (%) 
Single 422 9.6 47.10 114 (7.5) 308 (10.8) 
Married 3237 74 57.61 1293 (85.2) 1944 (68.0) 
Divorced 415 8.2 57.05 85 (5.6) 330 (11.6) 
Widowed 301 5.9 70.17 26 (1.7) 275 (9.6) 
Total 4375 100  1518 (100) 2857 (100) 
 
Single participants were younger than the married and divorced participants, and 
the widowed participants were older than the other participants [F(3, 4370) = 218.16 (p 
<0.001); Table 5-15]. There was no difference between the age of the married and 
divorced participants.  
The influence of marital status on the biometrics (baseline and change) are 
presented below, however, it is acknowledged that there are potential confounders. 
Firstly, the difference in age between the marital status categories may have confounded 
the marital status effects. Secondly, a significantly higher proportion of the male 
participants (85.2%) were married than the female participants (68%) [χ2(3,N = 4375) = 
177.55, p < 0.001; Table 5-15]. The linear regression analyses, shown later in this chapter, 
controls for these factors.  
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 Differences in Biometrics by Marital Status at Baseline 
One way ANOVA tests indicated that there were significant differences, at 
baseline, for marital status in TC levels [F(3, 4326) = 3.27, p = 0.02] but not for, HDL and 
LDL or TG (Figure 5-13). Post hoc analysis indicated that the single participants had 
significantly lower TC levels at baseline.  
 
  
*Sig at p= 0.05, ** Sig at p = 0.01, ***significant at p <0.001 
Units: TC, HDL,LDL,TG,FPG = mg/dL:  
 
Figure 5-13 Lipids Profile at baseline by marital status  
  
TC * HDL LDL TG
Single 188.52 55.12 126.53 141.32
Married 192.03 54.22 130.46 143.78
Divorced 197.37 54.83 131.24 146.01
Widowed 193.23 54.19 122.82 146.27
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There were significant differences, at baseline, between participants of various 
marital status for BMI [F(3, 4274) = 15.37, p <0.001] and SBP [F (3, 4311) = 22.33, p 
<0.001] but not for FPG or DBP(Figure 5-14). Post hoc analysis found that married and 
widowed participants had significantly lower BMIs than do the single or divorced 
participants and that single participants had significantly lower SBP than participants in 
other marital categories while the widowed participants had significantly higher SBP. 
 
  
*Sig at p= 0.05, ** Sig at p = 0.01, ***significant at p <0.001 
Units: FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Figure 5-14 FPG, BMI, BP at baseline by marital status  
 
  
FPG BMI *** BP Sys*** BP Dia
Single 99.25 32.77 129.1 79.54
Married 100.97 30.57 133.02 79.88
Divorced 102.69 32.23 132.64 80.58
Widowed 103.44 30.74 140.89 78.4
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 Baseline to Post-Intervention Changes within Marital Category 
Significant change from baseline to post-intervention was observed in all 
biometrics within all marital categories. The effect size was moderate for TC, LDL and BP 
for all marital categories and for FPG for all categories except the Single Marital Category. 
For all other biometrics the effect size was small (Table 5-16 through Table 5-19).  
Table 5-16 Baseline to post-intervention change single marital category 
 Single Marital Category  
  Baseline Post-intervention Change      
  Baseline SD Post SD Mean %  t df p Cohen's d 
TC 189.5 44.44 170.0 36.67 -19.5 10.3 13.94 385 <0.001 0.48 
HDL 54.9 27.73 50.6 25.99 -4.3 7.8 9.87 387 <0.001 0.16 
LDL 126.9 62.05 111.8 56.52 -15.1 11.9 11.78 375 <0.001 0.25 
TG 141.5 98.84 133.7 81.61 -7.9 5.6 2.37 386 0.018 0.09 
FPG 98.7 29.74 94.7 24.13 -4.0 4.1 4.08 384 <0.001 0.15 
BMI 32.7 9.64 31.8 9.22 -0.9 2.9 15.62 379 <0.001 0.10 
SBP 129.5 20.18 123.9 17.07 -5.6 4.3 6.99 381 <0.001 0.30 
DBP 79.8 12.19 76.5 10.88 -3.2 4.1 4.18 6.69 <0.001 0.28 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Table 5-17 Baseline to post-intervention change married marital category 
 Married Marital Category  
  Baseline Post-intervention Change      
  Baseline SD Post SD Mean  %  t df p Cohen's d 
TC 192.5 41.13 170.7 37.36 -21.8 11.3 45.92 3014 <0.001 0.56 
HDL 54.4 26.26 49.7 23.47 -4.8 8.7 30.14 3013 <0.001 0.19 
LDL 131.2 63.58 113.5 57.75 -17.7 13.5 35.21 2944 <0.001 0.29 
TG 144.7 88.90 132.2 73.03 -12.5 8.6 11.33 3010 <0.001 0.15 
FPG 101.0 28.24 94.1 19.63 -6.9 6.8 20.64 2964 <0.001 0.29 
BMI 30.6 6.90 29.6 6.59 -1.0 3.3 66.63 2935 <0.001 0.15 
SBP 133.2 18.92 126.7 20.04 -6.6 4.9 12.42 2958 <0.001 0.34 
DBP 80.0 11.19 75.7 9.61 -4.2 5.3 22.64 2957 <0.001 0.41 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
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Table 5-18 Baseline to post-intervention change divorced marital category 
 Divorced Marital Category  
  Baseline Post-intervention Change      
  Baseline SD Post SD Mean  %  t df p Cohen's d 
TC 197.9 40.99 179.1 38.20 -18.8 9.5 13.16 371 <0.001 0.48 
HDL 55.0 24.88 50.5 23.27 -4.4 8.1 8.73 370 <0.001 0.18 
LDL 133.1 58.51 119.9 59.19 -13.2 9.9 9.64 364 <0.001 0.22 
TG 146.7 88.34 138.6 79.58 -8.2 5.6 2.50 370 0.013 0.10 
FPG 102.7 31.85 96.6 25.89 -6.1 5.9 7.20 366 <0.001 0.21 
BMI 32.2 7.86 31.3 7.61 -0.9 2.8 22.47 354 <0.001 0.12 
SBP 132.6 17.70 126.7 15.24 -5.9 4.4 8.17 363 <0.001 0.36 
DBP 80.5 12.67 76.3 9.98 -4.2 5.3 6.78 363 <0.001 0.37 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Table 5-19 Baseline to post-intervention change widowed marital category 
 Widowed Marital Category  
  Baseline Post-intervention Change      
  Baseline SD Post SD Mean  %  t df p Cohen's d 
TC 194.0 41.30 177.2 36.14 -16.8 8.6 9.70 276 <0.001 0.43 
HDL 54.8 21.67 51.3 19.82 -3.5 6.4 6.31 276 <0.001 0.17 
LDL 123.9 52.97 111.8 48.94 -12.1 9.8 7.48 270 <0.001 0.24 
TG 145.6 76.85 139.0 71.39 -6.6 4.6 2.19 276 0.03 0.09 
FPG 103.3 26.32 97.8 20.30 -5.6 5.4 5.32 271 <0.001 0.24 
BMI 30.7 7.30 29.9 6.95 -0.8 2.6 16.24 267 <0.001 0.11 
SBP 141.3 19.95 133.2 17.72 -8.1 5.7 7.56 268 <0.001 0.43 
DBP 78.7 11.40 73.9 9.81 -4.8 6.1 7.48 267 <0.001 0.45 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
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 Differences in change from baseline to post-intervention in biometric measures 
between marital status categories 
There were significant differences between various marital status categories for 
changes in TC [F(3,4045)=4.54, p = 0.004] and LDL [F(3,3952) = 6.57, p < 0.001]. The 
differences in HDL and triglyceride change were not significant. Post hoc analysis showed 
that the married participants had significantly greater change in TC than the widowed 
participants and significantly greater change in LDL than the widowed and divorced 
participants (Figure 5-15). 
  
*Sig at p= 0.05, ** Sig at p = 0.01, ***significant at p <0.001 
 
Figure 5-15 Distribution of change in lipid profile by marital category 
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Divorced 18.82 4.34 13.19 8.18
Widowed 16.76 3.5 12.14 6.63
0
5
10
15
20
25
m
m
/d
l
Change in Lipid Profile by Marital Catagory
  150 
Significant differences were demonstrated between marital categories for changes 
in FPG [F(3, 3984) = 3.12, p = 0.025] and BMI [F(3, 3934) = 7.02, P < 0.001] but not for 
changes in SBP or DBP. Married participants showed significantly greater change in FPG 
then did single participants and significantly greater change in BMI than the widowed 
participants (Figure 5-16). 
 
  
Sig at p= 0.05, ** Sig at p = 0.01, ***significant at p <0.001 
Units: FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Figure 5-16 Distribution of change in FPG, BMI, SBP and DBP by marital category 
 
 Summary  
Regardless of marital status category significant changes were achieved by the 
participants in volunteer-delivered, community-based CHIP interventions. 
At baseline single participants had significantly lower SBP and TC while married 
and divorced participants had significantly lower BMI.  
FPG * BMI *** SBP DBP
Single 4.02 0.34 5.53 3.23
Married 6.86 1.01 6.55 4.24
Divorced 6.07 0.9 5.87 4.23
Widowed 5.55 0.79 8.06 4.78
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Marital status had a significant influence on the change in TC, LDL, FPG and BMI. 
Married participants had significantly greater reductions in TC, LDL, FPG and BMI. 
Widowed participants had smaller reductions in TC and LDL. Single participants had 
smaller reductions in BMI.  
5.3.5 Religious affiliation 
The majority of the programs analysed in this study were conducted under the 
auspices of the Seventh-day Adventist Church. Participants were therefore asked to 
identify whether or not they were members of the Seventh-day Adventist Church and this 
information was used to categorise them as either Seventh-day Adventists (SDA) or non-
Seventh-day Adventists (non-SDA). Of the participants in this sample 1171 (23.2%) 
identified themselves as SDA and 3845 (76.2%) as being non-SDA, while 29 (0.6%) 
participants did not give their religious affiliation. There was no difference between the 
SDA and non-SDA participants in age [t(1798) = -0.341, p = 0.733] or gender [t(5012) = -
0.537, p = 0.591]. 
 Differences in biometrics at baseline by Religious Affiliation Category 
SDA participants had lower biometric scores at baseline than the non-SDA 
participants for HDL, LDL, FPG and BMI at p < 0.001 and SBP at p = 0.029 however the 
effect size was small. There was no difference between the SDA and non-SDA participants 
for baseline TC, TG and DBP (Table 5-20) 
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Table 5-20 Baseline Biometrics by religious affiliation 
   Biometrics at Baseline by Religious Affiliation   
  SDA Non- SDA Difference      
  N Mean SD N Mean SD Mean % t df Sig Cohen’s d 
TC 1161 191.1 41.89 3800 193.7 41.96 -2.6 -1.4 -1.87 4959 0.061 -0.06 
HDL 1162 49.8 16.49 3798 56.1 27.64 -6.4 -12.8 -9.68 3275 <0.001 -0.29 
LDL 1147 118.9 46.34 3726 133.9 65.01 -15.0 -12.6 -8.65 2655 <0.001 -0.27 
TG 1161 142.7 87.95 3794 142.8 90.59 -0.1 -0.1 -0.02 4953 0.984 0.00 
FPG 1132 97.5 26.37 3771 102.5 29.56 -5.0 -5.2 -5.49 2057 <0.001 -0.18 
BMI 1141 29.9 7.31 3752 31.3 7.32 -1.4 -4.7 -2.10 4935 <0.001 -0.19 
SBP 1154 132.0 19.36 3783 133.4 19.56 -1.4 -1.1 -2.19 4935 0.029 -0.07 
DBP 1154 79.8 11.65 3779 79.9 11.53 -0.1 -0.1 -0.21 4931 0.836 -0.01 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
 
 Baseline to Post-Intervention Change within Religious Category 
There were significant reductions from baseline to post-intervention in all 
biometrics (p <0.001) for participants in both religious affiliation categories (Table 5-21, 
Table 5-22).  
 
Table 5-21 Baseline to post-intervention change for SDA participants 
  Baseline to Post-Intervention Changes for SDA Participants   
  Baseline Post-intervention Change      
  N Mean SD N Mean SD Mean % t df Sig Cohen's d 
TC 1075 191.6 41.64 1075 173.4 37.30 18.2 9.5 23.59 1074 <0.001 0.46 
HDL 1076 49.7 16.60 1076 49.6 15.48 0.1 0.3 12.65 1075 <0.001 0.01 
LDL 1060 119.6 47.07 1060 106.0 41.94 13.6 11.4 18.55 1059 <0.001 0.31 
TG 1075 144.0 88.63 1075 131.8 74.96 12.3 8.5 7.12 1074 <0.001 0.15 
FPG 1040 97.8 36.91 1040 92.9 20.74 4.9 5.1 9.63 1039 <0.001 0.17 
BMI 1033 30.0 7.37 1033 29.1 6.99 0.9 2.9 32.25 1032 <0.001 0.12 
SBP 1052 132.3 19.45 1052 125.6 31.33 6.7 5.1 7.03 1051 <0.001 0.26 
DBP 1052 79.9 11.76 1052 75.6 10.24 4.3 5.4 13.85 1051 <0.001 0.39 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
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Table 5-22 Baseline to post-intervention change for non-SDA participants 
  Baseline to Post-Intervention Changes for non-SDA Participants   
  Baseline Post-intervention Change      
  N Mean SD N Mean SD Mean % t df Sig Cohen's d 
TC 3551 194.1 41.80 3551 171.7 38.01 22.4 11.6 49.24 3550 <0.001 0.56 
HDL 3549 56.5 27.83 3549 51.8 24.98 4.7 8.2 34.56 3548 <0.001 0.18 
LDL 3461 135.7 65.69 3461 116.5 58.19 19.2 14.1 37.51 3460 <0.001 0.31 
TG 3546 143.3 90.65 3546 132.6 74.59 10.7 7.5 10.30 3545 <0.001 0.13 
FPG 3518 102.4 29.49 3518 95.5 20.07 6.9 6.8 31.95 3517 <0.001 0.28 
BMI 3453 31.3 7.27 34.53 30.3 7.00 1.0 3.3 71.42 3452 <0.001 0.14 
SBP 3481 133.5 19.30 3481 127.1 23.56 6.4 4.8 16.53 3480 <0.001 0.30 
DBP 3479 79.9 11.39 3479 75.8 9.86 4.2 5.2 23.48 3478 <0.001 0.39 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
 Baseline to Post-Intervention Changes between Religious Categories 
Non-SDA participants showed significantly greater reductions, than SDA 
participants in TC (11.6% vs 9.5%), HDL (0.3% vs 8.2%), LDL (11.4% vs 14.1%), FPG (5.0% vs 
6.9%) and BMI (2.9% vs 3.3%) at p <0.001. The differences in reductions in TG and BP 
were not significant (Table 5-23). 
Table 5-23 Comparison of change post-intervention by religious category 
  Change Post-Intervention By Religious Category   
  SDA Non-SDA Difference      
  N Mean SD N Mean SD Mean % t df Sig Cohen’s d 
TC 1075 18.2 25.29 3551 22.4 27.15 -4.2 -23.3 -4.73 1885 <0.001 -0.16 
HDL 1076 3.1 8.12 3549 5.3 9.09 -2.1 -68.4 -7.37 1962 <0.001 -0.25 
LDL 1060 13.6 23.91 3461 18.2 28.47 -4.5 -33.3 -5.15 2060 <0.001 -0.17 
TG 1075 12.3 56.52 3546 10.7 62.12 1.5 12.5 0.719 4619 0.472 0.03 
FPG 1040 4.8 16.19 3518 6.9 18.7 -2.1 -43.3 -3.53 1932 <0.001 -0.12 
BMI 1033 0.9 0.87 3453 1.0 0.84 -0.2 -17.2 -4.89 4484 <0.001 -0.18 
SBP 1052 6.7 30.75 3481 6.4 22.92 0.3 3.8 0.28 4531 0.777 0.01 
DBP 1052 4.3 10.11 3476 4.6 10.45 -0.2 -5.6 -5.68 4593 0.570 -0.02 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
 Comparison of Biometrics at Baseline and Post-Intervention by Religious 
Category 
Table 5-24 shows a comparison of the baseline and post-intervention biometric 
values for the SDA and non-SDA participants. At baseline the SDA participants had 
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significantly better biometric than did the non-SDA participants however the non-SDA 
participants had greater improvements in biometrics during the intervention.  The 
difference between SDA and non-SDA has reduced in just 30 days. 
 
Table 5-24 Comparison of biometrics at baseline and post-intervention by religious category 
Comparison of Biometrics between SDA and non-SDA at Baseline and Post-Intervention 
 Baseline Post-Intervention 
 SDA non-SDA 
% 
Difference 
SDA non-SDA 
% 
Difference 
TC 191.1 193.7 -1.4 173.3 171.7 0.9 
HDL 49.8 56.1 -12.8 46.5 51.1 -9.9 
LDL 118.9 133.9 -12.6 106.0 116.3 -9.8 
TG 142.7 142.8 NS 132.0 132.8 NS 
FPG 97.5 102.5 -5.2 93.1 95.4 -2.5 
BMI 29.9 31.3 -4.7 29.1 30.3 -4.2 
SBP 132.0 133.4 NS 125.5 127.1 NS 
DBP 79.8 79.9 NS 75.6 75.8 NS 
NS = not significant 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
 
 Summary 
While the SDA participants showed significantly better risk factor status at 
baseline than the non-SDA participants, the non-SDA participants showed significantly 
greater improvement in these risk factors, from baseline to post-intervention, than did 
the SDA participants. The health status of the SDA participants was still better post-
intervention than the non-SDA participants but the gap between the SDA and the non-
SDA had reduced over the period of intervention. 
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5.3.6 Body Mass Index  
In this section the impact of the participants’ level of obesity at program entry, as 
measured by a BMI, on their response to the intervention was examined.  
Data needed to calculate BMI was available on 4912 participants. Participants 
were grouped by weight at program entry according to the WHO BMI categories of 
Underweight, Normal, Overweight, Obese I, Obese II and Obese III (WHO, 2000).  As only 
37 participants were classified as underweight, they were included in the normal weight 
category. Table 5-25 shows the distribution of the participants across the various BMI 
categories. Also shown is the mean age participants and percentage of males in each 
category.  
 
Table 5-25 Frequency table and mean age for BMI categories 
BMI Range (kg/cm2) Frequency Percent Mean age % Male 
Underweight + Normal  <25 994 20.0 57.4±15.3 26.7 
Overweight 25-29.99 1504 30.6 58.5±12.8 35.4 
Obesity Class I 30 – 34.99 1206 24.6 57.8±11.8 34.7 
Obesity Class II 35 – 39.99 659 13.4 55.7±11.9 33.5 
Obesity Class III >40 549 11.2 54.5±11.4 29.1 
Total 4912 100.0   
 
There were significant differences between the mean ages of the different BMI 
categories [F(4, 4903) = 12.949 (p = < 0.001)]. Post hoc analysis indicated that the Obese 
Class II and Obese Class III participants were significantly younger than the lower BMI 
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categories. There was no significant gender difference between the various BMI 
categories (t(4911) = 0.145, p = 0.885)  
 Comparison of basline biometrics by Body Mass Index at program entry 
There were significant differences at baseline between the participants in the 
various BMI categories for TC, [F(4, 4868) = 10.89], HDL cholesterol, [F(4, 4867) = 42.91], 
LDL cholesterol [F(4, 4785) = 6.09] and, TG [F(4, 4863) = 106.39] at p < 0.001 (Figure 5-17).  
Post hoc analysis indicated that TC levels at baseline were significantly lower for 
participants in the Normal BMI categories than for participants in the Overweight, Obese 
Class I and the Obese Class III categories, but not significantly different from participants 
in the Obese Class II. Baseline LDL was lowest for participants in the normal category, 
peaking in the Overweight and Obese Class I category, but dropping off again in the two 
extreme obese categories. HDL was highest in those participants in the Normal BMI 
category and decreased as the BMI category increased.  TG levels were lowest in the 
Normal category and increased as the BMI increased (Figure 5-17). 
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*sig at p= 0.05, ** sig at p = 0.01, ***significant at p <0.001 
 
Figure 5-17 Comparison of baseline lipid profile by BMI category 
 
Significant differences were also observed, between participants in various BMI 
categories at program entry, for FPG [F(4, 481) = 123.58], SBP [F(4, 4864) = 105.34] and 
DBP [F(4, 4860) = 98.39] at p < 0.001. 
Post hoc analysis confirmed that for baseline FPG and BP, the lowest scores were 
in the Normal baseline BMI category and that the scores increased as the BMI increased 
peaking in the Obese Class III category (Figure 5-18). 
 
TC  *** HDL *** LDL *** TG ***
Normal (<25) 187.32 63.06 112.91 98.5
Overweight (25-30) 196.22 54.73 133.67 136.5
Obese Class I (30-35) 196.14 52.83 134.48 159.53
Obese Class II (35-40) 187.45 50.06 128.49 165.24
Obese Class III (>40) 193.04 48.44 123.66 172.91
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 *sig at p= 0.05, ** sig at p = 0.01, ***significant at p <0.001 
 
Figure 5-18 FPG and BP at baseline by BMI 
 
 Comparison of changes in biometric measures from baseline to post-
intervention within Body Mass Index categories 
Significant changes occurred from baseline to post-intervention in the biometric 
scores within all BMI categories at p < 0.001 except for TG in the Obese Class III category 
where p = 0.011 and for SBP in the normal category where there was no significant 
change (Table 5-26 to Table 5-30). 
FPG mg\dl *** SBP mmHg *** DBP mmHg ***
Normal (<25) 89.51 124.13 74.75
Overweight (25-30) 96.93 131.56 78.94
Obese Class I (30-35) 104.09 135.12 81.37
Obese Class II (35-40) 109.44 139.08 83.39
Obese Class III (>40) 118.6 141.33 84.28
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Table 5-26 Baseline to post-intervention change in participants with Normal BMI category 
 Normal BMI < 25 
 Baseline Post Change % t df p 
TC 188.0 169.8 18.2 9.7 23.51 912 <0.001 
HDL 63.7 59.0 4.7 7.4 13.10 912 <0.001 
LDL 126.5 111.6 14.9 11.8 17.19 904 <0.001 
TG 98.8 94.2 4.6 4.6 3.69 912 <0.001 
FPG 89.8 86.7 3.1 3.4 6.35 893 <0.001 
BMI 22.6 22.1 0.5 2.2 27.49 897 <0.001 
SBP 122.0 124.3 -2.23 -1.9 1.47 893 0.143 
DBP 74.7 72.0 2.7 3.7 8.45 893 <0.001 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Table 5-27 Baseline to post-intervention change in participants with Overweight BMI category 
 Overweight  BMI 25 – 29.99 
 Baseline Post Change % t df p 
TC 196.3 172.8 23.5 12.0 32.25 1408 <0.001 
HDL 54.1 49.9 4.2 7.7 21.38 1408 <0.001 
LDL 133.9 114.8 19.1 14.3 25.90 1381 <0.001 
TG 136.9 124.2 12.7 9.3 6.98 1408 <0.001 
FPG 96.9 91.7 5.2 5.4 12.72 1387 <0.001 
BMI 27.5 26.6 0.9 3.2 51.23 1387 <0.001 
SBP 131.8 125.1 6.7 5.1 16.47 1377 <0.001 
DBP 79.1 74.7 4.4 5.5 16.36 1377 <0.001 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Table 5-28 Baseline to post-intervention change in participants with Obese Class I BMI category  
 Obese Class I  BMI 30 - 34.99 
 Baseline Post Change % t df p 
TC 196.2 173.0 23.2 11.9 27.60 1130 <0.001 
HDL 52.8 48.1 4.7 8.90 20.36 1129 <0.001 
LDL 134.9 116.4 18.5 13.7 21.45 1098 <0.001 
TG 160.9 145.4 15.6 9.7 8.38 1129 <0.001 
FPG 103.9 96.8 7.1 6.9 13.53 1121 <0.001 
BMI 32.3 31.2 1.1 3.4 46.86 1125 <0.001 
SBP 135.4 128.0 7.4 5.4 17.01 1120 <0.001 
DBP 81.6 77.0 4.5 5.6 13.74 1117 <0.001 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
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Table 5-29 Baseline to post-intervention change in participants with Obese Class II BMI category  
 Obese Class II BMI 35 – 39.99 
 Baseline Post Change % t df p 
TC 193.4 171.0 22.4 11.6 20.70 607 <0.001 
HDL 50.2 45.6 4.6 9.2 14.09 607 <0.001 
LDL 128.7 111.3 17.3 13.5 16.09 588 <0.001 
TG 166.4 155.8 10.6 6.4 4.06 605 <0.001 
FPG 109.4 101.3 8.1 7.4 9.60 601 <0.001 
BMI 37.2 35.9 1.3 3.3 33.78 603 <0.001 
SBP 139.0 130.2 8.8 6.3 13.19 601 <0.001 
DBP 83.1 78.4 4.7 5.7 11.17 601 <0.001 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Table 5-30 Baseline to post-intervention change in participants with Obese Class III BMI category  
 Obese Class III 
 Baseline Post Change % t df p 
TC 188.0 170.9 17.1 9.1 14.83 498 <0.001 
HDL 48.7 44.0 4.7 9.6 12.83 498 <0.001 
LDL 124.6 112.0 12.6 10.2 9.93 485 <0.001 
TG 172.8 165.6 7.2 4.2 2.55 497 0.011 
FPG 118.9 106.4 12.5 10.5 10.38 490 <0.001 
BMI 45.8 44.2 1.6 3.5 29.49 497 <0.001 
SBP 141.5 132.9 8.6 6.1 10.47 486 <0.001 
DBP 84.4 79.3 5.1 6.0 10.36 487 <0.001 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
 Difference in change between baseline Body Mass Index categories 
There were significant differences between the participants in various BMI 
categories, in the changes, from baseline to post-intervention, in TC, [F(4, 4546) = 10.04] 
and in LDL cholesterol, [F(4, 4447) = 7.08] at P < 0.001 and in TG [F(4, 4542) = 4.87] at p = 
0.001. However there was no significant difference in changes in HDL cholesterol. 
Post hoc analysis showed that change in TC and LDL cholesterol was greatest in 
the overweight, Obese Class I and Obese Class II categories but was significantly lower in 
the normal category and Obese Class III categories. For TG the change was significantly 
less for the normal BMI category than for the other BMI categories (Figure 5-19). 
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* sig at p= 0.05, ** sig at p = 0.01, ***significant at p <0.001 
 
Figure 5-19 Change in Lipid Profile by baseline BMI Category 
 
There were significant differences between the changes achieved in FPG, [F(4, 
4483) = 25.30], BMI, [F(4, 4500) = 200.49], SBP, [F(4, 4468) = 8.99] and DBP, [F(44, 4466) = 
5.91] at p < 0.001 between participants in various baseline BMI categories.  
Changes in FPG and BMI were significantly lower in the normal baseline BMI 
category and increase significantly as the baseline BMI level increased. For changes in SBP 
and DBP the participants in the normal BMI category had significantly less change when 
compared with participants in the other BMI categories. 
 
TC *** HDL LDL *** TG **
Normal (<25) 18.27 4.72 14.94 4.6
Overweight (25-30) 23.44 5.09 19.1 12.62
Obese Class I (30-35) 23.25 4.7 18.45 15.59
Obese Class II (35-40) 22.54 4.62 17.38 10.78
Obese Class III (>40) 17.12 4.66 12.68 7.17
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* sig at p= 0.05, ** sig at p = 0.01, ***significant at p <0.001 
 
Figure 5-20 Change in FPG, BMI and BP by baseline BMI 
 Summary 
At baseline those participants in the normal BMI category demonstrated the 
lowest levels for the biometrics tested. For TG, FPG, SBP and DBP the level increased with 
each rise in BMI category. HDL levels decreased with increase in BMI. TC and LDL levels 
peaked in the overweight and obese I categories. The greatest degree of change from 
baseline to post-intervention occurred in participants in the overweight and obese I 
categories but significantly less change occurred in participants in the normal category 
and in the extremely obese categories for TC, LDL and TG. For changes in both FPG, BMI, 
SBP and DBP the amount of change increases as the BMI category increases. Differences 
in change in HDL across BMI categories were not significant. 
FPG mg\dl *** BMI kg/cm2 *** SBP mmHg *** DBP mmHg ***
Normal (<25) 3.01 0.49 2.26 2.77
Overweight (25-30) 5.16 0.87 6.66 4.33
Obese Class I (30-35) 7.09 1.11 7.31 4.49
Obese Class II (35-40) 8.08 1.24 8.89 4.81
Obese Class III (>40) 12.48 1.61 8.86 5.07
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5.3.7 Family history and previous history  
At baseline participants were asked to complete questions relating to their family 
medical history and own previous medical history. These questions were: 
1. One or both of your parents died before age 60:  of heart disease?   □Yes □No   
of diabetes?  □Yes □No 
2. Check (X) if you have ever been told by a physician that you have any of the 
following: 
Angina  (Yr)? 
__________ 
Abnormal EKG (last 3 
yrs)  
Gall bladder trouble  Ulcers 
Heart attack (yr)? 
______ 
Irregular heartbeats Gout Osteoarthritis 
Angioplasty (Yr)? 
_______ 
Stroke (Yr)? ________ Kidney disease Rheumatoid arthritis 
Bypass (Yr)? ________ High blood pressure Chronic bronchitis Overweight 
Heart failure (Yr)? ____ High cholesterol Emphysema Gout 
Blood clotting problem High triglycerides Thyroid disorder Cancer 
 
The participant responses to these questions were compared using t-test analysis 
to identify differences in baseline biometrics and change from baseline to post-
intervention, in the biometrics. Next all of the participants who had indicated a positive 
response to any of the above questions were grouped together and they were compared 
with those participants who had indicated that there was no previous history or family 
history were compared. 
 Family History 
Of the 3398 participants who responded to the question relating to a family 
history of heart disease 379 (11.02%) participants indicated that they had had a parent 
die from heart disease before the age of 60.  In response to the question about a family 
history of diabetes 144 (4.4%) of the 3266 participants who responded indicated that they 
had a parent die from diabetes before the age of 60. 
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At baseline, participants who reported that one or both parents had died from 
heart disease before the age of 60 had significantly higher TG, FPG and SBP (Table 5-31) 
than those participants who indicated that they had not had a parent die from heart 
disease before the age of 60. 
 
Table 5-31 Comparison of family history vs no family history of heart disease mortality at baseline 
 Family History of Heart  Disease Mortality 
 At baseline 
  Family History No Family History      
  N Mean SD N Mean SD t df Sig 
Cohen’s 
d 
TC 375 191.0 42.84 2989 193.2 41.65 -0.97 3362 0.330 -0.05 
HDL 375 53.3 28.67 2988 55.0 26.70 -1.15 3361 0.252 -0.06 
LDL 366 129.1 62.88 2938 131.2 63.14 -0.61 3302 0.540 -0.03 
TG 374 156.7 97.19 2985 143.1 87.99 2.57 453 0.001 0.15 
FPG 371 106.1 30.92 2953 100.9 27.59 3.09 447 0.002 0.18 
BMI 366 31.5 7.52 2970 31.0 7.45 1.14 3334 0.250 0.06 
SBP 376 136.1 19.33 2990 132.8 19.22 3.10 3364 0.002 0.17 
DBP 375 79.8 11.92 2988 79.8 11.21 0.03 3361 0.980 0.00 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Those participants who indicated that one or both of their parents had died from 
heart disease before the age of 60 had significantly greater reductions in FPG levels than 
did those participants who had indicated that they had not had a parent die from heart 
disease before the age of 60 (Table 5-32). Effect size however was small. 
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Table 5-32 Comparison of family history vs no family history of heart disease mortality post-intervention 
 Family History of Heart Disease Mortality  
  
  
  
Percentage Change Post-intervention   
Family History No Family History      
N Mean SD N Mean SD t df Sig Cohen’s d 
TC 353 10.2 13.93 2817 10.1 12.21 0.06 423 0.960 0.00 
HDL 353 6.6 20.08 2816 7.5 13.96 -1.05 3167 0.293 -0.05 
LDL 343 10.5 22.18 2754 11.4 19.19 -0.51 408 0.610 -0.04 
TG 352 -0.0 0.49 2814 0.0 0.37 -1.16 3164 0.250 -0.07 
FPG 349 6.2 13.12 2782 4.5 12.84 2.29 436 0.020 0.13 
BMI 344 3.0 2.40 2811 3.2 4.12 -0.98 3153 0.327 -0.06 
SBP 374 2.9 40.74 2793 4.3 16.69 -1.15 3138 0.250 -0.05 
DBP 374 4.5 12.98 2791 4.2 12.46 0.41 3136 0.680 0.02 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Those participants who reported that one or both parents had died from diabetes 
before the age of 60 had significantly lower TC, but higher FPG, BMI and SBP levels at 
baseline than did those participants who indicated that they had not had a parent die 
from diabetes before the age of 60. (Table 5-33). 
 
Table 5-33 Comparison of family history vs no family history of diabetes mortality at baseline 
 Family History of Diabetes Mortality  
  
  
  
At baseline   
Family History No Family History      
N Mean SD N Mean SD t df Sig  Cohen’s d 
TC 141 184.8 41.55 3091 193.1 41.90 -2.326 3230 0.020 -0.20 
HDL 142 53.4 26.08 3089 54.8 26.71 -0.572 3229 0.567 -0.05 
LDL 140 122.2 56.25 3035 131.0 63.38 -1.603 3173 0.109 -0.15 
TG 142 157.6 90.50 3085 143.8 88.43 1.817 3225 0.069 0.15 
FPG 140 120.4 41.13 3053 100.6 36.94 5.531 144 <0.001 0.51 
BMI 140 33.1 8.37 3069 31.0 7.46 3.194 3207 0.001 0.26 
SBP 142 136.5 17.47 3092 132.9 19.32 2.203 3232 0.028 0.20 
DBP 140 39.7 10.37 3091 78.8 11.16 -0.052 3229 0.958 -3.63 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
Those participants who indicated that one or both of their parents had died from 
diabetes before the age of 60 had greater reductions in TC, LDL, FPG levels but 
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significantly less reductions in BMI than did those participants who had indicated that 
they had not had a parent die from diabetes before the age of 60 (Table 5-34). The effect 
size was small.  
 
Table 5-34 Comparison of family history vs no family history of diabetes mortality percentage change post-intervention 
  
  
  
  
Family History of Diabetes Mortality  
Percentage Change Post-intervention   
Family History No Family History      
N Mean SD N Mean SD t df Sig Cohen’s d 
TC 133 5.8 13.48 2917 10.3 12.35 -4.135 3048 <0.001 -0.35 
HDL 134 5.0 14.11 2915 7.5 14.93 -1.923 3047 0.055 -0.17 
LDL 132 5.9 21.46 2847 11.3 19.61 -3.078 2977 0.002 -0.26 
TG 134 -0.6 0.66 2912 0.0 0.37 -1.795 3044 0.073 -1.10 
FPG 133 8.8 18.29 2879 4.5 12.60 2.669 138 0.009 0.28 
BMI 132 2.1 5.59 2902 3.1 2.41 -2.181 133 0.031 -0.27 
SBP 132 -2.6 64.67 2889 4.4 16.47 -1.247 132 0.215 -0.17 
DBP 132 3.7 14.11 2887 4.7 12.33 -0.530 3017 0.596 -0.07 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
 
 Previous History 
The question regarding previous history was completed by 5046 participants. The 
number of respondents who indicated that they had been told that they had various 
medical conditions is shown in Table 5-35. 
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Table 5-35 Distribution of participants self-reported previous history 
Previous history n % Previous history n % 
Angina 175 3.5 Gallbladder 425 8.4 
Heart Attach 210 4.2 Gout 121 2.4 
Angioplasty 160 3.2 Kidney Disease 113 2.2 
Bypass 110 2.2 Diabetes Myelitis 707 14.0 
Heart Failure   71 1.4 Peptic Ulcer 178 3.5 
Blood Clots 135 2.7 Thyroid 700 13.9 
Abnormal EKG 194 3.8 Osteoporosis 360 9.4 
Arrhythmia 566 11.2 Osteoarthritis 476 9.4 
Stroke 101 2.0 Rheumatoid Arthritis 162 3.2 
High Blood Pressure 1695 33.6 Overweight 2190 43.4 
High Cholesterol 1807 35.8 Bronchitis Emphysema 355 7.0 
High TG 1009 20.0 Cancer 437 8.7 
 
At baseline it was found that generally, those participants who indicated a 
previous medical history had significantly lower scores, for TC, LDL, HDL and DBP however 
significantly higher baseline scores for TG, FPG, BMI and SBP (Table 5-36) than those 
participants who did not indicate a previous medical history. A previous history of various 
components of vascular disease or diabetes impacted the greatest number of biometrics. 
 Post-intervention it was found that there were much fewer differences between 
the two groups and that a previous history of various components of vascular disease did 
not seem to have an impact. However participants with a previous history of diabetes 
show a significantly less reductions in lipid profile, and BMI with a greater reduction in 
FPG (Table 5-37). 
 Summary 
Previous medical history had a significant impact on the participants’ baseline 
biometrics. Those participants with a previous medical history of diabetes had greater 
change from baseline to post-intervention in lipid profile, FPG and BMI. 
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 A factor that needs to be considered when the impact of previous history is 
examined is that it is more likely that participants who indicated a previous history are 
taking medication for these conditions and that this medication could be a confounding 
factor. Unfortunately data were not collected on medication usage. 
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Table 5-36 Comparison baseline biometrics for previous history  
 
 Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
   
False
N % N % T Mean F Mean p T MeanF Mean p T Mean F Mean p T Mean F Mean p T MeanF Mean pT MeanF Mean p T MeanF Mean p T MeanF Mean p
175 3.5 4872 96.5 181.43 193.57 0.001 56.60 54.53 0.413 131.04 130.28 0.896 164.06 141.85 0.001 111.53 100.94 <0.001 32.58 30.93 0.004 136.61 132.92 0.014 78.33 79.92 0.074
210 4.2 4837 95.8 173.25 194.02 <0.001 49.68 54.82 0.004 109.91 131.19 <0.001 170.68 141.39 <0.001 115.20 100.71 <0.001 32.98 30.90 <0.001 136.84 132.89 0.017 77.61 79.97 0.004
160 3.2 4887 96.8 172.40 193.84 <0.001 46.96 54.85 <0.001 108.17 193.03 <0.001 169.61 141.73 0.006 111.64 100.97 0.001 32.13 30.95 0.047 135.26 132.98 0.148 76.73 79.97 0.001
110 2.2 4937 97.8 168.92 193.70 <0.001 48.26 54.74 0.008 106.46 130.85 <0.001 154.35 142.35 0.168 111.12 101.10 <0.001 31.54 30.98 0.346 138.24 132.94 0.005 76.63 79.94 0.003
Heart Failure 71 1.4 4976 98.6 176.94 193.38 0.001 47.95 54.70 0.028 117.26 130.49 0.080 173.31 142.18 0.015 117.13 101.08 <0.001 34.57 30.94 0.006 140.04 132.95 0.012 75.87 79.92 0.003
135 2.7 4912 97.3 193.04 193.15 0.974 51.64 54.68 0.176 131.54 130.28 0.817 163.97 142.03 0.005 111.07 101.04 0.001 34.60 30.89 <0.001 135.67 132.98 0.117 79.43 79.88 0.660
194 3.8 4853 96.2 184.88 193.49 0.010 52.46 54.69 0.233 125.97 130.49 0.320 151.27 142.29 0.172 104.04 101.20 0.183 31.75 30.96 0.160 135.39 132.96 0.093 78.88 79.91 0.231
566 11.2 4481 88.8 190.36 193.51 0.094 53.67 54.72 0.359 127.49 130.67 0.253 155.92 140.92 0.001 103.24 101.06 0.094 31.64 30.91 0.027 134.70 132.84 0.034 78.85 80.00 0.026
101 2.0 4946 98.0 180.00 193.42 0.002 55.83 54.58 0.627 123.40 130.45 0.260 139.11 142.69 0.644 114.34 101.04 0.001 31.60 30.98 0.408 137.44 132.96 0.023 77.99 79.90 0.099
1695 33.6 3352 66.4 191.23 194.12 0.024 53.16 55.33 0.005 128.08 131.43 0.078 162.66 132.45 <0.001 109.03 97.41 <0.001 33.47 29.74 <0.001 141.37 128.83 <0.001 82.40 78.58 <0.001
1807 35.8 3240 64.2 200.76 188.88 <0.001 52.90 55.55 <0.001 135.05 127.68 <0.001 164.81 130.19 <0.001 105.99 98.68 <0.001 31.82 30.53 <0.001 134.58 132.20 <0.001 79.61 80.01 0.231
1009 20.0 4038 80.0 197.58 192.05 0.001 47.28 56.23 <0.001 124.89 131.63 0.002 196.74 129.17 <0.001 111.08 98.86 <0.001 33.09 30.47 <0.001 136.90 132.08 <0.001 80.13 79.80 0.390
425 8.4 4622 91.6 192.94 193.17 0.913 52.83 54.77 0.099 126.68 130.65 0.207 166.91 140.36 <0.001 107.29 100.75 <0.001 34.25 30.69 <0.001 136.77 132.71 <0.001 79.69 79.88 0.747
121 2.4 4926 97.6 179.88 193.48 <0.001 46.88 54.79 0.001 117.90 130.61 0.027 183.45 141.61 <0.001 118.45 100.89 <0.001 37.48 30.83 <0.001 143.52 132.79 <0.001 80.60 79.82 0.093
113 2.2 4934 97.8 192.36 193.17 0.864 55.50 54.58 0.785 128.21 130.36 0.717 161.03 142.18 0.025 108.94 101.13 0.005 32.16 30.96 0.142 138.12 132.94 0.006 79.72 79.87 0.893
707 14.0 4340 86.0 178.60 195.53 <0.001 48.29 55.47 <0.001 115.28 132.70 <0.001 180.22 136.49 <0.001 138.06 95.28 <0.001 35.27 30. 3 <0.001 138.61 132.14 <0.001 78.94 80.02 0.021
178 3.5 4869 96.5 190.15 193.26 0.332 55.68 54.56 0.648 129.63 130.33 0.882 156.29 142.15 0.071 107.40 101.09 0.027 32.01 30.95 0.062 136.14 132.94 0.033 78.72 79.91 0.177
700 13.9 4347 86.1 194.81 192.88 0.261 57.40 54.15 0.004 134.27 129.67 0.105 148.06 141.73 0.084 102.04 101.19 0.457 31.97 30.84 0.001 133.66 132.95 0.379 78.83 80.03 0.011
360 7.1 4687 92.9 196.97 192.85 0.073 63.08 53.94 <0.001 132.79 130.12 0.428 131.80 143.56 0.018 94.48 101.53 0.021 28.63 31.17 <0.001 134.82 132.92 0.076 78.15 80.00 0.004
476 9.4 4571 90.6 196.59 192.79 0.610 55.77 54.67 0.011 136.81 129.63 0.040 159.20 140.88 <0.001 104.58 100.97 0.010 33.17 30.76 <0.001 137.26 132.61 <0.001 79.35 79.92 0.255
162 3.2 4885 96.8 195.52 193.07 0.467 52.74 54.66 0.350 128.93 130.35 0.778 172.38 141.64 <0.001 109.25 101.05 0.003 33.05 30.92 <0.001 139.40 132.84 <0.001 81.26 79.82 0.118
2190 43.4 2857 56.6 193.63 192.78 0.479 52.07 56.55 <0.001 129.48 130.49 0.413 164.57 125.76 <0.001 107.81 92.29 <0.001 34.92 27.98 <0.001 136.87 130.10 <0.001 81.11 78.91 <0.001
355 7.0 4692 93.0 195.32 192.99 0.315 54.93 54.58 0.800 130.35 130.31 0.990 154.09 141.75 0.013 106.76 100.90 <0.001 33.79 30.78 <0.001 135.75 132. 85 0.007 80.17 39.84 0.607
437 8.7 4610 91.3 192.12 193.25 0.593 56.19 54.45 0.176 127.75 130.56 0.366 148.44 142.06 0.158 103.08 101.14 0.186 30.87 31.00 0.724 137.99 132.58 <0.001 79.69 79.88 0.743
True T Cholest HDL LDL Triglycerides FPG BMI Bp Sys Bp Dia
Comparison of Baseline Biometrics by Previous History 
Previous history
Angina
Heart Attach
Angioplasty
High Cholesterol
High Triglycerides
Gallbladder
Gout
Kidney Disease
Diabetes Myelitis
Bypass
Blood Clots
Abnormal EKG
Arrhythmia
Stroke
High Blood Pressure
Bronchitis Emphysema
Cancer
Peptic Ulcer
Thyroid
Osteoporosis
Osteoarthritis
Rheumatoid Arthritis
Overweight
Participants with previous history had significantly higher results
Participants with previous history had significantly lower results
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Table 5-37 Comparison of baseline to post-intervention percentage change by previous history 
 
Units: TC, HDL,LDL,TG,FPG = mg/dL: SBP, DBP = mmHg: BMI = kg/m2 
False
N % N % T Mean F Mean p T MeanF Mean p T Mean F Mean p T Mean F Mean p T MeanF Mean p T MeanF Mean p T MeanF Mean p T MeanF Mean p
175 3.5 4872 96.5 9.700 10.300 0.560 6.65 7.41 0.524 10.94 11.24 0.860 0. 015 -0.002 0.582 4.83 4.47 0.788 3.11 3.05 0.816 4.840 3.62 0.567 4.46 4.30 0.877
210 4.2 4837 95.8 10.24 10.280 0.970 5.32 7.48 0.241 10.73 11.25 0.776 -0.013 -0.001 0.668 8.06 4.33 0.002 3.05 3.06 0.968 2.850 3.69 0.668 4.53 4.29 0.804
160 3.2 4887 96.8 9.68 10.290 0.630 6.72 7.41 0.585 11.14 11.23 0.964 0.016 -0.002 0.591 5.19 4.46 0.644 3.23 3.05 0.423 4.320 3.64 0.763 2.68 4.35 0.129
110 2.2 4937 97.8 11.19 10.260 0.469 3.77 7.48 0.246 11.32 11.23 0.975 0.014 -0.002 0.686 6.87 4.44 0.198 2.96 3.06 0.718 4.840 3.63 0.652 2.87 4.33 0.265
Heart Failure 71 1.4 4976 98.6 0.341 10.280 0.760 7.39 7.39 0.999 9.01 11.26 0.384 0.031 -0.002 0.485 7.21 4.45 0.190 3.38 3.05 0.435 4.580 3.65 0.937 2.81 4.32 0.341
135 2.7 4912 97.3 11.28 10.250 0.374 8.04 7.37 0.650 14.00 11.15 0.134 -0.006 -0.001 0.895 6.40 4.43 0.101 2.81 3.06 0.304 5.180 3.62 0.521 4.75 4.29 0.703
194 3.8 4853 96.2 8.75 10.340 0.103 7.11 7.40 0.797 9.98 11.28 0.413 -0.366 0.000 0.216 5.60 4.44 0.302 3.06 3.06 0.969 5.080 3.60 0.470 6.03 4.23 0.073
566 11.2 4481 88.8 9.83 10.330 0.390 6.78 7.47 0.320 10.03 11.38 0.183 0.272 -0.005 0.071 4.98 4.42 0.361 3.04 3.06 0.895 2.960 3.75 0.521 4.13 4.32 0.746
101 2.0 4946 98.0 9.75 10.290 0.691 6.71 7.40 0.658 13.28 11.19 0.313 -0.024 -0.001 0.570 8.87 4.40 0.012 2.06 3.07 0.126 4.490 3.64 0.760 2.43 4.34 0.162
1695 33.6 3352 66.4 10.71 10.060 0.107 7.37 7.40 0.941 12.26 10.71 0.018 0.007 -0.006 0.272 6.03 3.70 <0.001 3.30 2.93 <0.001 5.210 2.85 0.004 4.71 4.09 0.123
1807 35.8 3240 64.2 10.63 10.070 0.176 7.17 7.52 0.443 11.74 10.94 0.224 0.002 -0.004 0.617 5.51 3.90 <0.001 3.19 2.98 0.008 3.840 3.56 0.727 4.50 4.18 0.425
1009 20.0 4038 80.0 9.91 10.370 0.380 6.20 7.69 0.006 10.17 11.50 0.135 0.020 -0.007 0.062 5.93 4.12 0.001 3.27 3.00 0.008 4.470 3.45 0.291 4.68 4.20 0.316
425 8.4 4622 91.6 9.95 10.310 0.596 7.07 7.42 0.662 9.56 11.39 0.096 0.028 -0.004 0.070 5.48 4.39 0.117 3.27 3.04 0.103 5.090 3.53 0.264 2.22 2.31 0.897
121 2.4 4926 97.6 9.28 10.300 0.406 5.61 7.43 0.209 9.33 11.28 0.406 0.013 -0.002 0.686 7.93 4.04 0.043 3.61 3.04 0.033 2.430 3.69 0.650 8.00 4.21 0.003
113 2.2 4934 97.8 9.94 10.280 0.790 6.86 7.40 0.592 11.76 11.22 0.785 0.044 -0.002 0.235 3.77 4.50 0.702 2.72 3.06 0.200 5.850 3.61 0.398 4.94 4.29 0.617
707 14.0 4340 86.0 8.48 10.570 <0.001 5.90 7.63 0.006 8.73 11.62 0.001 -0.017 0.001 0.264 10.37 3.52 <0.001 2.68 3.12 <0.001 4.220 3.57 0.559 4.42 4.28 0.804
178 3.5 4869 96.5 8.26 10.350 0.041 5.91 7.44 0.202 8.92 11.31 0.156 -0.953 0.002 0.073 5.59 4.45 0. 397 2.84 3.06 0.310 -0.650 3.82 0.339 2.49 4.37 0.234
700 13.9 4347 86.1 9.33 10.430 0.040 7.62 7.35 0.665 10.10 11.42 0.134 -0.006 -0.001 0.763 4.34 4.49 0.923 2.97 3.07 0.371 4.500 3.52 0.388 4.43 4.28 0.788
360 7.1 4687 92.9 8.07 10.440 0.001 5.79 7.51 0.044 7.22 11.54 <0.001 -0.033 0.001 0.128 3.85 4.53 0.369 2.63 3.09 0.003 4.010 3.63 0.805 4.83 4.26 0.451
476 9.4 4571 90.6 8.67 10.440 0.006 6.17 7.51 0.077 9.47 11.41 0.068 -0.021 -0.001 0.273 3.98 4.54 0.399 3.02 3.06 0.766 5.240 3.50 0.196 4.90 4.24 0.317
162 3.2 4885 96.8 8.66 10.330 0.123 6.91 7.43 0.331 9.25 11.29 0.258 0.005 -0.002 0.849 7.08 4.40 0.017 2.81 3. 06 0.268 1.700 3.72 0.697 5.81 4.25 0.157
2190 43.4 2857 56.6 10.16 10.360 0.590 7.48 7.32 0.723 10.47 11.81 0.033 0.002 -0.004 0.049 5.55 3.66 <0.001 3.30 2.86 <0.001 4.780 2.76 0.010 4.71 3.89 0. 061
355 7.0 4692 93.0 9.89 10.300 0.570 8.09 7.34 0.381 9.96 11.33 0.254 -0.020 0.000 0.365 4.03 4.52 0.525 3. 1 3.05 0.775 4.200 3.62 0.704 4.01 4.32 0.678
437 8.7 4610 91.3 10.63 10.24 0.561 7.34 7.39 0.947 11.410 11.210 0.853 0.018 -0.003 0.299 5.35 4.20 0.167 3.21 3.04 0.237 6.090 3.42 0.053 4.60 4.27 0.635
Participants with previous history had significantly higher results
Participants with previous history had significantly lower results
Triglycerides Bp DiaBp SysBMIFPGLDLHDL
Comparison PostIntervention % Change by Previous History
True T Cholest
Angina
Heart Attach
Angioplasty
Bypass
Cancer
Previous history
Thyroid
Osteoporosis
Osteoarthritis
Rheumatoid Arthritis
Overweight
Bronchitis Emphysema
High Triglycerides
Gallbladder
Gout
Kidney Disease
Diabetes Myelitis
Peptic Ulcer
Blood Clots
Abnormal EKG
Arrhythmia
Stroke
High Blood Pressure
High Cholesterol
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5.4 Predictors of change in biometric measures: regression analyses  
In the previous section the influence of the selected participant characteristics 
(age, gender, marital status, religious affiliation, BMI, family history and previous history) 
on the biometrics have been examined in isolation of the other characteristics.  In this 
section the results of regression analyses which were used to explore the influence of 
these participant characteristics as predictors of the change in the biometric measures 
are presented. Multiple regression was carried out using backwards stepping criteria.  
The change from baseline to post-intervention in TC, HDL, LDL, TG, BMI, FPG, SBP 
and DBP was used as dependent variables. The impact of the following 11 independent 
variables, on each dependent variable was considered.  
1. Age  age at baseline 
2. Gender  gender (1 male, 2 female) 
3. Religiosity self-reported affiliation to the Seventh-day Adventist Church (1 SDA, 2 not SDA) 
4. Marital Status self-reported marital status (1 married, 2 single, divorced or widowed) 
5. BMI   weight in kilograms divided by height in centimetres squared at baseline 
6. Participants baseline level of the dependent variable 
7. Family History of CVD Mortality  self-reported (1 family history, 2 no family history) 
8. Family History of Diabetes Myelitis  self-reported (1 family history, 2 no family history) 
9. Previous History Diabetes Myelitis   self-reported (1 previous history, 2 no previous 
history) 
10. Previous History High Blood Pressure,  self-reported (1 previous history, 2 no previous 
history) 
11. Previous History High Cholesterol  self-reported (1 previous history, 2 no previous 
history) 
 
Assumptions of normality, linearity, homoscedasticity and independence of 
residuals were examined using residual scatterplots for each set of regression analyses. 
Further, the statistic variance inflation factor (VIF) was used to test for high levels of 
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collinearity and multicollinearity. Analysis of each set of data indicated these assumptions 
were appropriate.  
 
5.4.1 Summary of predictors of change  
Table 5-38 presents a summary of the impact of the 11 independent variables 
analysed in the regression analyses to predict the changes in the biometrics examined.  
 
Table 5-38, Summary the beta values associated with the respective predictors of change for TC, HDL, LDL, TG, FPG, BMI, 
SBP and DBP 
Summary Predictors of Change Showing R Squared and Beta Values 
Predictors TC HDL LDL TG FPG BMI SBP DBP 
No 
biometrics 
influenced 
R Square 0.256 0.237 0.235 0.316 0.480 0.213 0.142 0.344  
Age -0.087 0.012 -0.068    -0.092  4 
Gender (male/female) -0.190  -0.129 -0.032  -0.090   4 
SDA/non-SDA 0.086 0.084    0.059   3 
Marital Status   -0.039  -0.029 -0.079   3 
Baseline BMI  0.021  -0.118 -0.049 0.454 -0.048 -0.096 6 
Baseline Level of Factor 0.503 0.476 0.464 0.591 0.771 0.454 0.400 0.615 8 
Family History of CVD         0 
Family History of Diabetes 0.044  0.042 0.067  0.048 0.095  5 
Prev Hist Diabetes     0.125 0.094  -0.059 3 
Prev Hist High BP -0.040  -0.046     0.078 3 
Prev Hist High Cholesterol    0.059    -0.032 2 
Independent Variables 
Count 6 4 6 5 4 6 4 5   
Values shown were significant at the 0.05 level 
 
 
Table 5-38 is replicated in Table 5-39 with beta values replaced by arrows. An up 
arrow (↑) indicates that the greater change is toward the value shown in brackets and a 
down arrow (↓) indicates greater change is away from the value shown in brackets. For 
example the ↑ for Age (Younger) under TC indicates that younger participants had 
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greater change in TC while the ↓ for SDA (Yes) indicates that participants indicating an 
affiliation with the Seventh-day Adventist Church had less change in TC. 
Table 5-39 Graphical summary of predictors of change for TC, HDL, LDL, TG, FPG, BMI, SBP and DBP 
Summary Predictors of Change Showing R Square and Beta Values 
Predictors TC HDL LDL TG FPG BMI SBP DBP Count 
R Square 0.256  0.237 0.235 0.316 0.480 0.213 0.142 0.344  
Age         (Younger) ↑ ↓ ↑    ↑  4 
Gender     (Male) ↑  ↑ ↑  ↑   4 
SDA  (Yes) ↓ ↓    ↓   3 
Marital Status  (Married)   ↓  ↓ ↓   3 
Baseline BMI     (Higher)  ↑  ↓ ↓ ↑ ↓ ↓ 6 
Baseline Level of Factor  (Higher) ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ 8 
Family History of CVD (Yes)         0 
Family Hist of Diabetes   (Yes) ↓  ↓ ↓  ↓ ↓  5 
Prev Hist Diabetes    (Yes)     ↓ ↓  ↑ 3 
Prev Hist High BP  (Yes) ↑  ↑     ↓ 3 
Prev Hist High Chol   (Yes)    ↓    ↑ 2 
Count 6 4 6 5 4 6 4 5   
 
The R Square shows that this group of predictors accounted for around 48.0% of 
the variance in FPG but only 14.2% of the variance in SBP.  This indicates that there are 
other factors that contributed the variance. Unfortunately a key factor of the CHIP 
program and a potential predictor of changes in participant’s biometric measures, that 
was not able to be analysed due to a lack of data, is the change in participant’s diet. The 
CHIP program encourages participants to move towards a plant-based diet but data 
relating to changes in this area were not collected.  Also there was no data collected on 
compliance with the intervention.  
The one consistently strong predictor of change was the baseline level of that 
biometric and this was the strongest predictor of change for all eight biometrics 
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examined. A family history of CVD, however, did not register as a predictor for any of the 
biometric measures analysed. 
Of interest is the fact that the while, Baseline BMI showed a positive relationship 
to change in HDL an inverse relationship to change was found for TG, FPG, SBP and DBP. 
In this population those with a higher BMI at baseline had significantly less change in TG, 
FPG, SBP and DBP than participants with a lower BMI at baseline. This seems to be 
different from what would be expected as it appears that a higher BMI is normally 
correlated with a higher level of these biometrics and thus if there is a positive correlation 
between the baseline level of these biometrics and change, one would normally assume 
that a higher BMI at baseline would also be positively correlated with change in the 
biometric. This is not the case in this analysis.  
The regression analyses showed that younger participants had greater change in 
TC, LDL, FPG and SBP however age was not a predictor for the other dependent variables 
analysed. With regard to gender, male participants had greater change in TC, LDL 
cholesterol and BMI than did the female participants, however gender was not significant 
for the other biometrics analysed. With respect to religiosity, participants indicating that 
they had an affiliation with the Seventh-day Adventist Church were shown to have less 
change in TC, HDL and BMI, however religiosity was not shown as a predictor for change 
in the other biometrics analysed. Marital status was only shown to be a predictor for 
change in BMI with those participants who were married experiencing less change in BMI 
than the non-married participants. 
With regards to family history as an independent variable, a family history of CVD 
was not a significant predictor for any of the biometrics. A family history of diabetes was a 
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significant predictor for changes in LDL, BMI and SBP with those participants who 
indicated that they had a family history of diabetes mellitus achieving less change in LDL, 
BMI and SBP than those participants who indicated they did not have a family history of 
diabetes myelitis.  
In relation to participant previous medical history, those participants indicating 
they had a personal history of diabetes myelitis experienced less change in TG, FPG and 
BMI than those participants who did not indicate having a previous history of diabetes 
myelitis however those participants who indicated they had a previous history of diabetes 
myelitis achieved greater change in TC and DBP. A previous history of higher blood 
pressure was significant for changes in DBP and LDL. Less change in DBP was realised by 
those for those participants who indicated they had a previous history of high blood 
pressure and greater change in LDL was shown for those participants with a previous 
history high blood pressure. A previous history of high cholesterol was only a significant 
predictor for changes in TG with those participants who indicated they had a previous 
history of high cholesterol showing less change in TG. 
5.4.2 Summary 
Previous sections have shown that all participants can achieve significant 
improvements in risk factors of chronic disease from volunteer-delivered, community 
based CHIP interventions. This regression analyses demonstrates that those participants 
with the greatest risk, at baseline achieve the greatest benefits during the intervention. It 
also appears that greater change in the biometric indices is achieved by those participants 
who are younger, male and non-SDA. However it would appear that those participants 
with the highest BMI at baseline achieve less change than those participants with lower 
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BMI at baseline, for some biometrics. It would also appear that family history and 
previous medical history of the participants has some impact as a predictor of change in 
the biometrics analysed. 
5.5 Discussion 
The aim of this chapter was to address the second research question: “What is the 
impact of selected participant factors, including age, gender, marital status, religious 
affiliation, previous history, family history and body weight on the outcomes achieved by 
participants in the CHIP intervention?” The key finding of this chapter was that regardless 
of age, gender, marital status, religious affiliation, body weight, family history or previous 
history, significant improvements in the risk factors associated with MetS can be achieved 
through the CHIP intervention when delivered by volunteers to free-living individuals in 
their community. The analysis presented in this chapter also indicated that participant 
factors do factors influence the responsiveness of participants to the intervention. The 
effect of these factors is discussed in this section. 
5.5.1 Biometric level at baseline 
The greatest predictor of the change achieved in a particular biometric by 
participants in the CHIP intervention was the baseline level of that biometric. Participants 
in the highest risk category consistently achieved the greatest amount of change. This was 
demonstrated in the overall results (presented in Chapter 4), and the regression analysis 
reported in this chapter. The trend for participants with the greatest need achieving the 
greatest improvement has also been demonstrated in professionally delivered CHIP 
interventions (Aldana et al., 2008; Diehl, 1998; Englert et al., 2004; Englert et al., 2007) 
and in other professionally delivered lifestyle interventions (Ellsworth et al., 2004). 
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5.5.2 Gender  
A significant finding of this study was that gender had an impact on the outcome 
achieved by participants. This study found that at baseline, male participants had 
significantly lower mean TC (10.8%), HDL (28.2%) and LDL (5.5%) but significantly higher 
TG (10.4%), FPG (12.5%), SBP (2.6%) and DBP (3.1%) than did the female participants, 
however there was no difference between male and female participants for BMI at 
baseline. From baseline to postintervention, male participants showed significantly 
greater reductions in TC (14.7 %), LDL (24.1%), TG (55.6%), FPG (39.1%), BMI (13.9%), SBP 
(20.6%) and DBP (18.7%) and significantly lower reductions in HDL (55.5%) this indicates 
that male participants achieved better outcomes, during the intervention, than did the 
female participants. It was also found that male participants demonstrated the greatest 
change at a younger age than did the female participants.  
It is commonly perceived that there is a difference in health status between males 
and females. Men die younger, underreport their symptoms and their pride stops them 
from asking for help when they do get sick (Moynihan, 1998). But while men die younger 
it is often perceived that women have poorer health (Macintyre, Hunt, & Sweeting, 1996). 
Women generally have higher mortality and morbidity than men after a heart attack, 
angioplasty or bypass surgery (Koertge et al., 2003) but are less likely to be referred to 
cardiac rehabilitation programs following a coronary incident (Allen, Scott, Stewart, & 
Young, 2004).  
It has also been reported that men have a higher incidence of MetS. In a review 
article Regitz-Zagrosek, Lehmkuhl, and Mahmoodzadeh (2007) suggest that MetS is more 
common among men, however the incidents of MetS is rising in the female population 
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particularly among younger females. Ford et al. (2002) found that the age adjusted 
prevalence of MetS in the overall US population, was similar for males (24.0%) and 
females (23.4%) and Alberti et al. (2009) found that the unadjusted prevalence of MetS in 
the US population was 41.9% in males and 38.3% in females. As observed previously, the 
prevalence of MetS, in the participants in this study, of 52.6% for males and 45.6% for 
females is higher than in the general US population with males having a significantly 
higher prevalence of MetS than females. 
However, as with most questions relating to health, issues of gender are not 
simply issues of gender but are complicated by other factors such as ethnicity, socio-
economic status and education (Read & Gorman, 2006). Both physiological and 
psychological issues need to be considered. 
This study found that at baseline, male participants had significantly lower mean 
TC (10.8%), HDL (28.2%) and LDL (5.5%) but significantly higher TG (10.4%), FPG (12.5%), 
SBP (2.6%) and DBP (3.1%) than did the female participants, however there was no 
difference between male and female participants for BMI at baseline. These findings are 
comparable to other studies showing gender differences in health status on entry into 
lifestyle interventions (Cannistra, Balady, O'Malley, Weiner, & Ryan, 1992; Koertge et al., 
2003).  
While significant reductions were observed, from baseline to post-intervention, on 
all biometric measures for both male and female participants, male participants showed 
significantly greater reductions in TC (14.7 %), LDL (24.1%), TG (55.6%), FPG (39.1%), BMI 
(13.9%), SBP (20.6%) and DBP (18.7%) and significantly lower reductions in HDL (55.5%). 
This indicates that male participants actually achieved better health outcomes from CHIP, 
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in relation to MetS, than did the female participants. Other studies (Daubenmier et al., 
2007; Pischke, Weidner, Elliott-Eller, & Ornish, 2007; Roberts & Barnard, 2005) have also 
demonstrated greater change in male participants. While this study found that when 
adjustments were made for age and other baseline risk factors, gender was significant for 
TC and LDL and BMI but not for other risk factors Englert et al. (2007) found that gender 
was significant across all risk factors. In comparison the Multicentre Lifestyle 
Demonstration Project found that the improvement of female participants was similar to 
that experienced by the male participants (Koertge et al., 2003). 
There are physiological differences between males and females that need to be 
considered. Males have significantly greater muscle mass than do females, even among 
the elite athletes (Alway, Grumbt, Gonyea, & Stray-Gundersen, 1989). It has been 
suggested that there are gender specific pathophysiological differences in the in relation 
to MetS in that woman tend to develop peripheral adiposity with subcutaneous fat 
accumulation whereas men are more prone to central or android obesity. (Regitz-
Zagrosek, Lehmkuhl, & Weickert, 2006).  The central and android fat is more 
metabolically active and therefore easier to remove than fat on the hips and thighs. 
In studies looking at barriers to change it has been found that the most important 
barrier for women is self-esteem while for men it is time (Mosca, McGillen, & Rubenfire, 
1998). It also seems that different approaches need to be taken to encourage men to lose 
weight than that taken for women. In the Australian experience, it has been found that 
the hardest part is getting men to admit that they have a problem. It has also been found 
that humour is very effective when working with a male audience, but obesity is not a 
laughing matter for females (Egger, 2007, p. 212; Plater & Egger, 2011). There are, 
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however, some who do not think that humour should be used in such a weighty topic as 
obesity (Egger, 2010; Frank & Kahan, 2010).  
There are a number of factors that could have contributed to the greater benefits 
achieved by male participants. Marital status may be a factor with a significantly greater 
percentage of male participants (85.2%), than female participants (68%) indicating that 
they were married. Also, as two thirds of the participants in these CHIP programs were 
female (66.5%) as opposed to only one third being male (33.5%) it would seem that there 
was a greater chance that the male participants were attending the CHIP program with a 
spouse and while we do not have the data to analyse this detail others have shown that 
social support and spouse support may be an important factor in achieving the lifestyle 
changes (Verheijden & Kok, 2005). This is a question that needs to be researched in more 
detail in further studies. 
As pointed out in an earlier section of this chapter males achieve greater change in 
a younger age bracket then did the females. This would indicate that benefit in regards to 
Quality Adjusted Life Years may actually be higher for male participants then for female 
participants. 
While it is not fully understood why the effect of the CHIP intervention is greater 
for men than women the propensity for men to lay fat in the abdominal region which is 
more metabolically active and therefore easier to remove than fat on the hips and thighs 
may offer a physiological explanation. In addition, men tend to have more muscle mass 
and therefore a higher metabolic rate than women, so increases in physical activity and 
higher intakes of health promoting plant foods may be expected to more quickly 
ameliorate the previous adverse effect of lifestyle. A further explanation may be that 
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married men often attended with their spouses and therefore benefited from the 
household changes made by the women. 
5.5.3 Age 
For the CHIP participants in this study, it can be seen that at baseline mean TC, 
LDL, TG, FPG levels, BMI and DBP are lower in the younger and the older age groups 
peaking in the 50-59 age group while HDL levels rise with age peaking in the 70-79 age 
group and SBP continues to rise with age.  
The increasing prevalence of symptoms associated with MetS with age has been 
observed in the US populations (Ford et al., 2002; Ford et al., 2004) and worldwide 
(Regitz-Zagrosek et al., 2006). The attenuation of MetS in individuals 70+ has also been 
noted in general population studies of MetS (Hu et al., 2004). 
In this study, significant change was observed in all biometrics in all age categories 
except for TG and FPG in the 0-29 age categories. When the change was observed across 
age categories it was found that the largest changes were achieved for TC, LDL and HDL in 
the 40-49 age category and in the 50-59 age category for FPG and BMI. Although the 
changes are maximum for the 50-59 age group these are not significantly higher than the 
40-49 age group. This is consistent with the fact that these age groups showed the 
highest risk, at baseline.  
The indicators of risk for chronic disease can change with age. For instance, in 
relation to BP as a predictor of Chronic Heart Disease (CHD) risk Franklin et al. (2001) have 
shown that for patients <50 years of age DBP is the strongest predictor of CHD risk while 
for the 50 to 59 year old both BP indexes were compatible predictors. For those in the 
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60+ age group DBP was negatively related to CHD risk and pulse pressure became 
superior to SBP as a predictor of CHD risk (Franklin et al., 2001). 
The results of the current study, in relationship to age, would seem to indicate 
that if we can enrolled individuals in a lifestyle intervention program, such as CHIP, before 
they turn 40 we can have a significant impact on the risk factors for MetS and associated 
mortality and morbidity such as CVD and T2D, thus significantly impacting the lifespan 
and quality of life for these individuals. Fraser and colleagues suggest, from reviewing the 
Adventist Health Study data, that maximum benefit from changes to lifestyle habits is 
obtained if the changes are made before the age of 30, though significant benefits can be 
gained at any age (Fraser & Shavlik, 2001). 
5.5.4 Marital status 
A limitation of the data collection on marital status was that participants were 
only given before options of single, married, divorced or widowed and this did not make 
provision for participants who were in de facto or other relationships. 
A further finding of the study was that married participants generally achieve 
better outcomes than did the widowed, divorced or single participants. There has long 
been debate about the effect of marital status on the health of individuals. In 1980 it was 
suggested that marital status had no effect on health status (Hunt et al., 1980), however a 
number of epidemiological studies have since shown a clear interaction between social 
integration and mortality and morbidity, and evidence began to accrue that social 
integration had an impact on health including cardiovascular function (House, Landis, & 
Umberson, 1988). Marital status is a significant component of social interaction and 
marriage is the central relationship for a majority of adults. Being married is now seen as 
  183 
having major health benefits. Morbidity and mortality has been shown to be lower for 
married individuals than unmarried individuals (Kiecolt-Glaser & Newton, 2001) and  a 
meta-analysis found that singles have a 30% increased risk of mortality relative to married 
persons (Roelfs, Shor, Kalish, & Yogev, 2011). As with most issues relating to health the 
correlation between marital status and health status is not a simple relationship, factors 
such as age and also the quality of that relationship can have an impact on health status 
(Troxel, Matthews, Gallo, & Kuller, 2005).  
Gallo et al. (2003) suggest that the health benefits of marriage are greater for men 
than for women. A possible explanation for the greater health benefits for men in 
marriage could be that women are more likely than men to attempt to control others’ 
health behaviour and that the female partner is more active in encouraging the male 
partner to improve his health habits than vice versa (Kiecolt-Glaser & Newton, 2001; 
Umberson, 1992).  
Significant reductions in the risk factors relating to MetS were observed in this 
study by participants in all marital status categories. Further, analysis of the reduction in 
risk factors for MetS achieved during the intervention, by marital status, showed that 
participants in the married category had significantly greater reductions in TC, LDL, FPG 
and BMI. When other factors such as age and gender were corrected for by regression 
analysis, it was found that marital status was a significant predictor of change in LDL, FPG 
and BMI. 
5.5.5 Religious affiliation 
An analysis of the participants in the CHIP lifestyle intervention, in this study, 
showed that the SDA participants had significantly better biometric data, in regard to risk 
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factors associated with MetS, at baseline than the non-SDA participants. However the gap 
between the Adventist and the non-Adventist, in regard to risk factors associated with 
MetS, was reduced over the period of intervention.  
An ongoing research project from Loma Linda University has compared the health 
status of Seventh-day Adventist’s with that of the general population. These studies 
began with the Adventist Mortality Study from 1960-66 and then the First Adventist 
Health Study, from 1974-88 focusing on Adventists in California. Then in 2002 Adventist 
Health Study-2 began to analyse the health status of over 90,000 Seventh-day Adventists 
across North America. These studies have found that Adventists, as a population, have 
lower risk for most cancers, CVD and T2D which equates to decreased mortality and 
morbidity (Beeson, Mills, Phillips, Andress, & Fraser, 1989; Butler et al., 2008; Fraser, 
1988, 1994, 2005; Fraser & Swannell, 1981; Heuch, Jacobsen, & Fraser, 2005; Key et al., 
1999; Slavicek et al., 2008; Tonstad et al., 2011). A more detailed analysis of the Seventh-
day Adventist population has shown that Adventists who adopt a plant-based diet have 
significant advantages over those Adventists consuming a meat-based diet in such diverse 
areas as the onset of dementia (Giem, Beeson, & Fraser, 1993), prostate cancer (Mills, 
Beeson, Phillips, & Fraser, 1989), CVD (Slavicek et al., 2008), T2D (Tonstad et al., 2009) 
and MetS (Rizzo et al., 2011). It has been suggested that the advantages observed in the 
Adventist population, of up to 10 years additional lifespan, are the effect of healthier 
choices made by this population (Fraser & Shavlik, 2001). 
An analysis of the participants in the CHIP lifestyle intervention, in this study, 
showed that the SDA participants had significantly better biometric data, in regard to risk 
factors associated with MetS, at baseline than the non-SDA participants. This is consistent 
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with the findings of the Adventist Health Studies outlined above. It was also observed in 
the study that the gap between the Adventist and the non-Adventist, in regard to risk 
factors associated with MetS, was reduced over the period of intervention. This would 
tend to support the suggestion made by Fraser and Shavlik (2001) that it would seem that 
the health advantages experienced by Seventh-day Adventists are a factor of lifestyle 
choices and that these advantages can be achieved by others who choose to make these 
same lifestyle choices. 
5.5.6 Body Mass Index 
A further key finding was that participants in all BMI categories, at baseline, were 
able to achieve significant weight loss during the CHIP intervention. CHIP recommends a 
dietary fat intake of less than 20% of calories per day which on an 1800 calorie diet 
equates to around 40g of fat per day. While some studies have found that there is no 
correlation between fat intake and weight change(Forouhi et al., 2009) other researchers 
have found that a significant reduction in fat intake is associated with greater weight loss 
(Zulet, Berkenpas, & Martinez, 2005). Carmichael et al. (1998) found that greater initial 
weight loss was associated with greater decrease in fat intake and weight loss occurred in 
all participants who reported a fat intake of 40 g per day or less. In a review article of 
epidemiological and intervention studies Gaesser (2007) concluded that a low-fat diet 
with emphasis on fibre rich carbohydrates, particularly cereal fibre could be beneficial for 
weight loss.  
There has also been shown to be a correlation between fat intake and weight gain. 
Researchers from the Guttenberg study found a strong correlation between percentage 
of calories from fat and weight gain in women (Heitmann, Lissner, Sorensen, & Bengtsson, 
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1995; Lissner & Heitmann, 1995). An analysis of the Nurses’ Health Study found only a 
weak positive association between overall percentage of calories from fat consumption 
and weight gain, however it found a strong association with percentage of calories from 
animal, saturated and trans fat and weight gain (Field, Willett, Lissner, & Colditz, 2007).  
Weight loss with a low-fat diet in obese men with MetS has been found to decrease LDL 
and have positive effects on HDL (Ng, Watts, Barrett, Rye, & Chan, 2007) and a low-fat 
diet was shown to have a positive impact on the risk factors for cardiovascular disease 
within one week (Slavicek et al., 2008). The results from this analysis of CHIP participants 
would seem to support the benefits of a low-fat, high unrefined carbohydrate diet. 
Overall it was found that significant changes in the risk factors for MetS were 
achieved by participants regardless of baseline BMI, with those participants with the 
highest BMI, at baseline, achieving the greatest reductions in FPG, BMI, systolic and 
diastolic blood pressures. However the greatest changes in TC, LDL and TG were 
experienced by those participants in the Overweight or Obese I category, while those 
participants in the Obese II and Obese III categories, at baseline, experience significantly 
less change in these components of the lipid profile. While it has been suggested that 
lifestyle intervention may not be effective in the severely obese (National Institute of 
Health, 1998) it has been clearly shown that the extremely obese do respond very well to 
appropriate lifestyle intervention (Goodpaster et al., 2010; Unick et al., 2011). 
In this study regression analysis showed a negative correlation between baseline 
BMI and changes in LDL, FPG, SBP and DBP. This result was unexpected. A closer 
examination of the data shows that those participants in the Obese Class II and Obese 
Class III (BMI > 35) do not experience as much change in these risk factors as do those 
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participants who are overweight or categorised as Obese Class I (BMI < 35). It would seem 
that the extremely obese participants do not respond as well to this lifestyle intervention 
in the short term as do the less severely obese individuals in reducing their lipid profile, 
FPG and BP. However over the long term, moderate weight loss of 5% even in the 
extremely obese has been shown to be beneficial (Pasanisi, Contaldo, de Simone, & 
Mancini, 2001). Those in the Obese Class III showed an average drop in BMI of 1.61 BMI 
units which equates to a 4% drop in BMI for those with a BMI of 40 in just 30 days 
indicating that the CHIP intervention provided substantial benefits even for the extremely 
obese.  
5.6 Conclusion  
In this chapter an analysis of how selected participant factors contribute to the 
outcomes achieved in community-based, volunteer-delivered CHIP interventions has 
been presented.  
Male participants were shown to achieve greater improvement, in the risk factors 
associated with MetS, than the female participants, and to achieve the greatest change at 
a younger age than the female participants. Across all participants, greatest improvement 
occurred in the 40-49 age group and married participants did better than the single, 
divorced or widowed participants. With regard to religious affiliation it was found that 
SDA participants had better biometric scores at baseline however the non-SDA 
participants achieved greater improvements in the biometrics during CHIP intervention 
and that the gap between SDA and non-SDA participants had narrowed significantly by 
the end of the intervention. Participants with the highest BMI at baseline achieve the 
greatest improvements in BMI, FPG and BP however those participants in the highest 
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obesity categories, (obese II and obese III) showed significantly less improvement in their 
lipid profile than did participants whose weight place them in the overweight and obese I 
categories at baseline. 
The regression analysis showed that the single biggest predictor of change in the 
participant’s biometric profile was the participant’s baseline biometric level with those 
participants having the worst biometrics at baseline achieving the best results. However 
even this generalisation is not clear-cut, as discussed above, participants baseline BMI 
level did not follow this trend. Clearly the biochemical interactions that take place during 
a lifestyle intervention such as CHIP are very complex and only poorly understood.  
Unfortunate, no measures of compliance were taken for this data set. It can 
probably be assume that those who are most compliant achieved the greatest results. 
Ornish has shown a very clear dose response between compliance and outcome (Ornish, 
2009b; Ornish et al., 1990a). There is a need for more research looking at compliance 
level particularly with regard to dietary factors. 
This analysis has shown that regardless of age, gender, marital status, religious 
affiliation, baseline weight, previous history or family history, significant improvements in 
the risk factors associated with MetS can be achieved by participants in the CHIP lifestyle 
intervention when delivered by volunteers in their local community.  
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Chapter 6 Conclusion: Key findings, limitations and 
recommendations 
 
This dissertation makes a valuable contribution to the understanding of utilising 
lifestyle interventions to reduce the risk factors associated with MetS and chronic disease. 
Unique elements of the study include the large sample size and the use of volunteer 
facilitators in the context of a community-based lifestyle intervention.  
The study was guided by two research questions which are shown below with the 
key findings of the study: 
1. How effective is the Coronary Health Improvement Program (CHIP) 
lifestyle intervention for reducing selected risk factors of chronic 
disease associated with the Metabolic Syndrome, when delivered by 
volunteers to free-living participants in their community? 
This large cohort study has shown that significant and meaningful reductions in 
the risk factors associated with the Metabolic Syndrome can be achieved by the CHIP 
lifestyle intervention when delivered by volunteers to free-living participants in their 
community.  
2. What is the impact of selected participant factors including age, 
gender, marital status, religious affiliation, previous history, family 
history and body weight on the outcomes achieved by the CHIP 
intervention? 
This study has shown that regardless of age, gender, marital status, religious 
affiliation, previous history, family history and body weight, participants in the CHIP 
intervention can achieve significant improvements in the risk factors associated with the 
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Metabolic Syndrome, however, participant factors do influence the responsiveness of the 
participants to the program. In general, male participants achieved better results than 
females, and males tended to achieve their best outcomes at a younger age than the 
female participants. Married participants achieved better outcomes than single, divorced 
or widowed participants. SDA participants had better risk profiles at baseline, however, 
the non-SDA participants achieved better outcomes during the intervention. Participants 
who had the highest BMI at baseline achieved the greatest changes in BMI, FPG and BP, 
however, those participants with a BMI greater than 35 kg/m2 showed significantly less 
improvement in their lipid profile than those participants with a BMI between 25 and 35 
kg/m2.  
In this final chapter, the key conclusions from the study are presented. A 
discussion of the limitations of this research project is then presented followed by 
recommendations for further study.  
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6.1 Key findings  
The key findings of this study include: 
1. The CHIP life-style intervention achieves, within 30 days, significant 
reductions in the various risk factors associated with MetS. 
2. The CHIP intervention achieves the best outcomes among individuals 
with the highest level of risk at program entry. It was found that CHIP 
works best for those who need it the most. 
3. Significant improvements in the risk factors of MetS and chronic 
disease can be achieved by participants, in CHIP interventions, 
regardless of age, sex, gender, marital status, religious affiliation, 
previous history, family history or health status. However, some 
groups of participants achieve better results than others. 
4.  Volunteers, who have donated their time, can deliver CHIP lifestyle 
interventions to free-living participants in their community that 
achieve significant and meaningful reductions in the risk factors for 
chronic disease.  Further, that the outcomes achieved by volunteers 
are comparable to those achieved by paid health professionals.  
5. The utilisation of volunteer facilitators in the delivery of CHIP 
interventions maximizes the use of human and social capital. 
Volunteer facilitators provide the opportunity for a cost-effective, 
accessible and easily scalable approach for the delivery of lifestyle 
interventions 
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6.2 Limitations 
This study has shown that the CHIP intervention when delivered by volunteer 
facilitators achieve significant results over 30 days. However a significant limitation of this 
study is that the effects have only been demonstrated in the short term, data has only 
been collected for a 30 day period. Further research is needed to establish the long-term 
effectiveness of the CHIP intervention. 
 Several factors may have influenced the results observed in this study. Firstly, 
data were not collected on the participants’ compliance to the program and therefore the 
extent to which the participants adhered to the lifestyle changes promoted in the CHIP 
intervention cannot be factored into the analysis of the biometric changes. It can be 
assumed that not all participants completely embraced the lifestyle behaviour changes 
advocated in the program, however, this would have only diluted the overall significance 
of the results. The second limiting factor was that accurate data were not collected on 
changes in medication use throughout the 30-day intervention. Anecdotal reports from 
facilitators suggest that many participants, in consultation with their personal physicians, 
decreased or even ceased their medication use during the intervention. While this is a 
desirable outcome, it would have once again had the effect of diluting the overall 
significance of the results and diminishing the apparent effectiveness of the program as 
observed in the mean changes from baseline to post-intervention.  
A further limitation of the study is that participants were self-selected. As the 
participants were self-selected, they likely entered the program with an elevated 
readiness for change and hence willingness to engage in the intervention. In accordance 
with the transtheoretical model of behaviour change (Prochaska et al., 2013), a key 
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objective of the first few sessions of the CHIP intervention is to move individuals from 
pre-contemplation to action. Yet the participants were probably beyond the pre-
contemplation stage at program entry. It would be interesting to compare the outcomes 
observed in this study with participants who had not shown an initial interest in the 
program. 
In the absence of a control group, the extent to which regression to the mean 
explains the observed improvements cannot be determined. Consistent with regression 
to the mean is that the individuals with the most extreme baseline measures tended to 
experience the greatest improvements and hence inclination towards the norm. 
However, given the large size of the sample and that in some of the outcomes measured 
the high risk classifications moved 1.5 to 2 standard deviations, regression to the mean 
likely only explains a small component of the observed results. Noteworthy, several 
studies of CHIP in the United States have demonstrated the effectiveness of the 
intervention using a randomised control design and the magnitude of change observed in 
the present study is similar to the treatment groups of these studies (Aldana, Greenlaw, 
Diehl, Salberg, Merrill, Ohmine, et al., 2005; Englert et al., 2007; Merrill, Massey, et al., 
2008). 
Another potential confounder of the outcomes observed in this study is the 
Hawthorne effect. While the research team were not responsible for conducting the 
interventions, the participants’ behaviours and level of engagement with the program 
was undoubtedly influenced by the blood measures taken at baseline and post-
intervention. Given that the pre and post blood work is a standard component of the CHIP 
intervention, improvements achieved as a result of these accountability measures could 
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be considered part of the intervention itself. However, further research is needed to 
elucidate the influence of the unique lifestyle recommendations of the CHIP 
intervention—namely its emphasis on a whole-food, plant-based eating pattern—from 
the motivational properties of the pre and post-intervention measurements made on the 
participants. Certainly, the inclusion of accountability measures is likely to be an 
important component of lifestyle interventions targeting chronic disease.  
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6.3 Recommendations for further study 
This study has made an important contribution to the understanding of how 
lifestyle interventions can be utilised to combat chronic disease. While this study makes a 
valuable contribution, it also demonstrates the enormous potential for further research in 
this area.  
To address some of the limitations of the study outlined above there is a need for 
further studies of a randomised control design. Further studies also need to collect 
validated data on compliance to the intervention relating to changes in dietary habits and 
exercise levels. As the data analysed in this study was short-term (30 days), there is a 
need for long-term studies of the interventions effectiveness. 
While this study has explored the impact of some participant factors such as age, 
gender, religiosity, marital status, previous history and the baseline biometric levels, 
there is a need for more research in this area.  
There is also a need to study the impact the facilitator has on the outcomes 
achieved by the CHIP interventions. For instance, does the facilitator’s personal 
compliance to the recommendations of the intervention influence the outcomes achieved 
by the participants? Also, do voluntary facilitators who have some medical training, such 
as nurses, doctors or allied health professionals achieve better outcomes than those 
facilitators with no medical background? 
One of the primary questions facing Lifestyle Medicine is “How can lifestyle 
interventions be most effectively implemented?” The current study further expanded the 
body of knowledge surrounding this question by showing, in a large study, that volunteers 
can effectively facilitate lifestyle interventions. However, there is much to be learned. 
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